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ABSTRACT 
 
Craniofacial form is defined by a number of factors. A major contributor is the jaw 
musculature  especially  of  the  masseter  muscle,  as  differences  in  transcription  and 
translation of various genes have been documented from this tissue. Up to this point 
however, no reliable biological predictors of form have been identified.  
 
The aims of this study were therefore, to describe the transcriptome of the masseter 
muscle using microarray technology and to establish and correlate the expression levels 
of potential candidate and known “informative” genes in masseter muscle with selected 
clinical,  radiographic  and  dental  features  of  subjects  with  a  variety  of  craniofacial 
morphologies.  
 
A  total  of  29  patients  (18  deformity  and  11  control)  were  selected  from  the 
orthodontic/orthognathic clinics at the Eastman Dental and Whipps Cross Hospitals, 
London, and Riyadh Military Hospital, Saudi Arabia.  
 
Microarray results indicated five “novel” genes not previously reported in relation to the 
masseter  muscles  of  subjects  with  variable  craniofacial  morphologies.  Two  genes 
(KIAA1671 and DGCR6) were down-regulated in long face patients, one (SERGEF) 
was down-regulated in Class III patients and one (LOC730245) was up-regulated in 
Class II long faces and in all Class III subjects, compared to controls. Another gene 
(NDRG2) was down-regulated in Class II compared to Class III individuals. Subsequent 
quantitative  Reverse  Transcriptase  PCR  results  strongly  confirmed  that  the  “novel” 
gene SERGEF was down-regulated in relation to the clinical, dental and radiographic 
features of subjects with Class III appearance. SERGEF gene had a positive relationship 
to  the  number  of  dental  occlusal  contacts  and  ANB  angle.  The  “informative”  gene 
MHC7 was strongly related to both vertical and horizontal facial deformities.  
 
These data suggest that the expression profiles of a number of genes can be analysed 
and used to make assessments as to their role in the primary aetiology and successful or 
unsuccessful  treatment  of  patients  with  specific  craniofacial  morphologies. 
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1.1.  INTRODUCTION 
Structural (Boyd et al., 1989) and functional (Hunt and Cunningham, 1997) variations 
of the masseter muscle between individuals with various facial morphologies (Kiliaridis 
and Kalebo, 1991; Ariji et al., 2000) are well documented. Recent masseter muscle 
research in the orthodontic field has been driven by the hypotheses as to whether these 
differences could be detected on a transcriptome level, to be used, alongside the clinical 
diagnosis, as markers for specific craniofacial deformities (Nelson-Moon et al., 1998) or 
as predictors for success or relapse following treatment (Harzer et al., 2007).  In an 
attempt to answer these questions, scientists have proposed a set of candidate genes 
which have been reported in association with the development (Butler-Brown et al., 
1988), contraction (Eriksson and Thornell, 1983) regeneration (Singh et al., 2000) or 
adaptation (Auluck et al., 2005) of the masseter muscle. Out of the large number of 
human genes (Rabinowicz et al., 2000), very few genes have been selected and the 
results in relation to craniofacial deformities have been variable. Up to date no reliable 
predictors have been identified (Suchak et al., 2009).  
 
The aims of this chapter are therefore; to provide a general background of the structure 
and  function  of  the  masseter  muscle  in  both  normal  and  abnormal  craniofacial 
morphologies, to give an up to date summary of the masseter muscle genes that have 
been  tested  in  relation  to  craniofacial  discrepancies,  whilst  the  final  section  will 
elucidate  the  scope  of  new  gene  expression  technologies,  which  have  not  been 
implemented previously in masseter muscle research and which could provide valuable 
transcriptome data.  
 
1.2.  THE MASSETER MUSCLE 
The masseter muscle is one of the muscles of mastication that has been investigated 
extensively in humans. This has been due to its close relation to the mandible and its 
ease of accessibility (Yonemitsu et al., 2007). It is composed of two portions, the deep 
and the superficial bellies (Figure 1.1).  
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1.2.1.  GENERAL MASSETER MUSCLE STRUCTURE AND FUNCTION 
 
1.2.1.1.  Intrauterine growth 
Migration of cells originating from the paraxial mesoderm into the first branchial arch 
gives  rise  to  the  muscles  of  mastication  (temporalis,  masseter,  medial  and  lateral 
pterygoid), anterior belly of the digastric, mylohyoid, tensor tympani and tensor veli 
palatini.  Primitive  craniofacial  muscle  cells  are  evident  at  the  8
th  -  9
th  week  of 
intrauterine  life  and  are  called  myoblasts.  Following  differentiation,  the  myoblasts 
elongate and fuse together to form multinucleated cylindrical myotubes. The mature 
forms of the myotubes are called muscle fibres. A group of muscle fibres are called 
fascicles, and a group of fascicles forms the whole muscle (Figure 1.2). The highly 
specialised  processes  of  muscle  cell  proliferation  (Henriquez  et  al.,  2002), 
differentiation (Osses and Brandan, 2002) and fusion (Carrino eta al., 1999) into muscle 
fibres  and  fascicles  have  been  found  to  be  largely  influenced  by  the  surrounding 
connective tissue which is called the extracellular matrix (ECM).  
Figure 1.1: Anatomy of the masseter muscle. a) The superficial belly arises from the zygomatic 
process of the maxilla as well as the zygomatic arch and runs downwards in a diagonal direction 
to be inserted onto the lower lateral border of the ramus of the mandible and the gonial angle. b) 
The deep belly arises from the medial surface of the zygomatic arch and runs downwards and 
backwards to be inserted onto the upper half of the ramus of the mandible (adapted from Biel, 
2005). Chapter 1. Background 
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The ECM is organized into three main layers, endomysium, perimysium and epimysium 
(Figure 1.2), and is mainly a collection of collagens, glycoproteins and proteoglycans 
(reviewed in Velleman, 1999). This collection forms a dynamic network that surrounds 
and connects the different layers of the muscle (Lewis et al., 2001). Not only does the 
composition of the ECM affect the structural and functional state of the muscular tissue, 
but also the interaction and adhesion between the ECM and the muscle fibres (Grounds 
et al., 2005). It also contributes to the integrity of the muscle (Stetler-Stevenson, 1996). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By the 14
th - 15
th week of intrauterine life, all craniofacial muscles have established their 
sites of origin and insertion (Sperber, 1989). However, the contractile properties of the 
muscle fibres are not evident until the 22
nd week of gestation (Ringqvist et al., 1977) 
 
1.2.1.2.  Contraction of muscle fibres 
The contraction of a single muscle fibre is brought about by the motor unit within each 
myofibril, called the sarcomere. The sarcomere is composed of two types of filaments; 
the thin  actin and thick myosin protein  filaments. The myosin  filament  comes in a 
greater variety than the actin filament; it is composed of two heavy chains and four light 
Figure 1.2: General muscle structure. a) The epimysium is the outermost sheet that surrounds 
the whole muscle. b) The perimysium is the intermediate layer of the ECM that covers each 
fascicle. c) The endomysium is the innermost layer of the ECM and surrounds each fibre. ECM, 
extracellular matrix (adapted and modified from www.dkimages.com). Chapter 1. Background 
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chains,  while  the  actin  has  only  two  polypeptide  chains  namely,  troponin  and 
tropomyosin (Figure 1.3).  
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.1.3.  Postnatal growth and development 
Generally,  postnatal  growth  and  development  of  the  muscular  tissue  occurs  via  the 
elongation and increase in diameter of the muscle fibres (hypertrophy). Soon after birth, 
all muscle fibres have gained their contractile properties. A fully mature masticatory 
muscle often contains different subpopulations of slow, fast and hybrid muscle fibres 
(Ringqvist et al., 1982). However, depending on functional demands, the muscles of 
mastication  can  undergo  a  transitional  state  recruiting  different  muscle  fibres 
Figure 1.3: The motor unit in muscle fibres. Once there is an action stimulus, calcium ions 
binds  to  troponin,  which  subsequently  changes  the  tropomyosin  configuration  allowing  the 
interaction between both actin and myosin molecules, causing contraction and shortening of the 
muscle fibre. This contraction requires energy which is generated by the myosin heavy chain 
(MyHC)  heads  which  contains  an  adenosine  triphosphate  (ATP)  site  and  an  enzyme  called 
ATPase which hydrolyses the ATP into adenosine diphosphate (ADP) and provides the required 
energy. P: Released phosphate (adapted and modified from http://www.octc.kctcs.edu). 
 
ADP+P 
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(Kobayashi et al., 2001) and various contractile protein isoforms (Boyd et al., 1989). 
This  heterogeneity  in  muscle  structure  may  allow  for  adaptability  to  different 
developmental (Monemi et al., 1996; Raadsheer et al., 1996) hormonal (Eason et al., 
2000) and functional demands (Auluck et al., 2005) during postnatal life. 
 
Postnatal masseter muscle development has been largely related to mandibular growth 
(Yonemitsu  et  al.,  2007).  Both  the  deep  and  the  superficial  bellies  of  the  masseter 
muscle are inserted onto the posterior surface of the ramus and mandibular gonial angle, 
respectively.  The  posterior  surface  of  the  mandible  undergoes  progressive  postnatal 
remodelling, and therefore the masseter muscle is in a continuous alert state to readjust 
its site of insertion and so adapt to postnatal mandibular changes (Sperber, 1989).  
 
1.2.1.4.  Masseter muscle fibre types 
Several methods have been employed to classify muscle fibres (e.g. histochemical typ I, 
IIA and IIB fibres) (Brook and Kaiser, 1970; Barnard et al., 1971). However, with the 
evolution  of  science,  new  classifications  have  been  implemented  using  mainly 
molecular genetic techniques. This scheme includes the transcriptome (gene expression) 
and  proteomic  (protein)  expression  properties  of  the  myosin  heavy  chain  (MyHC) 
proteins (Gorza, 1990; Smerdu et al., 1994; Termin et al., 1989). The human masseter 
muscle has been reported to have various MyHC proteins encoded by various myosin 
heavy chain genes (MYH) (Table 1.1).  
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Table 1.1: Myosin heavy chain genes and endcoded proteins that have been used to classify 
human masseter muscle fibres.  
MyHC protein isoforms  Encoding 
gene* 
Description 
MyHC I  
(Smerdu et al., 1994) 
 
MyHC IIa 
(Eriksson and Thornell, 1983) 
 
(Ringqvist et al., 1982) 
MYH7 
 
 
MYH2 
-Reported in slow contracting muscle fibres 
 
 
- Reported in fast contracting muscle fibres 
 
 
-Both I and IIa MyHC isoforms have also been present in 
hybrid fibres where the masseter muscle can shift from slow 
to  fast  contracting  proteins  or  vice  versa,  depending  on 
functional demands 
MyHC IId/x 
(Smerdu et al., 1994) 
MYH1  -Reported  in  faster  contracting  muscle  fibres  as  well  as 
hybrid fibres with MyHC IIa but not MyHC I   
MyHC α –cardiac  
(d’Albis et al., 1993) 
MYH6  -Expressed  in  both  the  masseter  muscle  as  well  as  the 
cardiac  muscle  and  was,  therefore,  called  alpha  cardiac 
protein 
 
-Co-expressed in hybrid fibres  
MyHC embryonic 
(Monemi et al., 1996) 
 
MyHC neonatal 
(Sciote et al., 2003) 
MYH3 
 
 
MYH8 
-Both proteins are evident in the pre- and postnatal life of 
the masseter muscle as well as other muscles of mastication, 
which  tend  to  be  replaced  by  fast  or  slow  contracting 
isoforms in the postnatal form of other skeletal muscles such 
as limb muscle 
 
-Both proteins have been co-expressed in hybrid fibres 
MyHC: Myosin heavy chain protein. MYH: Myosin heavy chain gene. *(Yoon et al., 1992; Shrager et al., 
2000) 
 
 
1.2.1.5.  Masseter muscle extracellular matrix 
 The  ECM  is  a  versatile  structure  which  can  undergo  continuous  remodelling  via 
degradation and deposition. The synchronized rhythm between these two processes and 
the ability of the ECM proteins to perform these tasks under normal physiologic or 
pathologic  conditions  is  referred  to  as  ECM  turnover  (Stetler-Stevenson,  1996). 
Fibronectin, which is one of the non-collagenous glycoproteins, has been reported to 
regulate deposition (Sottile and Chandler, 2005), while the enzyme family of matrix 
metalloproteinases  (MMPs)  have  been  considered  to  control  degradation  during 
pathologic conditions (Stetler-Stevenson, 1996). Expression of the MMP enzymes has 
also  been  observed  during  normal  biological  conditions  such  as  cell  migration  and 
morphogenesis (Werb and Chin, 1998). Up- or down-regulation of the MMPs is said to Chapter 1. Background 
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be  regulated  by  a  group  of  other  enzymes  namely,  the  tissue  inhibitor  of 
metalloproteinases (TIMPs) (Lewis et al., 2001).   
 
The masseter muscle has been reported with an embryonic type of fibronectin which 
was not present in somatic cells (Price et al., 1998), as well as some of the MMPs and 
TIMPs such as MMP1, MMP2, MMP9, and the TIMP2 (Singh et al., 2000; Tippett et 
al., 2008).  
 
Both  muscle  fibres  (Pavlath  et  al.,  1998)  and  the  ECM  (Goldspink,  1998)  play  an 
important role in muscle adaptation and regeneration. Inability of the masseter muscle 
to attain normal growth or undergo remodelling has been reported to affect craniofacial 
morphology (Lowe, 1980; Schessl et al., 2006).  
 
1.3.  CRANIOFACIAL MORPHOLOGY 
Craniofacial morphology is orchestrated by both skeletal structures and muscular tissue 
(Lowe, 1980; Helm and German, 1996; Bresin and Kiliaridis, 2002; Satiroğlu et al., 
2005). Of the skeletal structures, the cranial base, the maxilla and the mandible have 
been found to contribute largely to variations in craniofacial morphology. The following 
sections will briefly describe the normal intrauterine growth and postnatal development 
of the cranial base, the maxilla and the mandible. 
 
1.3.1.  THE CRANIAL BASE 
 
1.3.1.1.  Intrauterine growth 
The cranial base appears in the 8
th week during intrauterine life as four midline and two 
lateral  structures which  later form  the frontal, ethmoid, sphenoid,  occipital,  and the 
temporal  bones.  These  bones  are  formed  through  endochondral  ossification  and  are 
united via synchondroses. The mid-sphenoidal synchondrosis divides the cranial base 
into anterior and posterior sections. Each section is derived from a distinct embryonic 
origin. The anterior cranial base is derived from migration of the neural crest cells, 
while the posterior portion is derived from cells of the paraxial mesoderm (Sperber, 
1989).  
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1.3.1.2.  Postnatal growth and development 
The general trend of postnatal growth and development of the cranial base is seen as a 
downward  and  forward  movement  which  has  been  mainly  attributed  to  downward 
development of the brain (Moss, 1968) and forward displacement of the spinal column 
(Björk,  1950).  The  anterior  cranial  base  is  determined  radiographically  as  a  line 
extending  from  nasion  to  the  mid-point  of  sella  turcica.  A  line  from  sella  turcica 
extending posteriorly to basion determines the posterior cranial base (Björk, 1955). The 
maxilla is attached to the anterior part while the mandible articulates with the posterior 
section. Discrepancies of the anterior cranial base can affect mid facial development 
(Ma  and  Lozanoff,  1996),  whereas  posterior  cranial  base  discrepancies  may  have  a 
marked influence on the position of the mandible (Ngan et al., 1997). 
 
1.3.2.  THE MAXILLA 
 
1.3.2.1.  Intrauterine growth 
Both  maxillary  processes  of  the  1
st  brachial  arch  give  rise  to  the  maxilla  and  the 
secondary palate, which unite at the middle at the median palatal suture. The maxilla 
grows by intramembranous ossification that begins during the 7
th week of intrauterine 
life.  
 
1.3.2.2.  Postnatal growth and development 
Postnatal growth  and development of the maxilla is seen in vertical, horizontal and 
transverse  dimensions.  Both  vertical  and  horizontal  development  of  the  maxilla  are 
affected  by  downward  and  forward  displacement  of  the  cranial  base.  During  this 
displacement, the sutures between the maxilla and the cranial base tend to open up and 
the space is filled with  bone deposits which contribute to vertical maxillary growth 
(Björk, 1955). Horizontal growth of the maxilla is also governed by downward and 
forward movement of the cranial base, as dramatic maxillary anterior bone resorption is 
evident and incremental bone deposition at the posterior tuberosity area occurs. This is 
to  accommodate  the  eruption  of  the  permanent  molar  teeth  later  in  life  (Björk  and 
Skieller, 1977). Transverse development of the maxilla is brought about by an increase 
in width of the median palatal suture which is more evident in the molar region than the 
anterior mid-canine area (Björk and Skieller, 1977; Korn and Baumrind, 1990). Sutural Chapter 1. Background 
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growth in the transverse and horizontal planes is completed around the age of 17 years 
(Björk, 1966), while vertical growth is still evident at the age of 21 years (Björk and 
Skieller, 1977). Dimensional variation of the maxilla in the vertical (Schendel et al., 
1976), horizontal (Guyer et al., 1986) and transverse (Wolford and Stevao, 2002) planes 
is seen in patients with craniofacial deformities. 
 
1.3.3.  THE MANDIBLE 
 
1.3.3.1.  Intrauterine growth 
The  mandible  appears  as  two  elevations  or  a  bilateral  structure  in  the  6
th  week  of 
intrauterine life. The paired bony structures of the mandible are joined together in the 
midline by a fibrocartilage in the mandibular symphysis during intrauterine life. By the 
end of the 1
st year of foetal life both halves have united by endochondral ossification. 
The mandible develops entirely by intramembranous ossification and grows by direct 
surface apposition, resorption and remodelling, except for the condyle which undergoes 
endochondral ossification and grows by synchondroses (Sperber, 1989).  
 
1.3.3.2.  Postnatal growth and development 
Postnatal growth and development of the mandible is more complicated than for other 
craniofacial  structures.  This  has  been  explained  by  Enlow  and  Harris  (1964)  in  a 
detailed study of 25 specimens of human mandibles aged 4 -12 years.  They found that 
during growth, each part of the mandible (coronoid process, condylar process, the neck 
of  the  condyle,  the  ramus,  the  body  of  the  mandible  and  the  chin)  undergoes 
remodelling to maintain the size and shape of the mandible. However, both the condyle 
(Marshall,  1958)  and  the  posterior  surface  of  the  ramus  were  more  likely  to  be 
mandibular  growth  sites  (Proffit  and  Fields,  2000)  and  to  undergo  progressive 
remodelling  until  later  in  life  (Enlow  and  Harris,  1964).  The  mandible  grows  in 
transverse, horizontal, and vertical directions. Transverse growth ceases first, prior to 
puberty, followed by horizontal growth at the age of 14-15 years in females and two 
years later in males (Hellman, 1927; Marshall, 1958). Similar to maxillary growth, the 
vertical growth of the mandible continues after horizontal growth has slowed or ceased 
and may extend until the age of 40 years (Lewis and Roche, 1988). This is to match the 
general vertical growth of the face that continues throughout life (Hellman, 1927). Both Chapter 1. Background 
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the size (Sanborn, 1955) and the position of the mandible (Björk, 1950; Kao et al., 
1995) are affected in patients with variable craniofacial discrepancies.  
 
One of the unique postnatal developmental features of the mandible that can cause large 
variations in vertical craniofacial features is mandibular growth rotation. Mandibular 
rotations are more pronounced than maxillary rotations (Björk and Skieller, 1977) and 
were first described by Björk (1955) with the aid of metallic implants. Björk (1969) 
described three centres of rotation of the mandible; the anterior, posterior or middle 
parts  of  the  mandible  (Figure  1.4).  The  reason  why  these  rotations  vary  from  one 
individual  to  another  is  not  clearly  understood.  However,  growth  of  the  condyle 
(Dibbets, 1990), the lower border of the mandible (Björk, 1969) and the cranial base 
(Björk and Skieller, 1983) all contribute to mandibular growth rotations.  
 
 
 
 
Figure 1.4: Mandibular growth rotations. a) If the centre of rotation is located at the lower 
anterior part of the mandible (incisor area), the mandible will move in a forward direction with 
an increased posterior face height and a normal growth of the lower anterior face height. b) An 
inverse relationship between the anterior and posterior face heights (increased posterior and 
reduced anterior face heights and vice versa) would occur if the centre of rotation is at the 
midpoint of the mandible (premolar region). c) If the posterior part of the mandible (the most 
distal lower molar area) is the centre of rotation, the mandible will rotate backwards with an 
increase in the lower anterior face height. d) When the mandible achieves a pendulum movement 
and swings either forwards or backwards around the TMJ this is considered a simple mandibular 
rotation rather than a growth rotation. This can be seen in patients with muscular dystrophy, 
where the mandible simply rotates backwards as a result of weak muscles, or during orthodontic 
treatment which causes extrusion of the molar teeth. TMJ: Temporo-mandibular joint. Chapter 1. Background 
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Variations in the growth or development of craniofacial skeletal or muscular tissues, 
during intrauterine or postnatal periods, may cause differences in craniofacial features. 
These differences could be within what is considered a normal range, as seen between 
individuals, or could be extreme as seen in patients with craniofacial deformities.  
 
1.4.  CRANIOFACIAL DEFORMITIES 
Craniofacial deformity is a broad term that includes all anomalies associated with any of 
the skull bones (Sperber, 1989). The UK National Statistics Office (2007) reported 683 
live births with congenital craniofacial anomalies. The majority were cleft patients (324 
live births), followed by syndromic patients with craniofacial deformities as a result of 
chromosomal  abnormalities  (320  live  births),  craniosynostotic  conditions  (28  live 
births) and the least were syndromic patients with craniofacial malformations that have 
developed due to teratogenic factors (11 live births). Nevertheless, other craniofacial 
developmental  deformities  have  been  reported  in  non-syndromic  individuals  (Björk, 
1950; Sassouni, 1969; Opdebeeck and Bell, 1978). As a result of the variable clinical 
phenotypes  and  different  pathogenic  mechanisms  of  craniofacial  abnormalities,  the 
Committee  on  Nomenclature  and  Classification  of  Craniofacial  Anomalies  of  the 
American  Cleft  Palate  Association  proposed  a  simple  classification  of  craniofacial 
anomalies  based  on  aetiological  factors,  anatomical  features  and  treatment  need 
(Whitaker  et  al.,  1981).  This  classification  has  grouped  patients  into  five  main 
categories:  1)  Clefts;  2)  Synostoses;  3)  Atrophy  (or  hypoplasia);  4)  Neoplasia  (or 
hyperplasia); 5) Unclassified.  
 
The unclassified craniofacial anomalies include either single or multiple organs and are 
best described by the shape of the affected part of the body (Whitaker et al., 1981). The 
organs are the tongue, nose, eyes, lips, ears and jaws. Single organ deformities are often 
seen in non-syndromic individuals while, if multiple organs are involved, the situation 
is  mainly  syndromic  and  can  be  seen  as  part  of  any  other  craniofacial  anomalies. 
Although the mechanism of development of unclassified anomalies might be different 
between syndromic and non-syndromic individuals, the clinical phenotype is similar. 
Orthodontists are often confronted with jaw deformities seen in all three dimensions of 
both syndromic and non-syndromic individuals. An example of jaw deformity seen in 
syndromic patients is the retruded position of the maxilla  observed in  cleft patients Chapter 1. Background 
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(Meazzini et al., 2008) or Crouzon syndrome (Wilkie, 1997), a prognathic mandible in 
Klinefelter syndrome (Gorlin et al, 1965), long face deformity seen in patients with 
muscular  dystrophy  (Kreiborg  et  al.,  1978)  and  unilateral  mandibular  discrepancy 
reported in hemifacial microsomia (Poswillo, 1974). Figure 1.5, shows the similarity of 
clinical appearance of jaw deformities observed in syndromic patients compared to non-
syndromic individuals.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Unclassified jaw deformities seen in all three dimensions of both syndromic and 
non-syndromic individuals. a) A female patient with Crouzon syndrome (fibroblast growth factor 
receptor-FGFR- gene mutation) having a prognathic lower jaw appearance as a result of an 
under developed maxilla, while the non-syndromic female has no craniosynostoses or any other 
deformities and is showing similar clinical jaw appearance. b) Two patients with a similar long 
face  clinical  appearance.  The  syndromic  patient  has  muscular  dystrophy,  while  the  non-
syndromic female has abnormal vertical facial growth with no muscular disease. c) A syndromic 
female with hemifacial microsomia compared to a non-syndromic female with similar unilateral 
mandibular discrepancy as a result of hemimandibular hyperplasia. Chapter 1. Background 
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1.4.1.  DESCRIPTION OF JAW DEFORMITIES 
Jaw deformities are described clinically based on the vertical, horizontal and transverse 
position  of  the  mandible  in  relation  to  the  maxilla  (Björk,  1955).  Patients  with 
transverse  skeletal  problems  have  been  reported  with  asymmetric  masseter  muscle 
structure (Kwon et al., 2007) and function (Dong et al., 2008), which may subsequently 
result in various transcriptome levels, depending on the investigated side of the masseter 
muscle. This aspect is beyond the scope of this project. Therefore, only vertical and 
horizontal jaw deformities will be discussed further.  
 
Jaw deformities often have both dental and skeletal components including, the maxilla, 
the mandible and both upper and lower dentitions. For diagnostic purposes and to ease 
treatment planning, orthodontists have combined both dental and skeletal components 
and have identified four basic facial patterns (Sassouni, 1969). Two facial patterns were 
reported  in  the  vertical  dimension,  the  long  (Schendel  et  al.,  1976)  and  short 
(Opdebeeck and Bell, 1978) faces, and two other extremes have been identified in the 
horizontal  dimension,  namely  Class  II  and  Class  III  (Houston  et  al.,  1992).  These 
patterns  were  applied  during  the  assessment  of  both  syndromic  and  non-syndromic 
individuals regardless of the aetiological factors that have resulted in the development 
of these features.  
 
1.4.2.  BASIC CRANIOFACIAL PATTERNS 
 
1.4.2.1.  Vertical facial patterns 
Orthodontists  usually  assess  vertical  facial  development  by  measuring  the  lower 
anterior face height (LAFH) which extends from under the nose to the lowest point of 
the chin (Houston et al., 1992). The LAFH is compared to general facial proportions, 
and in average cases is almost equal to the mid and upper anterior face heights. This 
simple method is often used clinically to classify patients into average, long or short 
faces.  Other  dental  and  radiographic  features  are  also  used  to  confirm  the  clinical 
diagnosis. These are listed below. 
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1.4.2.1.1.  The long face 
Generally,  patients  with  a  long  face  pattern  exhibit  increased  clinical  vertical 
dimensions, including lower and total anterior face heights and excessive display of the 
upper anterior teeth, which can be seen with or without dental anterior open bite (AOB). 
Radiographic findings include increased total and lower anterior face heights, vertical 
maxillary  excess  and  an  increased  mandibular  gonial  angle  (Schendel  et  al.,  1976; 
Fields et al., 1984) (Figure 1.6).  
 
1.4.2.1.2.  The short face 
Short  face  individuals  have  clinically  reduced  vertical  lower  and  total  anterior  face 
heights, dental deep bite, and a markedly reduced mandibular gonial angle as seen on 
radiographs (Opdebeeck and Bell, 1978) (Figure 1.6).  
 
1.4.2.2.  Horizontal facial patterns 
Horizontal  facial  patterns  are  assessed  by  the  antero-posterior  (AP)  position  of  the 
mandible in relation to the maxilla and the cranial base (Björk, 1950). A patient is 
diagnosed clinically as having an average antero-posterior profile when the position of 
the mandible is  at  or slightly behind  the maxilla (Houston et  al.,  1992).  Two main 
groups are associated with horizontal patterns, the Class II and Class III. 
 
1.4.2.2.1.  Class II 
Skeletal Class II is described clinically by the position of the mandible posterior to the 
maxilla with a retrognathic – bird-beak like appearance (Björk, 1955). Similarly, the 
dental  appearance  is  characterised  by  a  distal  position  of  either  the  lower  incisors 
(Foster  and  Day,  1974)  or  the  lower  first  molars  (Ackerman  and  Proffit,  1969)  in 
relation to the corresponding upper dentition. The radiographic appearance of a Class II 
pattern is often characterised by features such as a long anterior cranial base (Hopkin et 
al., 1968) a short posterior cranial base (Sayin and Turkkahraman, 2005), an obtuse 
cranial base angle (Enlow et al., 1982), a protruded position of the maxilla in relation to 
the cranial base (Ishii et al., 2002), increased maxillary length (Dhopatkar et al., 2002) 
and short mandibular body length (Enlow et al., 1982) (Figure 1.6).  
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1.4.2.2.2.  Class III 
Skeletal Class III is described clinically by forward positioning of the mandible ahead 
of the maxilla to give a prognathic appearance. Dentally, the lower incisors (Foster and 
Day, 1974)  or the lower first  molars  (Ackerman and Proffit,  1969)  are  in  a mesial 
position in relation to the corresponding upper dentition. Radiographically, Class III 
patients are often characterised by a short anterior cranial base (Björk, 1950; Hopkin et 
al., 1968; Ishii et al., 2002), a large posterior cranial base (Ngan et al., 1997) and an 
acute cranial base angle (Battagel, 1993; Proff et al., 2008). The maxilla may be short in 
horizontal  length  (Guyer  et  al.,  1986)  while  the  mandibular  body  length  may  be 
significantly increased (Sanborn, 1955, Dhopatkar et al., 2002) (Figure 1.6).  
 
Patient classification according to the various facial patterns is further complicated for 
two reasons. First, the long face (Schendel et al., 1976), short face (Opdebeeck and Bell, 
1978), Class II (Antonini et al., 2005) and Class III (Jacobson et al., 1974) have all been 
reported with various subdivisions and varying degrees of maxillary, mandibular and 
dental discrepancies. Second, it is common to see patients with a combination of both 
vertical and horizontal patterns rather than a single dimensional discrepancy (e.g. Class 
III long face or a Class II short face patient) (Sassouni, 1969; Proffit and White, 1990). 
The difficulties associated wih patient classification for genetic research (phenotype-
genotype relationship) will be discussed in Chapter 5. Figure 1.6 shows the classical 
appearance of the four basic facial patterns compared to an average individual. 
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Figure 1.6: The classical clinical, dental and radiographic appearance of the various facial 
patterns. All patients were non-syndromic. a) Clinical long face pattern showing radiographic 
obtuse  mandibular  gonial  angle  and  a  dental  AOB.  b)  Short  face  pattern  with  reduced 
mandibular gonial angle and a dental deep bite. c) A patient with average vertical and horizontal 
clinical, radiographic and dental features. d) A clinical Class II pattern with a retruded position 
of both the mandible and the lower dentition. e) A Class III pattern with a protruded appearance 
of both the mandible and the lower dentition.  Chapter 1. Background 
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1.4.3.  PREVALENCE OF CRANIOFACIAL PATTERNS 
The  prevalence  of  different  facial  patterns  varies  between  different  populations 
(Altemus, 1959; Foster and Day, 1974; Soh et al., 2005; Hassan, 2006). However, most 
of  these  epidemiological  studies  were  based  on  dental  patterns  rather  than  skeletal 
components of non-syndromic individuals (Table 1.2).  
 
Table 1.2: Vertical and horizontal dento-facial patterns in various populations. 
Population type  n  Age range 
(Years) 
Horizontal 
patterns 
Vertical 
patterns 
Class 
II% 
Class 
III% 
DB 
% 
AOB 
% 
Asians  (Soh et al., 2005) 
Chinese 
Malaysian 
Indians 
 
258 
60 
21 
 
17-22 
17-22 
17-22 
 
26 
18 
57 
 
23 
27 
5 
 
11 
13 
5 
 
5 
2 
0 
Africans 
Nigerians (Onyeaso, 2004) 
Kenyans (Ng’ang’a et al., 1996) 
African Americans (Altemus, 1959) 
 
334 
919 
3500 
 
12-17 
13-15 
12-16 
 
14 
10 
11 
 
12 
0 
5 
 
9 
7 
* 
 
14 
8 
* 
Caucasians 
British Caucasian (Foster and Day, 1974) 
Saudi Arabian Caucasian (Hassan, 2006) 
 
1000 
743 
 
11-12 
17-24 
 
27 
34 
 
3 
4 
 
54 
34 
 
2 
20 
n: Number of subjects included in the study. DB: Deep bite. AOB: Anterior open bite. *Not reported.  
 
 
Although the Class II and deep overbite patterns have a general higher prevalence than 
the Class III and AOB malocclusion in most populations, the Class III and AOB cases 
were more likely to seek surgical correction of their deformities later in life (Al-Deaij, 
2001; Chew, 2006) with females having a generally higher ratio than males, almost 2:1 
(Bailey et al., 2001; Ong, 2004). This was mainly attributed to the aesthetic (Ong, 2004) 
and functional (speech and chewing) problems associated with Class III and open bite 
cases (Rivera et al., 2000).  
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1.4.4.  AETIOLOGY OF CRANIOFACIAL PATTERNS 
 As stated earlier, vertical and horizontal jaw deformities can be seen in both syndromic 
and  non-syndromic  individuals.  However,  the  mechanism  of  development  of  such 
anomalies in syndromic patients has been mainly attributed to variations and mutations 
on a genomic level, such as T-box gene mutations in cleft patients (Arnold et al., 2006) 
or fibroblast growth factor receptor (FGFR) gene mutations, seen in craniosynostotic 
conditions. In contrast, observational genetic studies of non-syndromic individuals, with 
developmental jaw deformities have revealed a multifactorial type of inheritance (Litton 
et al., 1970) and varying degrees of effect of both genetic and environmental factors 
(Hunter, 1965; Dudas and Sassouni, 1973; Nakata et al., 1973). This may indicate the 
need  for  a  more  complex  approach  to  evaluate  the  genetic  predispositions  of 
developmental  craniofacial  patterns  seen  in  non-syndromic  individuals  than  for 
syndromic patients. This is due to the fact that the transcriptome expression of non-
syndromic individuals is modulated by both genetic and environmental factors, which 
makes it difficult to relate a specific gene to the clinical morphology. This suggests the 
importance  of  considering  both  genomic  and  transcriptome  backgrounds  during  the 
assessment of non-syndromic individuals with various craniofacial patterns. 
 
1.4.4.1.  Genetic studies of non-syndromic craniofacial patterns 
Genetic studies aimed at observing familial inheritance of non-syndromic craniofacial 
patterns between parents and offspring (Hunter et al., 1970; Johannsdottir et al., 2005), 
siblings (Harris and Johnson, 1991) and twins (Hunter, 1965; Carels et al., 2001), have 
revealed  that  linear  features,  such  as  mandibular  body  length  (Carels  et  al.,  2001; 
Johannsdottir et al., 2005), lower anterior (Dudas and Sassouni, 1973)  and posterior 
face heights (Johannsdottir et al., 2005) were all under a strong genetic influence. While 
upper  anterior  face  height  has  been  found  to  be  influenced  by  genetic  factors  only 
during  the  early  stages  of  development,  later  in  life  it  has  largely  responded  to 
environmental demands (Dudas and Sassouni, 1973).  Angular features on the other 
hand,  such  as  gonial  angle,  Sella-Nasion-A-point  (SNA)  and  Sella-Nasion-B-point 
(SNB) are largely controlled by environmental factors (Carels et al., 2001).  
 
The use of familial information is considered a valuable tool to ascertain the features 
inherited  from  other  craniofacial  parameters  which  can  respond  to  environmental Chapter 1. Background 
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stimulus (Harris and Kowalski, 1976; Carels et al., 2001). This would help clinicians to 
innovate  appliances  or  customise  treatment  to  take  advantage  of  the  surrounding 
environment and can contribute positively to the remodelling response and thereby help 
to stabilise the results of treatment.  
 
1.4.4.2.  Environmental factors affecting craniofacial patterns 
Several  environmental  factors,  for  example,  thumb  sucking  (Heimer  et  al.,  2008), 
respiratory need (Linder-Aronson, 1979), mouth breathing (Faria et al., 2002), muscular 
dystrophy (Eckardt and Harzer, 1996) and obesity (Sadeghianrizi et al, 2005) have been 
associated with specific craniofacial patterns. However, the mechanical load exerted by 
the  masticatory  muscles  (Kiliaridis,  1995)  in  response  to  normal  physiologic 
movements (Kubota et al., 1998), pathologic conditions (Matic et al., 2007), type of diet 
(Helm and German, 1996), orthodontic appliances  (Kuster and  Ingervall, 1992) and 
exercise (English  and Olfert, 2005)  have also  been  considered  major environmental 
stimuli that may alter craniofacial morphology (Gedrange and Harzer, 2004).  
 
Furthermore, masseter muscle activity (Kobayashi et al., 2001), size (Satiroğlu et al., 
2005),  volume  (Kitai  et  al.,  2002),  thickness  (Kiliaridis  and  Kalebo,  1991),  cross-
sectional area (Kitai et al., 2002), direction and orientation of the muscle fibres (Ariji et 
al.,  2000)  and  masticatory  efficiency  (Kim  and  Oh,  1997)  have  been  found  to  be 
significantly different between patients with variable craniofacial patterns. 
 
1.5.  MASSETER  MUSCLE  STRUCTURE  AND  FUNCTION  IN  RELATION 
TO CRANIOFACIAL PATTERNS 
 
1.5.1.  MASSETER MUSCLE ACTIVITY 
Muscular activity can be recorded using electromyography (EMG). Using this method it 
has been shown that muscle activity in Class III long face subjects is lower than in 
subjects  with  Class  I  average  and  long  faces,  Class  III  average  faces  and  Class  II 
individuals with average and long faces (Cha et al., 2007). Masseter muscle activity in 
relation  to  pure  vertical  features  has  been  reported  as  being  lowest  in  long  face 
individuals (Lowe, 1980) and highest in short face patients (Ueda et al., 2000; Serrao et 
al., 2003) compared to controls. Chapter 1. Background 
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1.5.2.  MASSETER MUSCLE SIZE AND SHAPE 
The size, volume, thickness, cross-sectional area and the direction and orientation of the 
muscle fibres have been measured using different types of magnetic resonance imaging 
(MRI) (van Spronsen et al., 1992), computerized tomography (CT scan) (Kitai et al., 
2002), and ultrasonography (Kiliaridis and Kalebo, 1991). The masseter muscle  has 
been reported as short, thin, of low volume and having a small cross sectional area in 
Class III (Ariji et al., 2000; Kitai et al., 2002) and long face patients (Kiliaridis and 
Kalebo, 1991; van Spronsen et al., 1992) when compared to controls. However, when 
compared to other facial patterns, long face individuals showed the thinnest, while short 
face patients exhibited the thickest masseter muscle volume compared to average face 
subjects (Satiroğlu et al., 2005). Furthermore, the orientation of the masseter muscle 
fibres in Class III patients compared to the controls was found to be in a more forward 
direction,  forming  an  obtuse  angle  with  the  Frankfort  horizontal  plane  (Ariji  et  al., 
2000; Kitai et al., 2002). It has been suggested that the more upright the direction of the 
masseter muscle fibres (as in short face patients) in relation to the Frankfort horizontal 
or functional occlusal planes, the greater the occlusal forces (Kitai et al., 2002).  
 
Other studies have assessed the relationship between the volume of the masseter muscle 
and  specific  craniofacial  skeletal  parameters.  The  results  have  indicated  a  positive 
correlation between masseter muscle volume and the ramus height (Kubota et al., 1998), 
posterior  face  height  (Benington  et  al.,  1999)  and  the  cross-sectional  area  of  the 
zygomatic arch (Kitai et al., 2002), while a negative correlation was observed in relation 
to mandibular inclination and gonial angle (Kubota et al., 1998; Benington et al., 1999). 
No relationship was found between masseter muscle volume and cranial width (Kitai et 
al., 2002). Furthermore, general anterior and posterior craniofacial vertical dimensions 
were more related to masseter muscle volume than cross-sectional area (Boom et al., 
2008). 
 
1.5.3.  MASSETER MUSCLE EFFICIENCY  
Masticatory  muscle  efficiency  has  been  defined  as  the  capability  of  the  muscles  to 
produce different functional commands such as swallowing, simultaneous chewing, and 
maximum occlusal bite (Gambareli et al., 2007). These commands can be affected by 
several factors such as the number of teeth acting, as well as the bite forces generated by Chapter 1. Background 
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the muscles of mastication. Therefore, masseter muscle efficiency has been assessed 
mainly via recording occlusal bite forces (Hunt and Cunningham, 1997) and counting 
the number of occlusal contacts (Shiratsuchi et al., 1991). Both long face individuals 
(Ingervall and Helkimo, 1978; Proffit et al., 1983) and Class III patients (Ellis et al., 
1996; Iwase et al., 2006) have demonstrated the lowest number of occlusal contacts and 
reduced bite forces when compared to average, short face and Class II subjects.  
 
1.5.4.  MASSETER MUSCLE FIBRE TYPE COMPOSITION 
Patients with short faces and dental deep bites have been reported as possessing higher 
numbers of fast contracting than slow contracting muscle fibres (Rowlerson et al., 2005; 
Hunt et al., 2006). On the other hand, both long face and average vertical dimension 
patients had higher proportions of slow contracting than fast contracting fibres, with the 
controls having a higher percentage than long face subjects. These findings were 50% 
and 43%, respectively (Boyd et al., 1989). Class II and Class III patients on the other 
hand, had a similar fibre type distribution (Rowlerson et al., 2005) with the number of 
slow contracting fibres being greater than that of fast contracting fibres. Nevertheless, 
Class III subjects had a large presence of hybrid fibres, particularly on the non-chewing 
side when compared to the Class I controls (Ringqvist, 1974). This was also evident in 
long face patients where hybrid fibres composed 43% of the fibre types compared to 
short face patients with only 9% (Rowlerson et al., 2005).  
 
The  relationship  between  craniofacial  form  and  muscle  structure  has  been  further 
investigated  based  on  the  MyHC  protein  content.  Neonatal  MyHC  that  is  usually 
abundant in the hybrid fibres has been found to be inversely related to the number of 
occlusal  contacts  (i.e.  the  lower  the  number  of  occlusal  contacts  the  higher  the 
expression of the MyHCneo protein) (Nelson-Moon et al., 1998; Hunt et al., 2006).  
 
The question remains as to whether the reported muscle differences between patients 
with variable craniofacial phenotypes were due to pre-programmed genetic defects of 
masseter muscle composition and hence function or due to adaptive behaviour by the 
masticatory  musculature  in  response  to  abnormally-developing  skeletal  structures. 
Further investigations have, therefore, been undertaken to understand musculo-skeletal 
function in patients with different craniofacial patterns. Chapter 1. Background 
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1.6.  EXPERIMENTAL STUDIES OF MUSCULO-SKELETAL FUNCTION 
 
1.6.1.  THE EFFECT OF DIET 
Animal models have been used to assess the effect of the physical properties of diet on 
the  development  of  craniofacial  phenotypes  via  the  mechanical  load  exerted  by  the 
masseter muscle. Pigs (Helm and German, 1996) and rats (Kiliaridis et al., 1985) that 
were  fed  a  soft  diet  had  less  masseter  muscle  activity  and  increased  vertical  facial 
development,  but  reduced  growth  rates  of  the  cranial  base  dimensions  and  bone 
deposition at the gonial region and the lower border of the mandible, compared to the 
controls  who  were  fed  a  normal  diet.  Further  investigation  was  recommended  to 
establish  the  effect  of  diet  composition  on  muscular  activity  and  bone  remodelling 
(Kiliaridis et al., 1985). 
 
1.6.2.  THE EFFECT OF EXERCISE 
Masticatory muscle exercise has been found to increase the functional capabilities of the 
masseter muscle (Kiliaridis, 1995). However, very few researchers have investigated the 
recruitment of the mechanical and physical properties of the masseter muscle produced 
by exercise as a supporting treatment for different craniofacial deformities, particularly 
patients with anterior open bite (AOB). English and Olfert (2005) demonstrated that 
masseter  muscle  exercise  could  be  used  synergistically  with  other  orthodontic 
appliances to treat skeletal AOB without the need for orthognathic surgical correction. 
However, extensive research is still required to explain musculo-skeletal adaptability to 
exercise (Hamilton and Booth, 2000).  
 
1.6.3.  THE EFFECT OF ORTHODONTIC APPLIANCES 
The mechanism of action of posterior bite blocks on the treatment of patients with AOB 
has  been  explained  in  terms  of  intrusion  of  the  posterior  teeth,  allowing  a  closing 
autorotation of the mandible and an upright direction of the masseter muscle fibres in 
relation to the occlusal plane, which subsequently increases the occlusal bite forces and 
masseter muscle activity (Kuster and Ingervall, 1992). This mechanism suggests that the 
masseter muscle adapts to modified skeletal and dental morphology. In contrast, the 
results of Bresin and Kiliaridis (2002) have explained the action of bite blocks in a 
reverse manner. This later study included two groups of young rats, one of which has Chapter 1. Background 
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been fed a hard diet while the other was fed  a soft diet; the aim being to  generate 
masseter muscles with different functional capabilities. Both groups were then supplied 
with posterior bite blocks. The rats with the soft diet had weaker muscle activity which 
in turn affected the intrusion capacity of the bite blocks compared to the hard diet group. 
This work suggests that masseter muscle efficiency affects the capabilities of bite blocks 
and further adaptability of skeletal structures.  
 
1.6.4.  THE EFFECT OF ORTHOGNATHIC SURGICAL TREATMENT 
The  process  of  orthognathic  surgery  requires  the  integration  of  pre-surgical 
orthodontics, surgery and post-surgical orthodontic phases (Proffit and Fields, 2000). 
The  masseter  muscle  undergoes  a  functional  (Hunt  and  Cunningham,  1997)  and 
structural (Boyd et al., 1989) adaptation in response to the different functional demands 
during the three stages of orthognathic treatment (Kobayashi et al., 2001). Table 1.3 
summarises these differences.  
 
Table  1.3:  The  effect  of the  three stages  of  orthognathic  treatment  on the  structure  and 
function of the masseter muscle. 
Orthognathic treatment stage  Effect on the masseter muscle  Proposed reason 
Pre-surgical  orthodontic stage 
(Kobayashi et al., 2001) 
 
-Increased muscle activity. 
 
-Aligned teeth. 
Surgical stage* 
 (Ellis et al., 1996) 
 
(Mayo et al., 1988) 
 
-Reduced bite force. 
-General muscle atrophy. 
-Reduction in CSA of fast and 
slow fibres in bimaxillary cases. 
 
-Patients cautious 
about the bite. 
Post-surgical orthodontic stage 
Short-term (≥ 1 year) 
(Hunt and Cunningham, 1997) 
 
(Kim and Oh, 1997) 
 
Long-term (1 year < ) 
(Iwase et al., 2006) 
 
 
-Reduced bite force in Class II. 
-Increased bite force in Class III. 
-Reduction in slow fibres. 
-Increase in fast fibres. 
-General rise in muscle 
efficiency but not to the level of 
patients with average facial 
features. 
 
 
-Aligned teeth and 
jaws and improved 
muscle activity. 
-Reduced 
regenerative abilities 
of masseter muscle. 
* Immediately after surgery and up to 6 months following surgery. CSA: Cross sectional area. Chapter 1. Background 
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This has raised the question as to whether the molecular composition of the masseter 
muscle could be considered as a marker for a specific facial pattern or as a predictor for 
the success of treatment. This has led to the investigation of the masseter muscle on a 
gene expression level. 
 
1.7.  GENE EXPRESSION STUDIES OF THE MASSETER MUSCLE 
Due to the lack of knowledge of the full genetic background of the masseter muscle it 
has  been  difficult  to  propose  a  set  of  candidate  genes  to  be  tested  in  response  to 
masseter  muscle  stimulation.  However,  scientists  have  selected  candidate  genes  as 
follows:  
  Genes  which  encode  previously  identified  contractile  and  unique  MyHC 
proteins of the masseter muscle (MYH genes) (Ringqvist et al., 1982; d’Albis et 
al., 1993; Smerdu et al., 1994).  
 
  Genes which encode some of the modulatory proteins which have been reported 
to have a major role in masseter muscle regeneration (such as fibronectin) (Price 
et  al.,  1998),  and  remodelling  (such  as  matrix  metalloprotenases  –  MMPs) 
(Singh et al., 2000).  
 
  Genes  which  have  been  reported  in  regenerating  muscles  in  response  to 
mechanical  stimulus  (such  as  insulin-like  growth  factors  (IGF))  (Goldspink, 
2006; Maricic et al., 2008). 
 
  Myostatin  gene  which  has  been  suggested  to  be  involved  in  the  adaptive 
behaviour of the masseter muscle (Maricic et al., 2008).  
 
Investigation  of  masseter  muscle  genes  in  patients  with  average  and  extreme 
craniofacial patterns has only recently been undertaken, and therefore very few studies 
are cited in the literature. Table 1.4 summarises the main findings of studies related to 
genes  of  the  masseter  muscle  and  their  expression  status  in  relation  to  various 
craniofacial patterns, and in response to different treatment stimuli. 
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Table  1.4:  Studies  of  masseter  muscle  genes  in  relation  to  craniofacial  patterns  and  in 
response to orthognathic surgery.  
Gene symbol  Main study findings 
MYH1 (fast IId/x) 
 (Suchak et al., 2009) 
(Gedrange et al., 2005) 
(Nelson-Moon et al., 1998; Suchak et al., 2009) 
 
-Inverse correlation to MMa  
-Low amounts in both Class II and Class III  
-No differences in long face vs. Ctrl 
MYH2 (fast IIa) 
(Gedrange et al., 2006) 
(Maricic et al., 2008) 
(Harzer et al., 2007) 
(Nelson-Moon et al., 1998; Suchak et al., 2009) 
 
-Higher in Class II than Class III patients  
-Increased following surgery (in both Class II and III) 
-Positive correlation to the DOC 
-No differences in long face vs. Ctrl 
MYH3 (embryonic) 
(Nelson-Moon et al., 1998) 
(Nelson-Moon et al., 1998; Suchak et al., 2009) 
 
-Inverse correlation to the DOC 
-No differences in long face vs. Ctrl 
MYH6 (α –cardiac) 
(Nelson-Moon et al., 1998; Suchak et al., 2009) 
 
-No differences in long face vs. Ctrl 
MYH7 (slow I) 
(Gedrange et al., 2006) 
(Maricic et al., 2008) 
(Harzer et al., 2007) 
(Nelson-Moon et al., 1998; Suchak et al., 2009) 
 
-Higher in Class II than Class III patients 
-Lower expression following surgery 
-Inverse correlation to the DOC 
-No differences in long face vs. Ctrl 
MYH8 (neonatal)  
(Nelson-Moon et al., 1998; Suchak et al., 2009) 
 
-No differences in long face vs. Ctrl 
Fibronectin* 
(Price et al., 1998) 
 
-No differences in long face vs. Ctrl 
MMP1, MMP2, MMP9, TIMP2 
(Singh et al., 2000) 
 
-No differences in long face vs. Ctrl 
Myostatin 
(Maricic et al., 2008) 
(Maricic et al., 2008) 
 
-No differences before and after surgery 
-Reduced expression in females than males 
IGF** 
(Maricic et al., 2008) 
 
-Increased after surgery up to 6 months 
MMa: Maxillary-mandibular angle. Ctrl: Control. DOC: Dental occlusal contacts. MYH: Myosin heavy 
chain genes. MMP: Matrix metalloproteinases. TIMP: Tissue inhibitor metalloproteinases. *Embryonic 
fibronectin splice variant EIIIA. **Insulin-like growth factor I-splice variant Ec (IGF-IEc).  
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It  is  evident  from  the  previous  review  that  the  masseter  muscle  holds  unravelled 
potentials in terms of craniofacial development as well as its adaptive behaviour to 
various treatment modalities. However, the genetic explanation of such potentials is still 
in  its  infancy,  as  only  small  numbers  of  human  masseter  muscle  genes  have  been 
investigated and no reliable predictors have been found to date. This may have been 
partly related to the limitations of molecular methods previously available. However, 
with the development of new technologies, it may be possible to discover new candidate 
genes which might take part in postnatal musculo-skeletal development and adaptation. 
 
1.8.  THE SCOPE OF GENE EXPRESSION TECHNOLOGIES 
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) is one of the 
most  sensitive  and  reliable  techniques  that  has  been  developed  to  measure  the 
abundance of either DNA or RNA (VanGuilder et al., 2008) and has been used in both 
human (Suchak et al., 2009) and animal (Ödman et al., 2008) masseter muscle gene 
expression research. However, qRT-PCR provides low-throughput data, whereby only a 
few  genes  can  be  tested  (Moody,  2001).  Microarray  on  the  other  hand,  is  a  high-
throughput type of gene expression technique where thousands of genes can be tested in 
one experiment. New genes have been found using this technique (VanGuilder et al., 
2008). Gene expression microarrays have been used to reveal part of the complicated 
molecular pathway in relation to various craniofacial anomalies.       
 
1.8.1.  GENE EXPRESSION MICROARRAYS IN OROFACIAL CLEFTS 
Cleft  lip  and/or  palate  patients  have  been  reported  with  various  genetic  mutations 
(Jezewski et al., 2003; Marcano et al., 2004; Andreou et al., 2007). However, it is not 
clear how these mutations function at a molecular level to develop syndromic and non-
syndromic orofacial clefts (Stanier and Moore, 2004). Park and colleagues (2006) have 
conducted a large microarray genotypic study of several families with neonates who 
were identified with non-syndromic orofacial clefts and were further linked to gene 
expression-based network data. The study discovered new candidate genes in various 
embryonic  tissues  of  cleft  lip  and  palate  patients  which  had  not  been  previously 
identified. It has been suggested that investigating these genes on various molecular 
levels would provide a new insight into the development of both syndromic and non-
syndromic orofacial clefts.  Chapter 1. Background 
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1.8.2.  GENE  EXPRESSION  MICROARRAYS  IN  CRANIOSYNOSTOTIC 
CONDITIONS 
Although both Crouzon and Apert syndromes have been reported with craniosynostoses 
(Wilkie,  1997)  and  fibroblast  growth  factor  receptor  2  (FGFR2)  gene  mutations 
(Anderson et al., 1998), both syndromes have different clinical phenotypes based on 
cranial,  facial  and  limb  variations  (Kimonis  et  al.,  2007).  The  molecular  genetic 
mechanism  responsible  for  such  differences  has  not  been  explained.  Carinci  and 
colleagues (2002) in a  microarray gene expression experiment  using fibroblast cells 
derived from the parietal bone of adult Crouzon and Apert syndrome patients during 
cranial  surgery  have  found  interesting  results.  Out  of  almost  19,000  cDNA 
(complementary DNA) sequences that were covered in the microarray experiment, two 
distinct sequences had differential expression between Crouzon and Apert patients. This 
discovery suggests different genetic mechanisms of the FGFR2 gene in the development 
of Crouzon and Apert phenotypes.  
 
1.8.3.  GENE  EXPRESSION  MICROARRAYS  IN  HEMIFACIAL 
MICROSOMIA 
Hemifacial microsomia (HFM) is one of the most common syndromes associated with 
faulty development of the 1
st and 2
nd branchial arches with no familial predisposition 
(Poswillo, 1974). However, the genetic cascade arising from the faulty development of 
the branchial arches leading to the asymmetric facial appearance has not been revealed. 
Cai and co-workers (2005) have studied extensively the gene expression profile of the 
1
st branchial arch in various craniofacial structures of aborted embryos using different 
high throughput gene expression techniques and comparing it to mouse models. The 
study has identified novel genes which were not reported earlier in the 1
st branchial arch 
of  humans.  Furthermore,  thousands  of  genes  were  expressed  differently  in  the  1st 
branchial arch between the 4
th and the 5
th week of embryonic development and were 
suggested to be candidate genes related to craniofacial anomalies such as orofacial clefts 
and hemifacial microsomia.   
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1.9.  STATEMENT OF THE PROBLEM 
Variations in the structural (Boyd et al., 1989; Rowlerson et al., 2005) and functional 
(Hunt and Cunningham, 1997;  Ariji  et  al.,  2000)  properties of the masseter muscle 
between non-syndromic patients with various craniofacial patterns are well documented. 
However, the genetic explanation of these differences is still pending and has yet to be 
revealed.  No  previous  gene  expression  experiment  has  incorporated  microarray 
technology to identify potential masseter muscle candidate genes in relation to various 
non-syndromic craniofacial patterns. Furthermore, the effect of the different vertical and 
horizontal craniofacial deformities, dental occlusion and cephalometric parameters on 
the gene expression of the myosin heavy chain genes of the masseter muscle has not 
been established fully.   
 
The  current  project  is  part  of  a  large  international  research  study  conducted  in 
collaboration with UCL/ Eastman Dental Hospital (EDH) in the United Kingdom and 
Riyadh  Military  Hospital  (RMH)  in  the  Kingdom  of  Saudi  Arabia  (KSA).  DNA 
genotyping and RNA gene expression microarrays are used to assess both the masseter 
muscle and the bones of the face of patients with variable craniofacial patterns before, 
during and after orthognathic surgery. However, the current study is included to provide 
the foundations for the main research to progress and is designed to identify potential 
novel masseter muscle candidate genes to be analysed and tested further in relation to 
craniofacial deformities. 
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1.10. AIMS OF THE PROJECT 
The aims  of the current study  are to use gene  expression microarray technology to 
ascertain whether any novel masseter muscle genes can be identified which respond 
differently in relation to various craniofacial patterns.  
 
The null hypotheses for this research are: 
 
1.  No  novel  masseter  muscle  genes  can  be  identified  in  relation  to  patients 
exhibiting different craniofacial patterns when using microarray technology. 
 
2.  There is no relationship between masseter muscle gene expression and various 
combinations of vertical and horizontal craniofacial patterns. 
 
3.  There is no correlation between masseter muscle gene expression and various 
vertical and horizontal cephalometric variables. 
 
4.  There  is  no  correlation  between  masseter  muscle  gene  expression  and  the 
number of dental occlusal contacts associated with craniofacial patterns. 
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1.11. LAYOUT OF THE THESIS  
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2.1.  INTRODUCTION 
Several  ethical,  clinical  and  experimental  issues  were  taken  into  account  when 
designing the current study. This is due to the nature of the tissue samples required as 
well as the number of different operating systems and analytical procedures available to 
describe both microarray and quantitative RT-PCR. The aims of this chapter are to give 
an overview of the materials and methods and of the genetic techniques used.  
 
2.2.  CLINICAL DESIGN 
The clinical design for the current research has been initiated by three main steps: 
 
1.  Setting the inclusion and exclusion criteria required for subject recruitment.  
 
2.  Initial sample size estimation. 
 
3.  A  pilot  audit  where  the  inclusion  and  exclusion  criteria  were  implemented 
during the assessment of previous hospital notes of patients who have attended 
the orthodontic/orthognathic clinic at the Eastman Dental Hospital (EDH).  
 
This is to assess whether sufficient numbers of patients matching the inclusion and 
exclusion criteria could be gathered from one hospital site as well as the assessment of 
the types of deformities encountered.  
 
2.2.1.  INCLUSION AND EXCLUSION CRITERIA 
The current research is a case-control study where two main cohorts were required; the 
deformity and the controls 
 
  Inclusion criteria 
Control group:  
-  Caucasian. 
-  Non-syndromic. 
-  Requiring the extraction of either/ both lower third molars (to aid in obtaining 
the muscle biopsy). Chapter 2. General materials and methods 
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-  Having average vertical and horizontal clinical facial appearance with no facial 
asymmetry and require orthodontic treatment to correct dental malocclusion (to 
justify obtaining lateral cephalometric radiographs).  
 
Deformity group:  
-  Caucasian. 
-  Non-syndromic. 
-  Requiring the extraction of either/ both lower third molars. 
-  Having a single or a combination of vertical and horizontal facial deformities 
with  no  facial  asymmetry  and  requiring  orthognathic  correction  of  jaw 
deformity. 
 
  Exclusion criteria  
Any patient who was diagnosed with any of the following criteria was excluded 
from the study: 
-  Syndromic. 
-  Racial categories other than Caucasian. 
-  Having asymmetric facial development. 
-  Did not require the extraction of either of the lower third molars. 
-  Previously  undergone  orthodontic  treatment  or  surgical  correction  of  facial 
deformity. 
-  Diagnosed with endocrine, connective tissue, muscle, autoimmune or bleeding 
disorders, bone disease or using prescribed drugs on regular basis. 
 
2.2.2.  INITIAL SAMPLE SIZE ESTIMATION 
It is appreciated that microarray technology allows analysis of a large number of genes 
from samples of limited availability. However, in the absence of data from a pilot study, 
sample  size  information  can  be  obtained  from  previous  experiments  (Stekel,  2003). 
Based on previously controlled in-vitro studies where the target p-value was 0.01 and 
the target log ratio was 2-fold, the number of the required arrays per group was 6, 
assuming normal distribution of gene expression. However, in-vivo studies contain two 
main sources of errors compared to one source of error in an in-vitro experiment. The 
first error is the biological error which is introduced from genotypic variations between Chapter 2. General materials and methods 
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individuals, whilst the second error is technical and may arise as a result of variations in 
sample collection, handling or purification of the genetic material, change of reagents or 
during  hybridization.  The  Bloomsbury  Centre  for  Bioinformatics/  Department  of 
Computer Science at UCL has provided a sample size estimate of 11 patients pre group 
(letter attached at Appendix A). This was conducted using data from previous studies, a 
target p-value of 0.05 and a target log ratio of 1.4-fold change. 
 
2.2.3.  THE EDH AUDIT 
Using the pre-determined inclusion and exclusion criteria of the deformity group and an 
estimated sample size per group, the hospital notes of all patients who were referred to 
the  Eastman  Dental  Hospital  (EDH)  for  surgical  jaw  correction  in  year  2004  were 
investigated. Surgical procedures were performed on 80 patients for the correction of 
facial deformities: 29 males and 51 females with an age range of 16-50 years, all non-
syndromic except for 3 syndromic females and 9 non-specific cases such as trauma or 
distraction  osteogenesis.  This  resulted  in  a  total  of  68  non-syndromic  patients  with 
various vertical and horizontal craniofacial patterns (Table 2.1). 
 
Table 2.1: Craniofacial deformities included in the 2004 EDH audit. 
Horizontal and vertical patterns  Number of patients 
Class III long face without AOB 
Class III average vertical face 
Class III long face with AOB 
Class III short face 
Total 
18 (including 3 asymmetry) 
11 
5 
3 (including 1 asymmetry) 
37 
Class II long face without AOB 
Class II long face with AOB 
Class II short face 
Class II average vertical face 
Total 
11 
9 
6 
5 (including 1 asymmetry) 
31 
AOB: Anterior open bite. 
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However,  of  the  68  non-  syndromic  craniofacial  deformities,  only  17  patients  with 
various  craniofacial  patterns  matched  the  required  inclusion  and  exclusion  criteria. 
Furthermore, other ongoing projects at the EDH were recruiting individuals with similar 
criteria to the current research and, ethically, it was not possible to recruite the same 
patient for two different studies. These factors suggested that one hospital site may not 
be sufficient to gather the appropriate sample size of patients with the recommended 
inclusion and exclusion criteria. Therefore, other hospital sites were included. 
 
2.3.  ETHICAL APPROVAL 
This study received three ethical approvals, one broad approval from the UCL Joint 
Research and Ethics Committees (REC) to be conducted at the Eastman Dental Hospital 
(EDH), as well as two other local ethical approvals to be conducted at associated sites 
including Whipps Cross University Hospital (WCH) in the UK and the Riyadh Military 
Hospital (RMH) in Saudi Arabia (all ethical approvals are included in Appendix A). 
 
2.4.  RESEARCH SUBJECTS 
 
2.4.1.  THE RECRUITMENT PROCEDURE 
Following the UCL REC guidelines, the invitation letter, leaflet and information sheet 
were supplied to both deformity and control groups. Each patient was given at least 24 
hours  to  decide  upon  participation  in  the  study  (documents  supplied  to  research 
participant is included in Appendix A). 
 
2.4.2.  RETROSPECTIVE RECALCULATION OF SAMPLE SIZE  
Following  the  microarray  experiment,  we  have  used  our  own  data  in  a  special 
microarray sample size estimation website: 
 
 http://bioinformatics.mdanderson.org/MicroarraySampleSize/ 
 
This is to calculate retrospectively the sufficiency of the sample size included in the 
current study. The website required a set of criteria that were mainly obtained from the 
microarray experiment. The following section will list the criteria that were used for the 
current research to recalculate the sample size. Chapter 2. General materials and methods 
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-  Total number of genes (this information was obtained from the GeneChip® data 
sheet (Affymetrix®, 2003) = 38,500 genes. 
 
-  Acceptable number of false positive genes (1 is mainly a standard that is used in 
microarray experiments) = 1 
 
-  Desired fold change = 2 
 
-  Desired  power  (0.7-0.8  is  a  standard  that  is  used  in  most  microarray 
experiments) = 0.8  
 
-  Standard deviation (the SD was calculated from the gene expression intensities 
of all probes included on the microarray chip) = 0.36 
 
Once all these criteria were submitted, an automatic computation of the sample size was 
obtained which revealed that 7 patients were recommended per group.  
 
2.4.3.  SUBJECTS INCLUDED  
A total of 38 individuals were recruited from the Orthodontic departments of the EDH, 
WCH  and  RMH.  Unfortunately,  six  deformity  patients  withdrew  prior  to  biopsy 
collection leaving 32 patients for the study. The samples collected from the 32 patients 
were  used  in  various  experimental  procedures  such  as  standardisation  of  the  RNA 
extraction protocol as well as the gene expression. This has resulted in a total of 29 
patients included in the final gene expression analysis (Figure 2.1).  
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The 29 subjects consisted of 11 control females, with an age range of 16-34 years (mean 
age 22.66 + 5 years) and 18 deformity patients (8 males and 10 females), with an age 
range of 16-36 years (mean age 23.94 + 6 years). The general sample size of both the 
deformity  and  the  control  group  was  considered  sufficient  for  the  microarray 
experiment. However, the deformity group was further subdivided based on various 
clinical, dental and radiographic criteria, which resulted in a smaller sample size than 
Figure 2.1: The number of patients and samples used in each experimental procedure. 1) A 
total of 6 biopsies collected from 4 patients were used to optimise the RNA extraction protocol. 
One sample out of the 6 had good RNA quality and was included further in gene expression 
experiments.  2)  The  sample  with the  good  RNA  quality as  well  as  25  other  samples  – each 
representing one patient, were used for gene expression microarray. 3) The remaining aliquots of 
the total RNA of the 26 samples used in the microarray experiment as well as 3 other samples 
(total 29) were used for the quantitative RT-PCR. 
† Some patients had one biopsy while others had two biopsies; this was depending on whether 
one or both lower third molars were extracted. However, only one biopsy representing each 
patient was used for the experimental procedure except where indicated by 
†.    
†† These patients were recruited at the initial stages of the study. However, due to patient related 
circumstances there was considerable delay in biopsy collection, and thus it was not possible to 
include these samples in the microarray analysis and were only included in the quantitative RT-
PCR.       Chapter 2. General materials and methods 
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recommended in some of the deformity subgroups. The different subdivisions of the 
deformity group as relevant to the gene expression experiment will be discussed later. 
 
2.4.4.  LATERAL CEPHALOMETRIC RADIOGRAPHS 
The  lateral  cephalometric  radiographs  were  taken  as  part  of  the  routine  initial 
orthodontic  diagnostic  procedure  of  both  the  deformity  and  the  control  groups. 
Radiographs  were  taken  at  the  three  hospital  sites  using  standardised  cephalometric 
techniques. Each patient was oriented with the head in the natural head position and the 
teeth in centric occlusion.   
 
2.4.4.1.  Cephalometric landmarks 
All pre-treatment lateral cephalometric radiographs of the subjects were hand-traced by 
the  investigator  using  a  sharp  pencil,  acetate  paper  and  illuminated  light  box.  Nine 
cephalometric landmarks were identified (Figure 2.2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Cephalometric landmarks. Sella (S), midpoint of sella turcica.  Nasion (N), the most 
anterior point of the frontonasal suture. Articulare (Ar), the intersection between the posterior 
border of the mandible with the lower border of the posterior cranial base. Gonion (Go), the most 
posterior  inferior  point  of  the  angle  of  the  mandible.  Menton  (Me),  the  lowest  point  of  the 
mandibular symphysis. Supramentale (B-point), the deepest point between the chin point and the 
mandibular alveolar crest. Subspinale (A-point), the deepest point between the anterior nasal 
spine and the maxillary alveolar crest. Anterior nasal spine (ANS), the tip of the bony process of 
the maxilla. Posterior nasal spine (PNS), the most posterior point of the bony hard palate in the 
sagital plane (Houston et al., 1992).    Chapter 2. General materials and methods 
 
40 
 
2.4.4.2.  Cephalometric variables 
Based  on  the  results  of  previous  studies,  the  most  significantly  different  vertical 
(Schendel et al., 1976; Opdebeeck and Bell, 1978) and horizontal (Björk, 1950; Reyes 
et al., 2006) cephalometric variables between average and craniofacial deformities were 
selected to be tested later against the gene expression data (Chapter 6). 
 
  Horizontal variables 
-  SNA  angle  (sella-nasion-A  point):  Indicates  the  horizontal  position  of  the 
maxilla in relation to the cranial base. 
-  SNB  angle  (sella-nasion-B  point):  Indicates  the  horizontal  position  of  the 
mandible in relation to the cranial base. 
-   ANB  angle  (A point-nasion-B point):  Indicates  the relationship  between the 
maxilla and the mandible in the horizontal direction.  
 
  Vertical variables 
-  TAFH length (total anterior face height): A linear measurement from N to Me 
perpendicular to the maxillary plane (ANS-PNS). 
-  LAFH%  (lower  anterior  face  height  percentage):  The  length  of  the  LAFH 
(ANS-Me)  perpendicular  to  the  maxillary  plane  divided  by  the  linear 
measurement of the TAFH (N-Me) and expressed as a percentage. 
-  TPFH length (total posterior face height): A linear measurement from S to Go 
perpendicular to ANS-PNS. 
-  RH length (Ramus height -Ar-Go): Linear measurement of the ramus of the 
mandible. 
-  SN-MP  angle  (SN-mandibular  plane):  Indicates  the  relationship  of  the 
mandibular plane (Go-Me) to the cranial base plane (S-N). 
-  SN-MxP angle (SN-maxillary plane): Indicates the relationship of the maxillary 
plane to the cranial base plane (S-N).  
 
The  SN-MxP  was  only  used  for  the  correction  of  the  value  of  the  ANB  angle,  as 
recommended by Mills (1987). Figure 2.3 demonstrates both horizontal and vertical 
measurements. 
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Figure 2.3: Horizontal and vertical cephalometric variables used. Chapter 2. General materials and methods 
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2.4.4.3.  Cephalometric norms 
Published cephalometric norms of both the British (Bhatia and Leighton, 1993) and the 
Saudi (Shalhoub et al., 1987; Taibah and Feteih, 2007) Caucasian populations, matched 
to the mean age of the subjects, were investigated to assess the possibility of pooling the 
data of both  groups for the current  research. The mean values  of both vertical  and 
horizontal cephalometric norms of the Saudi group (Table 2.2) were within the normal 
range of the British norms (Table 2.3). It was therefore, considered appropriate that the 
patients could be pooled.  
 
 Table 2.2: Saudi cephalometric norms. 
 
Radiographic 
variables 
SAUDI NORMS* 
Males  Females 
Mean  SD  Range  Mean  SD  Range 
HORIZONTAL 
SNA° 
SNB° 
ANB° 
 
81.6 
78.8 
2.8 
 
± 4.5 
± 3.7 
± 1.9 
 
77.0 – 86 
75.0 – 82.5 
0.9 – 4.7 
 
84.0 
81.0 
3.0 
 
± 6.0 
± 5.8 
± 2.4 
 
78.0 – 90.0 
75.2 – 86.8 
1.6 – 5.4 
VERTICAL 
LAFH% 
TAFH mm 
TPFH mm 
RH mm 
SN-MP° 
 
- 
122.8 
77.0 
42.1 
33.8 
 
- 
± 8.6 
± 8.9 
± 6.7 
± 5.0 
 
- 
114.2 – 131.4 
68.1 – 85.9 
35.4 – 48.8 
28.8 – 38.8 
 
- 
115.8 
72.0 
40.6 
28.0 
 
- 
± 7.2 
± 5.3 
± 4.7 
± 4.7 
 
- 
108.6 – 123.0 
66.7– 77.3 
35.9 – 45.3 
23.3 – 32.7 
SD: Standard deviation. The LAFH% was not reported in both Saudi studies *(Shalhoub 
et al., 1987; Taibah and Feteih, 2007). 
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Table 2.3: British cephalometric norms. 
 
Radiographic 
variables 
BRITISH NORMS* 
Males  Females 
Mean  SD  Range  Mean  SD  Range 
HORIZONTAL 
SNA° 
SNB° 
ANB° 
 
82.0 
79.7 
2.0 
 
± 4.6 
± 4.5 
± 3.0 
 
77.4  – 86.6 
75.2 – 84.2 
-1.0 – 5.0 
 
80.5 
78.0 
2.6 
 
± 3.4 
± 3.4 
± 2.4 
 
77.1 – 84 
74.6 – 81.4 
0.2 – 5.0 
VERTICAL 
LAFH% 
TAFH mm 
TPFH mm 
RH mm 
SN-MP° 
SN-MxP° 
 
55.0 
120 
80.0 
49.4 
31.8 
6.0 
 
± 1.8 
± 6.4 
± 4.0 
± 4.2 
± 6.8 
± 2.4 
 
53.2 – 56.8 
113.6 – 126.4 
76.0 – 84.0 
45.2 – 53.6 
25.0 – 38.6 
3.6 – 8.4 
 
54.6 
111 
71.4 
44.0 
34.3 
8.6 
 
± 1.9 
± 5.8 
± 4.3 
± 4.2 
± 6.0 
± 3.4 
 
52.7 – 56.5 
105.2 – 116.8 
67.1 – 75.7 
39.8 – 48.2 
28.3 – 40.3 
5.2 – 12.0 
*Derived from Bhatia and Leighton (1993). 
 
 
2.4.4.4.  Errors of the method 
 
2.4.4.4.1.  Magnification factor 
The  magnification  factors  (MF)  for  the  EDH,  WCH  and  RMH  cephalostats  were 
calculated using the formula: MF= Actual ruler size/Radiographic ruler size (Bergersen, 
1980). For example, 10mm/  11mm = 0.9.  Both EDH and RMH cephalostats  had a 
magnification  factor  of  0.9,  while  WCH  was  0.92.  All  linear  measurements  were 
multiplied by their designated magnification factors to compensate for enlargement and 
to obtain the true cephalometric value. 
 
2.4.4.4.2.  Correction of the ANB angle 
The ANB value was corrected to account for the variation in the projection of the N 
point between radiographs. For every degree that the SNA value was above the mean 
norm, 0.5 degree was subtracted from the ANB angle, and for every degree that the 
SNA value was below the mean norm, 0.5 degree was added to the ANB value. This 
correction was described by Mills (1987) and was recommended only in cases where 
the SN-MxP angle was within the average range.  Chapter 2. General materials and methods 
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2.4.4.4.3.  Assessment of reliability and reproducibility 
Reliability tests are conducted to assess random errors which are generally produced 
from poor quality radiographs or improper radiographic techniques that would affect 
landmark identification. Reproducibility measures systematic errors that depend mainly 
on  the  ability  of  the  investigator  to  obtain  repeated  radiographic  measurements 
(Houston, 1983). The lateral cephalometric radiographs of 25 subjects were selected at 
random and were traced twice on different occasions (at least two weeks apart). Both 
systematic and random errors were assessed using the Bland and Altman’s approach 
(Bland and Altman, 1986) using the STATA software v10 and included:  
 
  Lin’s  Concordance  Correlation  Coefficient:  This  test  assesses  both  the 
correlation and the agreement between paired readings by taking into account 
the linearity, vertical shift and the degree of angulation of the trend line between 
repeated measurements. The closer this value to 1, the better the concordance 
between the first and the second measurements. 
 
  A paired sample t-test: this test assesses systematic errors. If systematic biases 
were introduced, the paired t-test would show a significant p-value (p ≤ 0.05) 
between repeated measurements (Houston, 1983).  
 
  British  Standards  repeatability  and  reproducibility  coefficient  (CR):  This  test 
measures  random  errors  by  presenting  an  estimated  value  of  the  maximum 
difference  between  repeated  measurements.  The  value  is  calculated  by 
multiplying 1.96 by the standard deviation of the difference (SDD). The higher 
this  value  the  greater  the  difficulty  in  location  and  measurement  of  a 
radiographic parameter.   
 
  Limits of agreement: This parameter is presented as upper and lower values. 
95% of the readings should lie between both values. 
 
  Bland and Altman’s graphs: This is a graphical representation of the systematic 
and random errors as well as the agreement between paired measurements. The 
y-axis indicates the difference between two readings plotted against the x-axis Chapter 2. General materials and methods 
 
45 
 
which is the mean of the difference of paired measurements. Each graph has two 
mid horizontal lines and the upper and lower limits of agreement. The first mid 
horizontal line represents the perfect standard agreement at zero and the other 
mid line is the actual observed average agreement. The closer the observed line 
to the zero horizontal line, the less the systematic error. Furthermore, if both 
readings were in agreement they would lie at or near both horizontal lines. If 
random errors were introduced, the graph  would show scattered points away 
from  horizontal  lines  and  beyond  the  95%  limits  of  agreement.  Figure  2.4 
represent  examples  of  both  systematic  and  random  errors  as  viewed  by  the 
Bland  and  Altman  graph.  The  results  of  Bland  and  Altman’s  approach  are 
presented in Chapter 5.  
 
 
 
 
 
 
 
 
 
 
 
2.5.  TISSUE SAMPLES 
Both microarray and qRT-PCR gene expression results of previous studies indicated a 
superior representation of the underlying biology when the RNA was obtained from 
whole  fresh  biopsies  rather  than  tissue  cultured  cells  (Zaitseva  et  al.,  2006),  frozen 
samples (Eikmans et al., 2000), or formalin fixed paraffin embedded (FFPE) samples 
(Godfrey et al., 2000). Therefore, fresh muscle biopsies were obtained from all subjects.  
 
Figure 2.4: Examples of Bland and Altman graphs. The y-axis is the difference between two 
readings  while  the  x-axis  is  the  mean  of  the  difference  of  repeated  measurements.  1)  No 
systematic  errors  and  minimal  random  errors.  2)  Minimal  random  errors  and  increased 
systematic errors. 3) No systematic errors and marked random errors. 4) Both systematic and 
random errors are evident. Chapter 2. General materials and methods 
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2.5.1.  BIOPSY PROCEDURE 
During the extraction of the lower third molar, the incision was extended through the 
inner cheek to the anterior medial portion of the superficial belly of the masseter muscle 
(Boyd et al., 1989). A biopsy measuring approximately 3x3x3 mm (less than 100gm) 
biopsy was obtained from each patient. Figure 2.5 demonstrates the location of biopsy 
excision. 
 
 
 
 
 
 
 
 
 
 
 
2.5.2.  SAMPLE COLLECTION 
The samples were placed immediately into a tube containing RNA stabilising reagent 
(RNAlater®  Tissue  Storage  solution  supplied  by  Qiagen®)  and  kept  at  room 
temperature for no longer than 4h until transferred to a -80°C freezer. The RNAlater® 
reagent inhibited the actions of any RNAses (enzymes that degrade RNA moieties).  
 
2.6.  RNA EXTRACTION 
With the development of sensitive gene expression techniques, such as real-time PCR 
and microarrays, it has become mandatory to use high quality total RNA with no DNA 
contamination  (Nolan  et  al.,  2006).  Several  protocols  were  tested  to  generate  a 
standardised procedure to extract good quality and quantity RNA from masseter muscle 
biopsies to be used for the current microarray and real-time PCR experiments (please 
refer  to  Chapter  3  where  a  detailed  explanation  of  materials,  methods,  different 
protocols tested and the results of total RNA extraction procedures are presented fully).  
Figure 2.5: The site of masseter muscle biopsy. A cross sectional area of the masseter muscle 
showing the biopsy taken from the deep, anterior surface of the superficial belly (adapted from 
Boyd et al., 1989). Chapter 2. General materials and methods 
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2.7.  MICROARRAY 
 
2.7.1.  DEFINITION 
"A microarray is a scientific term derived from the Greek word mikro (small) and the 
French word arayer (arranged)" (Chaudhuri, 2005), and can be defined as microscopic 
elements  arranged  in  rows  and  columns  on  a  substrate  surface.  The  microscopic 
elements are mainly DNA, RNA or protein probes, while the substrate could be a two-
dimensional or a three-dimensional surface (Stillman and Tonkinson, 2001) made up of 
glass, nylon or silicon (Ramsay, 1998; Stoughton, 2005). The end product is composed 
of tens of thousands of probes immobilized on a small surface and is often called a chip. 
The whole system by which these gene chips are constructed and operated is called a 
platform. The current research utilises RNA gene expression. Therefore, the following 
sections  will  exclude  both  DNA  and  protein  systems  and  will  focus  only  on  gene 
expression platforms. 
 
2.7.2.  GENE EXPRESSION MICROARRAY ISSUES 
To accommodate the different gene expression experimental designs and to meet the 
requirements  of  microarray  users,  various  gene  expression  platforms  have  been 
introduced  to  the  market.  They  all  share  the  same  concept,  but  they  have  other 
fundamental differences. These differences were found to be in: 
 
  The substrate surface used (Ramsay, 1998; Stoughton, 2005). 
 
  The source (Lipshutz et  al.,  1999), length  (Tomiuk and Hofman, 2001), and 
number  (Alberts  et  al.,  2007)  of  the  RNA  probes  incorporated  during 
manufacturing. 
 
  The method by which the probe is attached to the surface substrate (Cheung et 
al., 1999; Lipshutz et al., 1999). 
 
  Type of target material used (Barker et al., 2005). 
 
  Labelling strategy (Do and Choi, 2007). Chapter 2. General materials and methods 
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  The number of samples hybridised per chip (Hardiman, 2004). 
 
  Normalisation, and the statistical methods used (Yauk et al., 2004; Shi et al., 
2006).  
 
With the presence of these differences, several issues have arisen indicating whether 
these variations would affect the accuracy, precision, specificity, and sensitivity of these 
systems.  Accuracy  has  been  defined  as  how  true  are  the  results  in  presenting  the 
underlying biology (Woo et al., 2004). This issue was resolved by coupling expression 
profiling microarray experiments with other highly sensitive gene expression methods, 
such as quantitative RT-PCR (Shi et al., 2006). Precision, on the other hand, has been 
defined as  the ability of a platform to  show similar results  when the  experiment  is 
repeated several times (Woo et al., 2004). This has been tested by introducing technical 
replicates  into  the  design  of  gene  expression  experiments,  by  hybridising  the  same 
sample onto two different chips (of the same platform) followed by comparing and 
contrasting the results of both chips (Irizarry et al., 2005). Specificity is “the ability to 
identify  sequences  up  to  a  certain  homology”  (Hardiman,  2004),  and  this  has  been 
found to  be  affected by the source, length,  and the number of probes  implemented 
during manufacturing, which may be variable between platforms (Tomiuk and Hofman, 
2001; Walker et al., 2006; Alberts et al., 2007). Sensitivity was described as “the lowest 
concentration  of  the  target  material  at  which  an  acceptable  accuracy  is  obtained” 
(Moreau et al., 2003), and this has also been found to be affected by the probe design 
(Stoughton, 2005).  
 
Two other issues need to be considered when regarding microarray studies: first, the 
integration of microarray results from different gene expression platforms, and second, 
presenting and storing the high-throughput data generated by these experiments in a 
standardised and easy-accessible manner. The first problem has been managed by the 
selection of high quality microarray platforms that have been tested for their reliability 
and repeatability (Shi et al., 2006), as well as adapting the appropriate normalisation 
procedures for each platform before combining the data (Shippy et al., 2004; Carter et 
al., 2005). The second problem has necessitated internationally-agreed guidelines called 
MIAME (minimum information about a microarray experiment), which standardise the Chapter 2. General materials and methods 
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format of publishing or exchanging microarray results (Brazma et al., 2001). As for 
storing microarray data, several websites  have been designed to store both raw and 
normalised data of different gene expression platforms (Parkinson et al., 2005), while 
other sites can offer a re-evaluation of the original probe design of specific platforms 
(Liu  et  al.,  2007).  Table  2.4  summarises  the  microarray  issues  and  the  solutions 
implemented to resolve them. 
 
Table 2.4: Microarray issues. 
Microarray issues  Definition  Solutions 
Accuracy  How true are the results in presenting 
the underlying biology? 
- Confirm the results of any expression 
profile microarray experiment with 
other sensitive gene expression 
methods, mainly qRT-PCR 
Precision  The ability of a platform to show 
similar results when the experiment 
is repeated several times 
- Technical replicates 
Specificity  The ability to identify sequences up 
to a certain homology 
- Prior knowledge of the source and the 
whole probe sequence 
- Using a single long probe or multiple 
short probes presenting each gene 
Sensitivity  The lowest concentration of the 
target material at which an 
acceptable accuracy is obtained 
- Using a single long probe or multiple 
short probes PER gene  
- Amplification of the target material 
prior to hybridisation 
Integration of 
microarray data 
Combining the results of different 
studies (with similar or different 
microarray platforms) that are 
designed to answer the same 
scientific question 
- Careful review of the probe sequence 
in each platform  
- Combine platforms with similar probe 
sequences  
- Normalise the data of each platform 
using its designated software prior to 
combining the data 
Storing and publishing 
data 
The way of storing, publishing, 
exchanging or presenting microarray 
data 
- Follow MIAME guidelines  
- Use special websites to store the data 
that can be retrieved or reanalysed 
again 
 Chapter 2. General materials and methods 
 
50 
 
2.7.3.  PRINCIPLES OF GENE EXPRESSION MICROARRAY PLATFORMS 
The concept of a gene expression microarray platform has been reviewed by several 
authors  (Cheung  et  al.,  1999;  Duggan  et  al.,  1999;  Lipshutz  et  al.,  1999),  and  is 
summarised into five major stages: 
 
1.  Manufacturing a chip that is composed of tens of thousands of RNA probes that 
are immobilised onto a microscopic surface.  
 
2.  The laboratory procedure: This stage is mainly about the formation of labelled 
target material, hybridisation, scanning and generating raw data. 
 
3.  Gene chip quality control: This is to ensure that the experiment is conducted 
successfully and no technical errors are introduced.  
 
4.  Pre-processing data: This stage includes normalisation to remove any biological 
sources of variations and also to measure the level of expression of each gene.  
 
5.  Data analysis: This is the final stage where a series of analytical methods are 
conducted to make sense of the underlying biology.      
 
Hardiman (2004) in a detailed review of the different gene expression platforms found 
that most of the chips that are available on the market with complete gene coverage 
were  restricted  to  animals,  plants,  bacteria  or  viruses.  However,  some  vendor 
corporations such as Affymetrix® were supplying gene chips with a comprehensive 
coverage of the human genome. Affymetrix® GeneChips® have been reported to have 
high accuracy (Rogojina et al., 2003), precision (Woo et al., 2004), specificity (Järvinen 
et al., 2004), and sensitivity (Yauk et al., 2004) when tested by several laboratories 
(Irizarry et al., 2005; Wang et al., 2005), scientists (Bosotti et al., 2007), and when 
compared to other platforms (de Reyniès et al., 2006). It was for these reasons that 
Affymetrix® GeneChips® were selected for this research.  
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2.7.4.  PROPERTIES OF AFFYMETRIX® GeneChips® 
 
2.7.4.1.  The substrate 
Glass surfaces are the most commonly used type of substrate as they are durable, rigid, 
can withstand high temperature during hybridisation, can undergo surface modification 
to allow for the attachment of genetic elements and have low fluorescence in order not 
to affect the scanned image during normalisation. Glass substrates are usually treated 
with special reagents to enhance hydrophobicity and facilitate covalent attachment of 
the genetic material to the surface. These reagents also restrict spread and interaction 
beteween neighbouring probes (Duggan et al, 1999). The Affymetrix® substrate is a 
two-dimensional 1.28 x 1.28 cm glass surface.  
 
2.7.4.2.  The probe 
The term probe in this thesis describes the genetic element that is immobilised onto the 
substrate surface during manufacture and, according to MIAME guidelines is called the 
reporter. The source (Alberts et al., 2007), the length (Walker et al., 2006), and the 
number of probes representing each gene (Shippy et al., 2004) were all found to be 
different between the Affymetrix® and other microarray platforms. 
 
2.7.4.2.1.  Source of the probe 
The Affymetrix® system uses the exact mRNA sequence copied from the sense strand 
derived from a public genetic database, such as UniGene (Schuler et al., 1996), to attach 
each nucleotide to the substrate and continue building an oligonucleotide probe. This 
procedure  is  called  in-situ  synthesis  and  produces  high-density  oligonucleotide 
platforms. This type of platform requires complex equipment to be manufactured and 
can only be generated by commercial laboratories such as Affymetrix® (Yauk et al., 
2004).  
 
2.7.4.2.2.  Length of the probe 
Probes are either short (mainly 25 bases) or long (mainly 60 bases) oligonucleotides 
(oligos). Affymetrix® had some technical problems with designing long probes using 
its own in-situ technique and has, therefore, decided to manufacture short probes of 25 Chapter 2. General materials and methods 
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bases. However, to improve both specificity and sensitivity, several probes are used to 
represent each gene and thus the set-up is a probe-set rather than a single probe. 
 
2.7.4.2.3.  Number of probes presenting each gene 
Affymetrix® has designed a probe-set for each gene. The probe-set is composed of 
eleven probe pairs scanning different regions of the required gene. Each probe pair 
consists of two sequences. One sequence matches exactly the required genetic sequence 
and is called the perfect match (PM), while the other has an identical sequence to the 
PM except for a single nucleotide difference at the middle of the sequence and is called 
the mis-match (MM).  
 
2.7.4.3.  The method of immobilising the probe onto the substrate 
Affymetrix® uses the in-situ synthesis technique to deposit the probes onto the substrate 
surface (Lipshutz et al., 1999). In-situ technology requires previous knowledge of the 
mRNA sequence of the selected gene. Once the first nucleotide is immobilised onto the 
glass  surface,  the  other  nucleotides  are  joined  by  covalent  bonds  between  the  5’ 
hydroxyl group on the backbone of one nucleotide and the phosphate group on the other 
nucleotide. During each round, a single nucleotide is deposited to the appropriate region 
of the array. To ensure this property, a protective group is added to each nucleotide on 
the 5’ position. Once this nucleotide is chosen to be covalently attached to the other 
nucleotide on the surface, the protective group is converted into an active hydroxyl 
group in a process called deprotection. This aids attachment to the phosphate group of 
the previous nucleotide. The process is then repeated until the exact length of the probe 
is reached. 
 
Companies use different methods of deprotection, when acid is used, the process is 
called chemical deprotection, while the term photodeprotection is implemented when 
light  is  used  to  convert  the  protective  group  into  a  hydroxyl  group.  The 
photodeprotection  procedure  can  be  done  with  or  without  a  mask.  The  maskless 
procedure relies on using micro-mirrors to redirect light onto the appropriate parts of the 
glass slide. Affymetrix®, on the other hand, adapts the photodeprotection procedure 
using a mask and the technique is called photolithography. The mask allows the light to Chapter 2. General materials and methods 
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pass  at  certain  areas  and not  others  to  build up the required oligonucleotides.  Each 
round requires a different mask, and each mask is expensive to construct. 
  
2.7.4.4.  The hybridisation system 
Generally,  the  hybridisation  system  of  microarray  platforms  could  be  either  a  one-
colour or a two-colour system. This is based solely on the number of samples hybridised 
onto the same chip. Both systems have proven their efficiency (Irizarry et al., 2005), 
however,  the  choice  of  either  system  depends  upon  the  experimental  strategy.  For 
example,  two-colour  platforms  are  mainly  chosen  when  conducting  time  point 
experiments, while the one-colour chip could be used in case-control studies such as 
disease identification in different individuals compared to controls. The Affymetrix® 
platform is a one-colour system and is suited for the design of the current research.  
 
2.7.4.5.  Affymetrix® GeneChip® generations 
With the discovery of new genes and improved sequencing techniques, Affymetrix® 
has  introduced  several  generations  of  human  gene  expression  GeneChips®.  Each 
contains  a  different  number  of  genes,  similar  and  dissimilar  probe-sets  and  covers 
different  sections  of  the  genome.  To  ensure  maximum  accuracy  and  precision  of  a 
microarray experiment it is recommended to use the same version of the array chip for 
all samples within the experiment. The most comprehensive human Affymetrix® gene 
expression GeneChips® were the U133 plus 2.0 array and the Exon array. Both arrays 
have similar accuracy (Robinson and Speed, 2007). However, the U133 plus 2.0 array 
showed better precision and sensitivity than the Exon array (Abdueva et al., 2007). 
Therefore the U133 plus 2.0 array was selected for the current microarray experiment.     
 
2.7.5.  MICROARRAY MATERIALS AND METHODS 
The following sections will describe briefly the aims and objectives of each microarray 
step. All laboratory procedures were conducted following the Affymetrix® GeneChip® 
Expression Analysis Technical Manual. Summary of the kits, machines and software 
used are listed in Appendix B, while details of the laboratory protocol are available at 
Appendix C.  
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Affymetrix® experiments require specialised instruments, software and bioinformatics. 
Therefore,  an  Affymetrix®  microarray  core  facility  provider  was  used  (ALMAC 
Diagnostics™,  UK).  The  normalisation  procedure  and  initial  data  analysis  were 
provided  by  the  Bloomsbury  Centre  for  Bioinformatics  (BCB)/  Department  of 
Computer  Science  at  UCL,  while  the  final  statistical  analysis  was  conducted  at  the 
Eastman Dental Institute.  
 
2.7.5.1.  RNA samples used 
A total of 26 RNA samples were used for the microarray gene expression technique. 
This represents the number of subjects recruited at the time of the microarray procedure. 
The RNA sample of one of the Class II patients (male) was hybridised twice onto two 
different GeneChips® to act as a technical replicate.  
 
2.7.5.2.  Sample preparation 
  Addition of poly-A control genes into the purified RNA 
The poly-A control genes are derived from B.subtilis and are named dap, lys, phe, thr 
and trp. They are absent in eukaryotic cells. During hybridisation, each of the five genes 
will bind to a special probe-set included in the original design of the Affymetrix® array 
chip. The reason for spiking in these genes into the RNA sample was to act as internal 
controls to ensure the success of the laboratory process. 
  
  Addition of Oligo-dt primers 
These primers are designed specifically with a poly-T tail. The unique design of these 
primers would allow them to bind to the poly-A tail of the mRNA, initiating cDNA 
synthesis of only the mRNA within the total RNA pool (Figure 2.6). A special promoter 
called  T7  is  attached  to  the  oligo-dt  primers.  This  promoter  is  derived  from  a 
bacteriophage and is capable of initiating in-vitro transcription (IVT) of only the sense 
strand of the cDNA to generate anti-sense cRNA which is part of the adapted strategy 
by Affymetrix®. This strategy was initially reported and fully described by Van Gelder 
and colleagues (1990). 
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2.7.5.3.  cDNA/cRNA synthesis and amplification 
Affymetrix®  adopts  a  linear  amplification  strategy  via  IVT  rather  than  exponential 
amplification. The IVT generates a single-stranded (ss) anti-sense cRNA as the final 
target  material  rather  than  double-stranded  (ds)  cDNA.  However,  the  process  of 
generating cRNA starts with cDNA synthesis (Figure 2.6). cDNA/cRNA synthesis can 
be  conducted  either  in  one-cycle  or  two-cycles.  For  samples  with  low  starting 
concentration the two-cycle protocol is recommended and was used for this study.  
 
2.7.5.4.  Synthesis of biotin-labelled cRNA 
The Affymetrix® system uses an indirect labelling procedure (Do and Choi, 2007). The 
cRNA is first labelled with a special protein called biotin during the IVT reaction at this 
stage, while the fluorescent dye (streptavidin-phycoerythrin –SAPE), which has strong 
affinity to the biotin, is incorporated later after hybridisation and during the staining 
step (Figure 2.6).  
 
2.7.5.5.  cRNA fragmentation  
The  fragmentation  reaction  has  been  optimised  by  Affymetrix®  to  generate 
concentrated  cRNA  fragments  of  35  to  a  maximum  of  200  bases.  These  fragments 
hybridise later to the probes on the array chip (Figure 2.6).  
 
2.7.5.6.  Hybridisation 
Prior to hybridisation, the fragmented cRNA was mixed with a cocktail solution. The 
cocktail mixture included four hybridisation control genes derived from E.Coli (bioB, 
bioC, bioD genes) and P1 bacteriophage (cre gene). These controls are pre-synthesised 
as biotin-labelled cRNA transcripts in different concentrations (with the bioB having the 
least concentration while cre the highest). The reason for mixing these controls with 
each sample was to evaluate the labelling and hybridisation efficiency. The cocktail 
mixtures containing the fragmented cRNA and the control genes were then incubated 
overnight  to  allow  the  biotin-labelled  fragmented  targets  to  hybridise  to  their 
complementary probes. Any un-hybridised fragments would remain in the solution and 
would therefore need to be washed (Figure 2.6).  
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2.7.5.7.  Washing and staining 
  Initial washing 
Initial washing was conducted to remove any non-hybridised fragments (Figure 2.6).  
 
  Staining 
The staining strategy relies on the physical properties of the biotin protein attached to 
the cRNA, which is capable of binding to streptavidin. A staining solution containing a 
set of anti-streptavidin antibodies that can bind to streptavidin was also added in order 
to provide an amplified signal during scanning (Figure 2.6).  
 
  Final washing 
A final wash was provided to clean the array chip from any remaining un-attached 
stains prior to scanning.  
 
2.7.5.8.  Scanning (data extraction) 
Data extraction begins with producing an image of the array chip. The intensity of each 
probe  on  the  chip  can  be  assessed  generally  by  visualising  the  different  coloured 
features on the generated image. Black signals represent un-hybridised probes, while 
coloured signals represent hybridised probes. The coloured signal intensity varies from 
one hybridised probe to the other depending on the gene expression. The lighter the 
signal intensity, the greater the gene expression. The signal intensity level increases 
from dark-blue followed by blue, light-blue, green, yellow, orange and red, and the 
highest are white coloured signals (Figure 2.6). However, no conclusions can be drawn 
from these images. They are only used to generate special data files that are further used 
for data analysis. 
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Figure 2.6: The Affymetrix® laboratory workflow.  
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2.7.6.  GeneChip® QUALITY CONTROL 
A quality control step is usually carried out prior to data pre-processing. This is to 
ensure an efficient labelling and hybridisation procedure as well as proper scanning 
(Wilson and Miller, 2005). Seven quality control measures have been used to assess the 
efficiency  of  the  microarray  laboratory  procedure,  these  are  explained  in  detail  in 
Chapter 4. 
 
2.7.7.  PRE-PROCESSING OF DATA 
Pre-processing of data was conducted at the BCB/UCL using the CEL files, Simpleaffy 
package (Wilson and Miller, 2005), Bioconductor v2.0 (Gentleman et al., 2004) and R 
v2.5.0. The process was carried out in two main steps: firstly, background adjustment 
and normalisation and, secondly, summarisation of probe intensity level.  
 
2.7.7.1.  Background adjustment and normalisation 
The generated raw data contains non-biological sources of signals derived from the 
optical noise of the scanner as well as non-specific hybridisation. Both unwanted signals 
are called noise (Wu et al., 2004). The process of separating raw noise from the actual 
signal within one chip is called background adjustment while, if conducted within all 
chips  included  in  the  experiment,  it  is  called  normalisation.  Once  all  systematic 
variations are removed between arrays, the data are viewed in different formats of plots, 
histograms and charts to assess and exclude any poorly correlated chips (description of 
the graphs, histograms and charts are presented in Chapter 4).  
 
2.7.7.2.  Summarisation of probe intensity value 
The aim of this step is to generate a single expression value for each gene. Affymetrix® 
gene chips contain both the perfect match (PM) and mis-match (MM) probe-set design 
and because of this, different types of algorithms have been developed to summarise the 
intensity  value  for  each  gene.  For  example,  some  methods  would  subtract  the  MM 
values from the PM (such as the Affymetrix® default called average difference), while 
others would divide the values and produce a ratio. Irizarry et al., 2003 and Wu et al., 
2004, have found that inclusion the MM values produces errors in the results. They 
have recommended summarising the PM values only and taking the log transformation 
which has provided better accuracy and sensitivity. The GCRMA algorithm was used Chapter 2. General materials and methods 
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for the current experiment. This type of algorithm ignores the MM probes and relies on 
the  average  log  of  the  PM  probes,  as  well  as  using  sequence  information  and  the 
guanine-cytosine (G-C) base pairing to exclude any non-specific hybridisation signals. 
Therefore, it is called GC robust multi-array average (GCRMA) (Wu et al., 2004). 
 
2.7.8.  MICROARRAY DATA ANALYSIS  
 
2.7.8.1.  Grouping of subjects for microarray data analysis 
Microarray experiments generate massive high-throughput genetic data, which makes it 
difficult to analyse when related to complicated craniofacial phenotypes. Therefore, a 
simple type of subject grouping was adopted, similar to previous genotype-phenotype 
masseter muscle gene expression studies, based on either vertical (Nelson-Moon et al., 
1998; Suchak et al., 2009) or horizontal (Gedrange et al., 2005 and 2006; Harzer et al., 
2007) facial  parameters. A total  of 26 patients  were  grouped twice based on either 
vertical or horizontal facial appearance. Both clinical and radiographic patterns were 
confirmed by two orthodontists; the researcher and an orthodontic consultant.  
 
  Vertical grouping 
Vertical  facial  development  was  assessed  clinically  by  lower  anterior  face  height 
(LAFH) in relation to mid and upper face heights regardless of the horizontal deformity 
and  also  radiographically  using  the  TAFH  (mm)  (compared  to  British  and  Saudi 
cephalometric norms discussed earlier in Section 2.4.4.3). This classification grouped 
patients into 12 control (average both clinical and radiographic appearance) and 14 long 
face  (increased  both  clinical  lower  anterior  face  height  and  radiographic  TAFH) 
subjects. Both groups contained sufficient numbers of patients to draw conclusions in 
relation to vertical facial deformities. 
 
  Horizontal grouping 
Horizontal diagnosis was revealed by assessing the position of the mandible in relation 
to  the  maxilla  without  considering  vertical  facial  appearance,  both  clinically  and 
radiographically  (using  the  ANB  angle).  This  generated  three  groups  including  11 
controls (the position of the mandible was at or slightly behind the upper jaw and a 
radiographic  ANB  angle  1-4°),  5  Class  II  (clinical  retrognathic  appearance  and  a Chapter 2. General materials and methods 
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radiographic ANB angle of > 4°) and 10 Class III (clinical prognathic appearance and a 
radiographic ANB angle of < 0°) individuals. Both the Class III and control groups 
contained sufficient sample size to draw conclusions from the microarray analysis in 
relation to prognathic appearance. However, the Class II pattern had a reduced number 
of  patients  (5)  compared  to  the  initial  (11  patients)  and  retrospective  (7  patients) 
calculated  sample  size.  Therefore,  caution  was  recommended  when  assessing 
interpretation of data with regard to retrognathic deformity. 
 
2.7.8.2.  Generating differentially expressed gene lists 
Differentially expressed genes are often determined by using multiple hypothesis testing 
and  a  cut-off  p-value  of  0.05.  This  would  usually  generate  large  numbers  of  false 
significant results. A Benjamini-Hochberg test or a Bonferroni correction is often used 
to correct for multiple testing. However, the criteria are very stringent for microarray 
data (Leung and Cavalieri, 2003). Microarray data analysis for the current research was 
conducted  using  the  GCRMA  files  and  LIMMA  package  (Bioconductor  v2.0) 
(Gentleman et al., 2004). This type of analysis provides a type of t-test modified to 
accommodate  the  large  amount  of  data.  The  p-values  were  calculated  without  any 
correction and the false significant results were minimised by choosing a cut-off p-value 
of 0.001. Any gene with an uncorrected p-value ≤ 0.001 was considered differentially 
expressed between the deformity and the control group. The analysis was conducted 
twice: first, to generate a differentially expressed gene list of the vertically classified 
groups (Long face vs. control); second, to generate a differentially expressed gene lists 
between horizontally classified groups (control vs. Class II vs. Class III).  
 
2.7.8.3.  Filtering the data 
A forward stepwise logistic regression analysis (SPSS v14) was used to narrow down 
both generated gene lists from the microarray experiment. Genes with a p-value of ≤ 
0.001  were  considered  significantly  different.  The  results  of  the  microarray  data 
analysis are presented in Chapter 4. 
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2.8.  QUANTITATIVE RT-PCR 
 
2.8.1.  INTRODUCTION 
In  general,  PCR  techniques  have  been  designed  to  amplify  only  a  DNA  sequence. 
Therefore, if RNA is the target material it has to be converted into complementary DNA 
(cDNA) in a process called reverse transcription (RT) prior to any application. In gene 
expression experiments the generated cDNA is further amplified via the PCR technique 
and the whole process is called reverse transcription polymerase chain reaction (RT-
PCR) (Robert and Farrell, 2005).  
 
2.8.2.  THE  CONCEPT  OF  REVERSE  TRANSCRIPTION  (RT)  AND  THE 
POLYMERASE CHAIN REACTION (PCR) 
The RT step is a single reaction conducted mainly at room temperature using a special 
enzyme called reverse transcriptase, usually random primers are used. These primers are 
designed to flank different regions of the genetic sequence and initiate the conversion of 
most of the RNA into cDNA (Nolan et al., 2006). The PCR step is exponential and is 
conducted in several reactions to generate millions of copies of the required sequence 
using  a  set  of  gene  specific  primers  (GSP),  an  enzyme,  a  buffer,  dNTPs  and  a 
thermocycler machine.  
 
The primers are synthetic short single strand oligos (mainly 25-30 bases) targeting only 
the required gene to be amplified. Two primers are often designed to determine the 
beginning and the end of the region of interest. The enzyme on the other hand, is called 
DNA  polymerase  and  is  capable  of  duplicating  the  region  of  interest.  The  Taq 
polymerase  is  an  example  of  a  naturally  derived  enzyme  from  a  bacterium  called 
Thermus  aquaticus  and  is  often  used.  The  buffer  provides  a  suitable  chemical 
environment  for  the  enzyme  to  work,  while  the  dNTPs  (deoxyribonucloside 
triphosphate) are the building blocks used by the polymerase enzyme to build up the 
required sequence during the reaction. The PCR reaction is conducted in cycles (mainly 
35-40  cycles),  with  each  amplification  cycle  undergoing  three  phases,  namely 
denaturation, annealing and elongation. Each phase requires a different temperature as 
provided  by  a  thermocycler  machine.  The  temperature  varies  from  one  protocol  to Chapter 2. General materials and methods 
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another depending on the enzymes and primers used. Figure 2.7 describes the basic 
steps for RNA amplification using the RT-PCR technique. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.8.3.  QUANTITATIVE vs. END POINT TO MEASURE GENE EXPRESSION 
The  level  of  expression  of  a  particular  gene  is  detected  by  incorporating  a  special 
fluorescent dye during the cDNA amplification. The higher the gene expression, the 
greater the fluorescence intensity. The gene expression intensity can be detected either 
at the end of the PCR procedure or during amplification. If the standard PCR technique 
is used for amplification, the level of expression is determined at the end of the reaction 
by  running  the  PCR  products  on  an  agarose  gel,  a  procedure  called  end-point 
measurement  while,  if  the  level  of  expression  is  measured  during  the  amplification 
phase of the PCR, the procedure is said to be in real-time. There is a direct relationship 
between the level of expression of a particular gene and the amplification cycle at which 
the fluorescence will occur (i.e. the earlier the cycle at which the fluorescence will occur 
Figure 2.7: General principles of the reverse transcription (RT) and the PCR technique. A) The 
RT step uses the reverse transcriptase enzyme and random primers to generate a hybrid of the 
RNA  template  and the  1st  strand cDNA.  B)  During  the  1st  PCR  cycle  the  RNA  template is 
degraded and a hybrid of both 1st and 2nd strands-cDNA are formed. C) The 2nd PCR cycle 
starts by using the ds-cDNA as a template, gene specific (GS) primers and the DNA polymerase 
enzyme to amplify the gene of interest (marked in red). The PCR step has 3 phases that occur in 
each cycle, for demonstration purposes, the 3 phases are only described at the 2nd cycle. By the 
end of the 2nd cycle the required gene will amplify by 2 copies, 4 copies in the 3rd cycle, 8 copies 
in the 4th cycle, and so on until a certain number of cycle n.  
Elongation  Denaturation  Annealing Chapter 2. General materials and methods 
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the higher the gene expression). This relationship cannot be detected by the end-point 
procedure.  Therefore,  real-time  PCR  has  the  advantage  of  being  more  sensitive  in 
detecting minute variations in the level of expression (Schmittgen et al., 2000). This is 
achieved by using a special thermocycler that is equipped with a sensitive camera and a 
monitor to display the accumulated fluorescence of the gene in each amplification cycle.  
 
Real-time PCR provides a quantitative measurement of the expression of a particular 
gene and it has, therefore, been called the quantitative reverse transcriptase polymerase 
chain reaction (qRT-PCR). The qRT-PCR has been reported with high agreement and 
concordance with the Affymetrix® gene expression chips (Shi et al., 2006; de Reynie’s 
et  al.,  2006)  and  was,  selected  therefore,  as  a  sensitive  gene  expression  technique 
parallel to microarrays to assess genes of interest.  
 
2.8.4.  TYPES OF qRT-PCR 
Two types of qRT-PCR are available, absolute and relative quantification. Both types 
have been  reported with  accurate, precise and sensitive results  (Cikos et  al.,  2007). 
However, the selection of one type over the other is governed by the design of the 
experiment. Absolute quantification provides a precise measurement by comparing the 
level of expression of an unknown sample to another standard reference template with 
known gene expression, such as the detection of viral load in a sample. The procedure is 
called the standard curve method. Relative quantification, on the other hand, is used to 
answer  most  clinical  questions  and  provides  a  relative  quantification  of  the  gene 
expression of one sample compared to a calibrator or a control sample, as in time-point 
experiments  or  case-control  studies.  This  procedure  relies  on  the  differences  in  the 
crossing threshold (Ct) cycle value between a sample and a control. The Ct value is the 
cycle at which a significant increase in the fluorescence of a particular gene is detected. 
Therefore, the procedure is called the comparative Ct method (Cikos et al., 2007). The 
relative qRT-PCR (comparative Ct method) was adopted for this research.  
 
2.8.5.  qRT-PCR PROTOCOL 
The following sections will describe the materials and methods used for the qRT-PCR 
experiment. Summary of the kits, machines and software used are listed in Appendix B 
while details of the laboratory protocol are available at Appendix C. Chapter 2. General materials and methods 
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2.8.5.1.  RNA samples used 
The 26 RNA samples used for the microarray experiment as well as three extra RNA 
samples purified from newly collected samples (total 29 samples) were used for the 
qRT-PCR procedure. 
 
2.8.5.2.  cDNA synthesis 
cDNA synthesis and amplification can be conducted either in one-step or two-steps. In 
the one-step method, all the reagents and primers of both the reverse transcription and 
the relative quantification real-time PCR amplification steps are mixed together in a 
single tube. Having all the reagents mixed in the same tube produce less contamination 
and saves time. However, the reaction is not optimised and the single enzyme (which 
performs both reverse transcription and amplification) is less efficient than having two 
separate enzymes performing under different optimal conditions (Easton et al., 1994). In 
the  two-step  procedure,  one  enzyme  is  used  to  perform  the  reverse  transcription  to 
generate cDNA, and the second enzyme is used to perform the amplification. Each step 
is performed under different optimal conditions. Although the two-step method is more 
time consuming than the one-step procedure, it is more flexible and sensitive when used 
for research purposes (Nolan et al., 2006). Therefore, the two-step method was selected 
for the relative quantification real-time PCR technique. 
 
2.8.5.3.  Endogenous reference gene 
The use of endogenous reference controls such as housekeeping genes in qRT-PCR 
reactions is a routine procedure. The expression of these genes often remains stable in 
all  cells  under  different  biological  and  experimental  conditions  (Robert  and  Farrell, 
2005). Based on these  grounds,  endogenous  genes  are used to  demonstrate that the 
overall expression of a target gene is not a result of variations in the RNA content, 
degradation  or  experimental  errors  and  is  a  true  biological  variation.  The  most 
commonly  used  housekeeping  genes  are  the  ß-actin,  ß2-microglobulin  (ß2M)  and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The expression of some of these 
genes has been found to be variable in different tissues (Lee et al., 2002) and it is 
important to select the appropriate control gene for the tissue of interest. GAPDH has 
been found to be the least variable among different tissues (Lee et al., 2002) and more 
stable in skeletal muscles of patients with different age categories (Touchberry et al., Chapter 2. General materials and methods 
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2006)  and  under  different  environmental  conditions  (Jemiolo  and  Trappe,  2004). 
Therefore, the GAPDH gene was selected for the current qRT-PCR experiment. 
 
2.8.5.4.  Fluorescent dye chemistry 
Fluorescent dyes are classified based on their binding specificity into either specific or 
non-specific dyes (Busten and Nolan, 2004). The non-specific dyes, for example the 
SYBR® Green dye, are added as a separate reagent into the PCR mixture and bind to 
any  double  stranded  genetic  molecule  that  is  generated  during  the  amplification 
reaction. This type of dye has the advantage of being cheap and can be incorporated into 
any optimised PCR reaction. However, it can bind to any double strand target including 
primer-dimer (two primers attached to each other) which might affect its specificity. 
The specific dyes, on the other hand, are included within the original design of the 
primers. The design would include two gene specific primers plus a fluorescent probe 
and  the  whole  design  is  called  an  assay.  Different  types  of  assays  are  available 
commercially, and their differences were observed in the shape of the fluorescent probe. 
Some assays have linear probes such as the TaqMan®, while others contain looped 
probes such as Beacons® and Scorpions®. The unique chemistry used to generate the 
specific dyes is more expensive than that for the non-specific ones (Busten and Nolan, 
2004) but the earlier provide higher specificity, sensitivity and accuracy (Levesque-
Sergerie et al., 2007). Furthermore, the TaqMan® assay is the most commonly used 
type of the specific dye and has shown high agreement with the Affymetrix® platform 
(Shi  et  al.,  2006).  Therefore,  the  TaqMan®  chemistry  was  chosen  for  the  current 
research (Figure 2.8). 
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Figure 2.8: The TaqMan® chemistry. The linear probe included in the TaqMan® assay is an 
oligonucleotide sequence that is designed to anneal close to one of the primers on one of the 
cDNA strands. One end of the probe (usually the 5’) contains a fluorescent reporter dye (R), 
while  the  other  end  (3’)  has  a  quencher  (Q).  As  long  as  the  reporter  remains  on  the  same 
oligonucleotide sequence and in close proximity to the quencher, no fluorescence will occur. a) 
Both primers as well as the probe are designed to attach to the designated gene and are in close 
proximity to each other. b) Once the polymerase enzyme extends the primer, it will encounter the 
probe on the 5’ end and will hit and release the reporter dye (R) into the solution. c) Following 
the  release  of  the  reporter  dye,  it  is  no  longer  quenched  and  fluorescence  will  occur.  This 
fluorescence will increase by each PCR amplification cycle. Chapter 2. General materials and methods 
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2.8.5.5.  Normalisation and calculation of gene expression values 
The  normalisation  process  is  required  to  remove  any  source  of  variation  in  RNA 
concentration and cDNA preparations between different samples. This procedure, and 
the calculation of the final gene expression value, is not a direct process and require the 
use of the Ct value in several equations. These equations have been described in detail 
by Livak and Schmittgen (2001) and will be discussed briefly in the following sections. 
All Ct values were exported from the qRT-PCR machine, and were transferred to an 
Excel  spreadsheet  where  the  gene  expression  value  was  calculated  using  the  final 
equation 2
-∆∆Ct. Figure 2.9 shows an example of a qRT-PCR amplification plot by which 
the Ct values were derived.  
 
  Step 1 (repeatability) 
Objective: To ensure high precision, both the target and the reference genes were 
experimented in quadruplicates. This produced several Ct values which were 
summated to produce an average Ct value obtained for both genes. 
Equation: = Average Ct of reference gene 
           Average Ct of target gene 
 
  Step 2 (normalisation)  
Objective:  To normalise the average Ct  of the  target  gene in  relation  to the 
average Ct of the reference gene of the same sample thereby producing the ∆Ct 
Equation: = Average Ct target – Average Ct  reference = ∆Ct 
 
  Step 3 (calibration) 
Objective: One of the control samples, which had average vertical and horizontal 
craniofacial features, both clinically and radiographically, was selected as the 
calibrator  sample  (C).  This  was  to  produce  ∆∆Ct  for  each  sample.  During 
calibration, the calibrator sample was also calibrated to itself to produce a value 
of zero. The reason for generating a zero value for the calibrator sample was to 
produce a value of one when used in the next equation, and one would act later 
as a baseline for relative gene expression comparison. 
Equation: = ∆Ct target – ∆Ct calibrator = ∆∆Ct 
 Chapter 2. General materials and methods 
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  Step 4 (gene expression value) 
Objective: The fourth equation was derived from the belief that each gene was 
doubled  during  each  amplification  cycle,  assuming  92-100%  amplification 
efficiency (Livak and Schmittgen, 2001). The equation transferred the calibrator 
value into 1 which acted as a baseline for gene expression comparison. The 
generated gene expression values of the other samples which were higher or 
lower from the baseline were considered a fold change. The results were then 
used for further data analysis to assess the significance of the difference. 
 Equation: = 2
-∆∆Ct 
  
 
 
 
 
 
 
 
 
 
 
 
 
2.8.6.  qRT-PCR DATA ANALYSIS 
All qRT-PCR data analysis will be discussed in Chapter 6, including the various patient 
groupings and the different types of statistical analyses employed. 
Figure  2.9:  An  example  of  calculating  the  relative  gene  intensity  value  using  the  2
-∆∆Ct 
equation.  Both  GAPDH  and  target  gene  for  each  sample  have  been  tested  in  quadruplicate 
reactions. These are presented as 4 lines in close proximity. The background noise is the level 
where no fluorescence is seen, usually up to cycle 13. The Ct threshold is the cycle at which a 
detectable increase in the fluorescence is observed. The later the Ct value the lower the gene 
expression, as in the deformity target gene, occurring at almost Ct 30. The Ct values obtained 
from the quadruplicate reactions are summated to produce the average Ct for each gene. For 
example,  to  calculate  the  gene  intensity  value:  1)  Calculate  the  ∆Ct  (deformity=30-18=12; 
calibrator=25-21=4); 2) Calculate ∆∆Ct (deformity=12-4=8; calibrator= 4-4=0); 3) Calculate 
2
-∆∆Ct  (deformity=2
-9  =0.004;  calibrator=2
0  =1).  Interpretation  of  the  data  indicates  that  the 
deformity patient has a relatively lower gene expression (0.004 fold change) compared to the 
calibrator sample.  Chapter 2. General materials and methods 
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2.9.  SUMMARY OF THE DESIGN OF THE STUDY 
A summary of the design of the current research is presented in Table 2.5. 
 
Table 2.5: Design of the current study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials  Design 
ETHICS 
Ethical approval  
 
Three sites (EDH, WCH, RMH) 
SUBJECTS 
Type of study 
Types of craniofacial deformities included 
Experimental variable   
Diagnostic tools  
 
Case control study (Deformity vs. Control) 
Class II, Class III and long faces 
Gene expression level 
Lateral cephalometric radiographs 
TISSUE SAMPLES 
Tissue of interest 
Type of tissue used 
Sample storage   
 
Masseter muscle 
Fresh muscle biopsy 
RNAlater® 
MICROARRAY 
Platform 
GeneChip® generation 
 
Affymetrix® 
HG U133 plus 2.0 array  
qRT-PCR 
Type of RT-PCR 
cDNA synthesis 
Fluorescent dye chemistry 
Endogenous reference gene  
Comparative Ct method   
 
Relative quantification  
Two-step procedure 
TaqMan® assay  
GAPDH 
2
-∆∆Ct  
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3.1.  INTRODUCTION 
Several protocols for RNA extraction from human masseter muscle tissue have been 
reported in the literature (Monemi et al., 1996; Price et al., 1998; Singh et al., 2000; 
Gedrange et al., 2005). Most of these protocols are based on the Guanidinium-Acid-
Phenol-Chloroform method originally described by Chomczynski and Sacchi (1987). 
Although this method has provided good RNA yield (Deng et al., 2005), high DNA 
contamination  has  also  been  reported  when  compared  with  other  RNA  extraction 
methodologies  (Deng  et  al.,  2005;  Schagat  et  al.,  2008).  Both  gene  expression 
microarray (Hatfield et al., 2003) and quantitative RT-PCR (Peters et al., 2004) require 
high quality RNA with no DNA contamination. Therefore, it was important for the 
current study to assess a range of RNA purification techniques, procedures and reagents 
to optimise the RNA extraction protocol, with minimal genomic DNA contamination.  
 
3.2.  STEPS TO ELIMINATE DNA CONTAMINATION 
Various  procedures  have  been  recommended  to  eliminate  DNA  contamination  from 
RNA samples. These were vigorous disruption and homogenisation (Berglund et al., 
2007), the use of silica membrane spin columns (Deng et al., 2005) and application of 
DNase digestion reagents (Peters et al., 2004). 
  
3.2.1.  DISRUPTION AND HOMOGENISATION 
Disruption  is  performed  to  break  down  the  cell  membrane,  nuclear  membrane  and 
connective tissue proteins to release the genetic material (DNA and RNA) within the 
cell, and is often conducted using lysing buffers (chemical disruption). Homogenisation 
is the process of reducing the viscosity of the lysate solution which aids the release of 
the  DNA  and  RNA  from  the  surrounding  protein  membranes.  Homogenisation  is 
mainly  performed  using  different  types  of  grinding  machines  (mechanical 
homogenisation) (Robert and Farrell, 2005). Depending upon the nature of the tissue, 
some would require disruption and light homogenisation, while other tissues with high 
connective  tissue  content  would  necessitate  disruption  combined  with  vigorous 
crushing. Skeletal muscles have significant connective tissue (extracellular matrix) and 
protein  content  (contractile  proteins  of  the  muscle  fibres)  and  it  was  therefore 
recommended  to  use  both  chemical  (lysing  buffers)  and  aggressive  mechanical Chapter 3. Optimisation of RNA extraction protocol 
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(crushing and grinding) techniques to release the RNA material (Robert and Farrell, 
2005).  
 
The Guanidinium-Acid-Phenol-Chloroform method (Chomczynski and Sacchi, 1987) 
that was adopted by previous masseter muscle researchers was based on different types 
of  chemical  lysing  buffers  combined  with  either  mortar  and  pestle  or  standard 
homogenisers to perform mechanical disruption and homogenisation (Price et al., 1998; 
Singh et al., 2000; Gedrange et al., 2005 and 2006; Harzer et al., 2007). However, the 
use of standard homogenisers was less efficient when compared to a vigorous disruption 
procedure including vessels containing ceramic beads placed in a special reciprocating 
machine (Berglund et al., 2007). The vigorous protocol  conducted by Berglund and 
colleagues (2007) was performed on fibrotic skin tissue using ceramic beads (lysing 
matrix D®) placed in a special device called the FastPrep® machine, with a speed of six 
metres per second for 40 seconds and placed on ice for 5 minutes, repeated three times. 
The  FastPrep®  machine  is  a  reciprocating  device  which  can  accommodate  twelve 
lysing matrix vessels, and has a rotation range of 4-6.5 metres per second (Figure 3.1). 
Furthermore, several types of lysing ceramic and stainless steel beads are available on 
the market and it was not known whether muscular tissue would behave in the same 
manner as skin when the lysing matrix beads and the FastPrep® machine were used for 
disruption and homogenisation. Therefore, it was decided to test different types of beads 
and various speed settings of the FastPrep® machine to optimise the disruption and 
homogenisation of masseter muscle tissue samples.  
 
 
Figure 3.1: The FastPrep® machine. 1) Applying different lysing matrix vessels, which contain 
the lysing buffer, the beads  and the sample, into the reciprocating device. 2) All twelve slots of 
the  FastPrep  machine  are  filled  with  the lysing  matrix  vessels.  3)  Ready  for  disruption  and 
homogenisation.  Chapter 3. Optimisation of RNA extraction protocol 
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3.2.2.  THE PURIFICATION TECHNIQUE 
The  aim  of  the  purification  technique  is  to  separate  RNA  from  DNA  and  protein 
following the disruption and homogenisation procedure (Robert and Farrell, 2005). The 
Chomczynski and Sacchi (1987) method relies on the organic solvent properties of acid-
phenol and chloroform to separate the lysate solution based on density,  leaving two 
main layers  within the  same tube; the  aqueous phase which contains  RNA and the 
organic  phase  which  contains  DNA  and  protein.  An  alternative  and  more  recently 
developed  silica  membrane  technology  has  been  reported  to  produce  less  DNA 
contamination (Deng et al., 2005; Schagat et al., 2008). This technology incorporates a 
silica-gel-membrane spin column® which has selective binding abilities that can attract 
and  bind  RNA  to  the  membrane.  The  filtration  of  DNA  and  proteins  through  the 
membrane can then be discarded. Furthermore, the working time of the Guanidinium-
Acid-Phenol-Chloroform procedure was around six hours compared to one hour of the 
silica  membrane  technology  (Santiago-Vázquez  et  al.,  2006).  Therefore,  the  silica 
membrane technology was selected to purify high quality RNA samples with minimal 
DNA contamination. 
 
3.2.3.  DNase DIGESTION 
Although  silica  membrane  technology  markedly  reduces  the  DNA  contamination, 
DNase  digestion  reagents  were  still  provided  as  an  optional  step  that  can  be  used 
separately with any extraction procedure. DNase digestion can be performed on-column 
during RNA purification or as a separate step following RNA elusion (Bustin, 2002). 
Samples without DNase digestion were reported with 25% DNA contamination, while 
the use of both procedures (on-column and after elusion protocol) markedly eliminated 
DNA to leave less than 2% contamination (Peters et al., 2004). However, for samples 
with expected low RNA yield it is preferable to use the on-column rather than the post-
elution digestion procedure (Bustin, 2002). Therefore the on-column DNase digestion 
method was chosen in the present study.  
 
During the course of this  study, a recently published human masseter muscle study 
(Suchak  et  al.,  2009)  has  successfully  used  ceramic  beads  (lysing  matrix  D®),  the 
FastPrep® machine and silica membrane technology to purify total RNA from fresh 
human masseter muscle biopsies which was then used for quantitative RT-PCR gene Chapter 3. Optimisation of RNA extraction protocol 
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expression. However, the machine settings were not reported and no DNase digestion 
step was performed.  
 
The aims of the above newly developed protocol within this research were therefore, to 
use all possible means of DNA elimination from fresh human masseter muscle biopsies, 
as both microarray and quantitative RT-PCR gene expressions require high quality and 
purity RNA samples. This was achieved by: 
 
1.  The  use  of  different  types  of  beads  including  the  lysing  matrix  beads®  to 
ascertain the best type that can perform proper disruption and homogenisation of 
masseter muscle biopsies. 
 
2.  The use of different  settings  of the FastPrep® machine to  provide sufficient 
disruption for muscular tissue without RNA degradation, that may occur as a 
result of heat generated from the crushing process. 
 
3.  Assess  the  use  of  the  silica  membrane  technology  (RNeasy®  mini  kit  from 
Qiagen™) with and without DNase digestion step. 
 
3.3.  MATERIALS AND METHODS 
The following sections will describe briefly the materials and methods used for total 
RNA  extraction.  All  laboratory  procedures  were  conducted  following  the  RNeasy® 
mini kit technical manual. However, optimisation procedures and modifications within 
the original RNeasy® mini kit protocol will be discussed in details. Summaries of kits 
and machines used are listed in Appendix B, while details of the final RNA extraction 
protocol are available at Appendix C.  
 
3.3.1.  INHIBITION OF RNase ACTIVITY 
RNases are a group of enzymes that are present in almost all cells and can degrade 
RNA. The RNase activity should be inhibited at all stages of RNA preparation (Robert 
and Farrell, 2005). All working surfaces and instruments (e.g. centrifuge, pipettes and 
bottles) were cleaned with special wipes (RNaseZap® wipes) which remove RNases. 
Furthermore, the tips, centrifuge tubes and water used were also RNase free. Chapter 3. Optimisation of RNA extraction protocol 
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3.3.2.  SOURCES OF THE SAMPLES USED 
A  total  of  six  masseter  muscle  biopsies  collected  from  four  subjects  were  used  to 
standardise the total  RNA extraction protocol. Two patients  had both right  and left 
biopsies, while the other two patients had the biopsy taken from one side only. 
 
3.3.3.  THE AMOUNT OF STARTING MATERIAL 
Based  on  the  binding  capacity  of  the  spin  columns  of  the  RNeasy®  mini  kit,  the 
required amount of starting tissue was not more than 30 mg. Using microscissors and 
stainless steel tweezers, each muscle biopsy was cut, weighed (30 mg each), and then 
transferred into a clean tube without any RNAlater® to be disrupted and homogenised. 
 
3.3.4.  DISRUPTION AND HOMOGENISATION 
 
3.3.4.1.  Chemical disruption 
Following the manufacturer’s protocol, chemical disruption was performed using the 
RLT® lysing buffer mixed with 2-Mercaptoethanol. Both materials are strong reagents 
that can dissolve proteins to release the RNA from the cells. Furthermore, the RLT® 
buffer included guanidinium thiocyanate which inhibits RNase activity. 
 
3.3.4.2.  Mechanical homogenisation 
  Optimisation procedure 
Three different types of beads (lysing matrix D®, lysing matrix A® and cold stainless 
steel beads) (Figure 3.2), and three different settings of the FastPrep® machine (1 round 
40s, 1 round 20s and 2 rounds of 20s) were tested to standardise the disruption and 
homogenisation procedure (Table 3.1). The stainless steel beads (supplied by Qiagen®) 
were kept cold in a fridge prior to use, in order to reduce the heat generated in the 
reciprocating machine.  
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Table 3.1: Nine different protocols tested to standardise the disruption and homogenisation 
method. 
Beads type  Machine settings  Cooling down 
Protocol 
no 
No of 
rounds 
Speed/ 
round 
Time 
Lysing matrix D 
(1.4mm ceramic 
spheres) 
1 
2 
3 
1 round 
1 round 
2 rounds 
6 
6 
6 
40s 
20s 
20s 
Once, 5m after disruption 
Once, 5m after disruption 
Twice, 5m between and after rounds 
Lysing matrix A  
(one ¼’’ ceramic 
bead with  garnet 
matrix) 
4 
5 
6 
1 round 
1 round 
2 rounds 
6 
6 
6 
40s 
20s 
20s 
Once, 5m after disruption 
Once, 5m after disruption 
Twice, 5m between and after rounds 
Stainless steel (StSt) 
(2 stst beads) 
7 
8 
9 
1 round 
1 round 
2 rounds 
6 
6 
6 
40s 
20s 
20s 
Once, 5m after disruption 
Once, 5m after disruption 
Twice, 5m between and after rounds 
s: Second. m: Minute.  
 
 
 
 
Figure 3.2: The various types of beads used for optimising the disruption and homogenisation 
procedure. The lysing matrix D contains small 1.4mm white ceramic spheres. The lysing matrix A 
contains  one  ¼’’  ceramic  bead  with  grain-like  garnet  matrix.  The  third  tube  contained  two 
stainless steel beads.  Chapter 3. Optimisation of RNA extraction protocol 
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3.3.5.  RNA PURIFICATION 
The lysate solution generated from the disruption and homogenisation was spun down 
and then transferred to a clean tube. To initiate the selective binding of RNA to the 
silica membrane, the lysate solution was mixed with an equal amount of 70% ethanol. 
 
3.3.5.1.  Binding 
The lysate was passed through the column membrane by centrifugation. The RNA was 
bound to the filter membrane, while the flow-through supernatant containing the DNA 
and protein contaminants passed through the filter and collected in a tube which was 
then discarded.  
 
3.3.5.2.  Elimination of DNA contamination 
  Optimisation procedure 
To  test  whether  a  DNase  digestion  step  was  required  for  the  RNA  purified  from 
masseter muscle tissue, each of the first three protocols described earlier in Table 3.1 
was  repeated  twice  using  the  same  tissue  samples;  once  with  DNase  digestion  and 
secondly without DNase digestion. The DNase digestion step was performed using the 
manufacturer’s  protocol  of  the  RNase-free  DNase  set®  kit.  The  DNase  digestion 
reagent was kept on-column for 15 minutes at room temperature. 
 
3.3.5.3.  Washing 
Following the manufacturer’s protocols for both the with and without DNase digestion, 
the filter membrane was washed and centrifuged several times using different buffers to 
remove any remaining DNA or protein contaminants attached to the membrane. The 
RNA remained attached to the silica membrane.  
 
3.3.5.4.  Elusion 
30µl  of  RNase  free  water  was  applied  to  the  membrane  for  five  minutes  at  room 
temperature  to  dissolve  the  bound  RNA.  This  was  followed  by  centrifugation  at 
maximum speed to elute the total RNA in a clean tube. The total RNA was distributed 
into 6 equal aliquots, each containing 5µl and was kept at -80°C for further use. 
 
 Chapter 3. Optimisation of RNA extraction protocol 
 
78 
 
3.3.6.  RNA QUALITY CONTROL 
 
3.3.6.1.  RNA quantity 
The  quantity  of  RNA  was  assessed  using  a  spectrophotometer  which  measures  the 
optical density (OD) of the RNA at a wavelength of 260nm. The RNA concentration 
(µg/ml) was then calculated using the OD260 value multiplied by the dilution factor 
(dilution factor = total volume/ RNA volume).  
 
3.3.6.2.  RNA purity 
The purity of RNA was routinely assessed by the A260/A280 ratio that is derived from 
the spectrophotometer. The A260/A280 ratio is generated from the light absorbance of 
the genetic material at a wavelength of 260nm and the protein at 280nm. Acceptable 
RNA purity was represented by a ratio of 1.68-2.06. Samples having an A260/A280 
ratio lower than 1.68 (protein contamination) or higher than 2.06 (DNA contamination) 
were excluded from the experiments.  
 
3.3.6.3.  RNA quality 
The quality of RNA was assessed using an Agilent 2100 Bioanalyser® and the RNA 
6000 Nano LabChip kit (detailed protocol at Appendix C). The Nano chip contains 
microcapillary channels that are filled with gel. Once the RNA has been loaded into the 
chip,  the  nucleic  acid  is  separated  based  on  size  by  a  voltage-induced  system  and 
fluorescence  occurs  by  incorporating  a  fluorescent  dye  during  the  preparation 
(Schroeder et al., 2006). The fluorescence is laser-induced by a Bioanalyser machine. 
The quality of total RNA was assessed by observing the 18 and 28 subunits (S) of the 
ribosomal RNA (rRNA) that was viewed as an image on the computer using special 
software supplied by the same company. The image was composed of two components, 
the y-axis which is the fluorescence (Fu) and the x-axis which is the size of the fragment 
(nucleotide –nt) and was presented as a line with several peaks. Figure 3.3 describes the 
basic components of an electropherogram. 
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The amount, quality and purity of the total RNA sample has a large impact on the 
shape, length and the position of the peaks including the 18S and 28S of the rRNA 
peaks generated on the image. For example, the higher the amount and yield of the total 
RNA,  the  greater  the  18S  and  28S  rRNA  peaks  (low  amounts  of  total  RNA  are 
presented  as  short  peaks).  Following  the  manufacturer’s  guidelines  for 
electropherogram image interpretation, the DNA contamination could be seen as a peak 
signal  at  the  inter-region  or  the  precursor-region.  RNA  degradation  often  occur  as 
several  well-defined  peaks  at  the  fast,  inter  or  precursor  regions.  Elevation  of  the 
baseline, particularly at the inter-region would indicate partially digested RNA. Any 
peaks  at  the pre- or post-region or rising of the marker signal  were not  considered 
critical.  Any  samples  with  obvious  DNA  contamination  or  RNA  degradation  were 
excluded  from  further  experimentation.  Figure  3.4  illustrates  some  examples  of  the 
good and poor RNA quality outputs ranging from a scale of 1-10, where 10 was the best 
quality.  Samples  with  electropherogram  similar  to  the  scale  1,  2,  3,  4  and  5  were 
excluded from the experiments.  
 
 
Figure 3.3: Components of good RNA quality as viewed by the electropherogram image. Fu, 
fluorescence; nt, nucleotide.   Chapter 3. Optimisation of RNA extraction protocol 
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Figure 3.4: Electropherogram images showing different RNA qualities. 1, contains no RNA and 
is presented as a flat line with no peaks. 2-5, shows poor quality degraded RNA shown by the 
vertical  arrow  indicating  an  elevated  baseline  with  several  indistinct  peaks.  6  and  7  are 
acceptable RNA samples with distinct peaks and slightly raised baseline. 8-10 represent good 
quality  RNA  with  varying  degrees  of  height  between  the  18S  and  28S  peaks  (adapted  from 
Mueller et al., 2004). Chapter 3. Optimisation of RNA extraction protocol 
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3.4.  RESULTS 
 
3.4.1.  THE EFFECT OF DIFFERENT BEADS AND MACHINE SETTINGS ON 
THE  DISRUPTION  AND  HOMOGENISATION  OF  MASSETER 
MUSCLE BIOPSIES 
Generally, the lysing matrix D® showed better RNA quality than the lysing matrix A 
and the stainless steel beads. This was similar to the results of Suchak and colleagues 
(2009) who used the lysing matrix D® and the FastPrep® machine to purify total RNA 
from  fresh  human  masseter  muscle  biopsies  to  be  used  for  real-time  PCR  gene 
expression analysis. The lysing matrix D® contained several 1.4mm ceramic spheres 
which  have  aided  in  the  disruption  and  homogenisation,  while  the  lysing  matrix  A 
contained one 1/4’’ ceramic bead with a garnet matrix. The garnet matrix was a material 
that is very similar to sand, and even though the lysate solution was spun down prior to 
transferring to the spin column, traces of the garnet matrix were still present in the 
lysate solution and partially clogged the silica membrane. This may have resulted in 
reduced  efficiency  of  the  membrane  to  eliminate  DNA  contamination.  All  three 
stainless steel protocols showed high RNA degradation, which may have been attributed 
to the heat generated from the stainless steel material while crushing and vibrating.  
 
As for the machine settings, protocol 3 of the lysing matrix D® with two rounds of 20 
seconds (speed 6 metres per second) and cooling down for 5 minutes in between rounds 
was the best protocol. This protocol resulted in an intact RNA in both the lysing matrix 
D® and A. This may have been attributed to two reasons. First, less time (20s) for the 
heat to be generated than the 40s protocol. Second, the process of cooling down twice 
may have prevented RNA degradation. Figure 3.5 demonstrates the Bioanalyser profile 
and the A260/A280 ratio of the nine different protocols for RNA extraction. 
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Figure 3.5: Total RNA quality of the nine different protocols. Protocol 1, using lysing matrix 
D® with machine settings of 1 round, 40s and cooling down once, has shown low RNA content 
presented by the small 18S and 28S peaks as well as DNA contamination with a middle peak 
between both subunits of the rRNA and a high A260/A280 ratio. Protocol 2, using lysing matrix 
D®  with  machine  settings  of  1  round,  20s,  and  cooling  down  once,  has  shown  slight  RNA 
degradation presented as an elevated baseline as well as DNA contamination with a large peak 
at the post-region. Protocol 3, using lysing matrix D® with machine settings of 2 rounds, 20s and 
cooling twice, has shown good RNA quality with flat baseline and two distinct peaks. However, a 
small hump was evident at the post-region indicating slight DNA contamination. Protocols 4, 5 
and 6 of the lysing matrix A with the different machine settings have shown mainly mild-moderate 
RNA degradation with various baseline elevations and DNA contamination as presented by the 
peaks at the middle and post regions. Protocols 7, 8 and 9 of the stainless steel have shown 
severe RNA degradation with a single peak only or several indistinct peaks (as in protocol 9). Chapter 3. Optimisation of RNA extraction protocol 
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3.4.2.  THE EFFECT OF DNase DIGESTIONS ON RNA PURIFICATION 
The use of the DNase digestion step during total RNA purification produced better 
RNA quality (with minimal DNA contamination) than the standard RNeasy mini kit 
procedure (without any DNase digestion). This indicated that, whilst the use of silica 
membrane spin columns can reduce DNA contamination, skeletal muscles would still 
require a DNase digestion step to produce a pure RNA sample. Figure 3.6 shows the 
electropherogram  of  the  three  different  protocols  that  were  used  with  and  without 
DNase digestion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Total RNA quality with and without DNase digestion.  All three protocols have 
shown less DNA contamination when the DNase digestion step was used. DNA contamination 
was evident in all three protocols without the DNase digestion step. DNA contamination at the 
mid  region  (as  in  protocol  1)  and  the  precursor  region  (as  in  protocol  2)  were  considered 
critical, while protocol 3 also shows DNA contamination but at the post-region which was not 
considered  critical  for  gene  expression  analysis.  The  RNA  degradation  that  was  present  in 
protocol 1 and 2 both with the DNase step and without were related to the machine settings. Chapter 3. Optimisation of RNA extraction protocol 
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3.5.  QUALITY CONTROL OF TOTAL RNA SAMPLES 
Total RNA was purified from masseter muscle biopsies of 29 subjects using the lysing 
matrix D® for disruption and homogenisation, machine settings of 2 rounds, each round 
for 20 seconds at speed of 6 and cooling down twice for 5 minutes on ice in between 
rounds.  The  DNase  digestion  step  on-column  was  also  performed.  Generally,  all 
samples  exhibited  acceptable  A260/A280.  Most  of  the  samples  showed  good  RNA 
quality  with  two  distinct  peaks,  a  flat  baseline,  no  DNA  contamination  or  RNA 
degradation  as  viewed  by  the  electropherogram  image  of  the  Bioanalyser.  Other 
samples were considered with acceptable quality such as samples 1, 8, 9, 16 and 25 
which demonstrated  a small  hump  at  the post-region indicating a non-critical  DNA 
contamination. Samples 3, 19, 21, 22, 23 and 29 showed reduced 28S peaks which 
indicated slight RNA degradation, and samples 24 and 26 showed widening of the 18S 
rRNA which has also indicated slight RNA degradation. The differences in the total 
RNA quality as viewed by the Bioanalyser profile may have been attributable to due 
variations  in  the  connective  tissue  content  between  individuals,  which  may  have 
affected disruption and homogenisation and resulted in slight RNA degradation or DNA 
contamination. However, DNA contamination was seen at the post-region area which 
according  to  the  manufacturer’s  guidelines  was  not  considered  critical  criterion. 
Therefore, all samples were still considered acceptable as all other electropherogram 
criteria, as well as the A260/A280 ratios were within the acceptable range (1.68-2.06), 
and they were therefore included in the gene expression experiments. Figure 3.7 shows 
the quality control of the 29 total RNA samples. 
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Figure 3.7: Quality control of all 29 total RNA samples included in the current research. All 
samples marked with a green tick were of good quality showing acceptable A260/A280 ratio, 
distinct  18S  and  28S  rRNA,  flat  baseline,  no  RNA  degradation  or  DNA  contamination.  The 
remaining samples were of acceptable quality where samples 1, 8, 9, 16 and 25 had slight DNA 
contamination at the pos-region area which was not considered critical. Samples 3, 19, 21, 22, 23 
and 29 showed reduced 28S peak, while samples 24 and 26 demonstrated slight widening of the 
18S, all of which may have indicated a slight RNA degradation. All samples were accepted for 
gene expression experiments.   Chapter 3. Optimisation of RNA extraction protocol 
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3.6.  SUMMARY AND CONCLUSIONS 
An  optimised  protocol  has  been  developed  to  disrupt  and  homogenise  fresh  human 
masseter muscle biopsies using the lysing matrix D®, the FastPrep® machine with 20 
seconds, speed 6, 5 minutes cool down on ice, which was repeated twice. A DNase 
digestion step was incorporated for 15 minutes during total RNA purification and silica 
membrane spin columns were used for elusion. The protocol has proven its efficiency 
with  good  purity,  quality  and  integrity  of  29  total  RNA  samples  as  shown  by  the 
A260/A280 ratios and the Bioanalyser profiles. 
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Chapter 4. Discovery of masseter muscle candidate 
genes in relation to non-syndromic craniofacial 
deformities: A microarray analysis 
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4.1.  INTRODUCTION 
Microarray  gene  expression  has  been  used  successfully  to  identify  novel  candidate 
genes in relation to various craniofacial syndromic phenotypes such as clefts (Park et 
al., 2006), craniosynostoses (Carinci et al., 2002) and hemifacial microsomia (Cai et al., 
2005).  However,  this  technique  has  not  been  used  previously  to  unravel  masseter 
muscle candidate genes in relation to various non-syndromic craniofacial deformities.  
 
The present research has managed to fully hybridise a total of 27 U133 Plus 2.0 array 
GeneChips® (including the technical replicate) (materials and methods are presented in 
Chapter 2, Section 2.7.5). This was using the total RNA purified from fresh human 
masseter  muscle  biopsies  of  11  control  and  15  deformity  patients  (details  of  RNA 
extraction and quality control are presented in Chapter 3). The aim of this chapter is 
therefore, to present the results of the various analytical steps of the GeneChip® data 
that  have  generated  the  differentially  expressed  gene  lists  between  vertically  and 
horizontally classified craniofacial groups. 
 
4.2.  AFFYMETRIX® GeneChip® QUALITY CONTROL 
Following hybridisation of all U133 Plus 2.0 array chips, a GeneChip® quality control 
step was conducted to ensure efficient labelling and hybridisation procedures as well as 
proper scanning prior to data pre-processing. This has included seven quality control 
measures: 1) Poly-A controls; 2) 3’/5’ ratio of both ￟-actin and GAPDH endogenous 
reference  genes;  3)  Values  of  the  hybridisation  controls;  4)  Percentage  of  genes 
expressed; 5) Background values; 6) Raw noise; 7) Scaling factor.  
 
Both technical replicate samples were used during the GeneChip® quality control (QC) 
and pre-processing data. However, during the microarray statistical analysis, only the 26 
samples were included. Samples were numbered from 1 to 27 starting with the 1st batch 
going  through  to  the  4th  batch  samples.  Both  samples  1  and  2  were  the  technical 
replicates (R) and had comparable results. Out of the 27 samples, 25 passed the seven 
QC measures, while the remaining two samples (number 10 and 15) failed only the 
3’/5’ ratio of both control genes. Although samples number 7, 8, 16, 19, 20, 22 and 23 
had a higher ß-actin 3’/5’ ratio than the Affymetrix recommendations, the GAPDH ratio 
was acceptable. However, all samples were included in the pre-processing procedure to Chapter 4. Microarray gene expression 
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further assess the correlation between samples and to identify any outliers. Table 4.1 
summarises the general GeneChip® quality control results, while details of the quality 
control values for each sample Appendix D. 
 
Table 4.1: GeneChip® quality control measures. 
Quality control measure  Standard 
good quality 
GeneChip® QC of the 
current project 
Assessment of technical errors (Poly-A control genes) 
Five prokaryotic genes (dap, lys, phe, thr) were spiked-in 
during sample preparation. Any technical errors would 
prevent the expression of these genes. 
Similar 
expression of 
the five genes 
between 
different array 
samples. 
-All 27 samples passed. 
Assessment of RNA quality and  labelling (3’/5’ ratio)  
Both GAPDH and ß-actin are long genes and if RNA 
degradation occurs it usually starts at the 5’ end, while 
labelling occurs from the 3’ end. Poor RNA quality or 
inefficient labelling would produce large variations in the 
expression between 3’ and 5’ probes resulting in a high 
ratio.    
Ratio < 3 for 
both GAPDH 
and ß-actin 
genes. 
-25 samples passed, 
including both technical 
replicates. 
-2 samples failed both 
genes (samples 10 and 
15). 
-7 samples failed the ß-
actin gene (samples 7, 8, 
16, 19, 20, 22 and 23). 
Assessment of the labelling process (hybridisation controls) 
Four prokaryotic control genes (bioB, bioC, bioD and cre) 
were spiked-in during hybridisation and are prepared in 
different concentrations. They should have increasing 
intensities reflecting their increasing concentrations.  
Increasing 
intensity call 
starting from 
bioB < bioC < 
bioD < cre. 
-All 27 samples passed 
Assessment of technical replicates (% of genes expressed) 
The number of probe-sets expressed relative to the total 
number of probe-sets. 
Technical 
replicates 
should have 
less than 10% 
difference 
-Both technical replicates 
had a difference of 4.9% 
(passed). 
Assessment of the effect of the scanner (Background values) 
Arrays scanned with the same scanner should have 
comparable background values. 
No specific 
Affymetrix 
guidelines. 
Typical range 
20-100 
-All 27 samples had 
comparable background 
values (passed). Chapter 4. Microarray gene expression 
 
92 
 
Quality control measure  Standard 
good quality 
GeneChip® QC of the 
current project 
Raw noise values 
Noise is the pixel-pixel variation of probes on the scanned 
array chip. Both the scanner and sample quality can affect 
this value. 
Comparable 
values 
between 
chips. 
-All 27 samples had 
comparable raw noise 
value (passed). 
Scaling factors 
In arrays containing large number of transcripts it is 
expected that some of the genes will be expressed 
differently between samples, while the majority would not 
change. The aim of scaling is to produce similar average 
intensities of the unchanged genes across all arrays. A broad 
range of scaling factor would indicate variable RNA quality 
or quantity between samples. 
Affymetrix 
recommend a 
range of 
scaling factor 
less than 3 
fold-change (< 
3 SD) 
-All 27 samples had a 
scaling factor less than 3 
(passed). 
All 27 samples passed 6 quality control measures. As for the 7th measure which was the 3’/5’ ratio, 2 
samples failed the 3’/5’ ratio of both genes and the other 7 samples failed the 3’/5’ ratio of ￟-actin gene 
only. 
 
 
4.3.   PRE-PROCESSING OF DATA AND NORMALISATION 
Pre-processing of data included normalisation and removal of any systematic variations 
between arrays. The data were viewed in different formats of plots, histograms and 
charts to assess and exclude any poorly correlated chips. Sample number 15 was the 
least correlated sample and showed large variations in relation to all other samples. 
Although  this  sample  showed  a  good  Bioanalyser  profile  when  the  total  RNA  was 
assessed  in  the  previous  Chapter  3  (Figure  3.7,  sample  number  15),  partial  RNA 
degradation might have occurred during the laboratory procedure. Table 4.2 summarises 
the  results  obtained  from  the  different  plots  and  histograms.  All  graphs,  plots, 
histograms and charts are presented in Appendix D. 
 
Table 4.2: Description of normalisation graphs used. 
Normalisation graph  Standard good quality  Normalisation results for 
the current project 
Box plots 
Used to identify outliers in 
microarray normalised data. 
Normalised box plots of all samples 
should have comparable medians. 
-No obvious outliers were 
detected (passed). Chapter 4. Microarray gene expression 
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Normalisation graph  Standard good quality  Normalisation results for 
the current project 
Perfect-match (PM) histogram   
This histogram represents a 
measurement of the density of the 
probe intensities of the PM 
probes. Used also to identify 
outliers. 
Normalised date would show 
density skewed to the right with 2 
distinct peaks. All samples should 
have similar histogram appearance. 
-Typical histogram 
appearance. 
-No obvious outliers were 
detected (passed).  
PM vs. MM histogram 
The mis-match (MM) probes 
measure non-specific 
hybridisation while PM probes 
measure specific hybridisation. It 
is expected that the PM probes 
will produce strong intensities 
while the MM probes weaker 
intensities. 
Normalised data would show 
differences between the PM and 
MM curves. 
-All samples had typical 
histogram appearance 
(passed). 
RNA degradation plot 
The probe-sets for each control 
gene were designed with 11 
probes (0-10). The 0 probe 
presenting the most 5’ sequence 
and the 10th probe is the most 3’ 
sequence. Since RNA degradation 
starts at the 5’ end, and labelling 
occurs from the 3’ end, therefore 
it is expected that the probes at the 
3’ have higher intensity than the 
probes at the 5’. 
Intensities of the genes were 
expected to be higher towards the 
3’ probes. 
-All samples showed typical 
RNA degradation plot 
appearance (passed). 
MvA plots  
A graphical representation of 
general gene expression variation 
between two samples only within 
the same classified group. The 
fold-change (M) at the y-axis is 
plotted against the average 
fluorescence intensity (A) of both 
samples at the x-axis. 
If both samples are highly 
comparable they will have a 
symmetric appearance around the 
x-axis (leaf like appearance). 
-Sample 8 and 15 showed 
large variations when 
compared to other samples 
within the same classified 
group. Chapter 4. Microarray gene expression 
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Normalisation graph  Standard good quality  Normalisation results for 
the current project 
Correlation plot 
This is a heatmap of the chip-chip 
Spearman’s rank correlation 
coefficients. This plot can detect 
outliers. 
 Arrays of technical replicates 
should have a correlation 
coefficient near to 1.0.  Other chips 
also should have high correlation 
coefficient near (0.97-1.0)  
-Both technical replicates had 
a high correlation around 
0.98. 
-Sample 8 showed acceptable 
correlation to other samples 
with a correlation coefficient 
of almost 0.95 
-Sample 15 showed the least 
correlation coefficient of 
almost 0.90.  
All  samples  showed  comparable  normalised  data  except  for  sample  15  that  was  the  least  correlated 
sample. 
 
 
4.4.  DIFFERENTIALLY EXPRESSED GENE LISTS 
Sample number 15 (Class II long face) failed the 3’/5’ ratio during quality control, it 
was  the  least  correlated  sample  when  viewing  the  MvA  plots  and  the  correlation 
heatmap and showed large variations in relation to other samples. Therefore, it was 
excluded from further analysis.  
 
A total of 25 normalised GCRMA files (excluding the technical replicate sample) were 
analysed twice to generate two separate differentially expressed gene lists. First, a gene 
list  for  the  vertically  classified  groups,  and  a  second  for  the  horizontal  craniofacial 
groups.  These  classifications  were  based  on  simple  craniofacial  criteria  similar  to 
previous masseter muscle gene expression studies (Nelson-Moon et al., 1998; Gedrange 
et al., 2005 and 2006; Harzer et al., 2007; Suchak et al., 2009). All significant genes had 
a p-value of ≤ 0.001. 
 
4.4.1.  DIFFERENTIALLY EXPRESSED GENE LIST OF THE LONG FACE 
The first analysis produced a differentially expressed gene list between 11 long face 
patients vs. 14 controls. Out of 38,500 array genes, 19 genes were found to be down-
regulated and 12 up-regulated in long face patients compared to the controls (total of 31 
genes) (Table 4.3).  
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Table 4.3: Differentially expressed gene list for the long face pattern. 
Affy probe-set ID  Gene symbol  Chromosome  Fold change 
Long face vs. Ctrl 
Down-regulated genes 
209829_at 
213645_at 
207864_at 
1554549_a_at 
243829_at 
201797_s_at 
208024_s_at 
1558942_at 
225525_at 
1557567_a_at 
216497_at 
217365_at 
213445_at 
221924_at 
219521_at 
1554451_s_at 
217647_at 
206459_s_at 
241934_at 
 
Up-regulated genes 
214357_at 
221950_at 
229414_at 
1568658_at 
207563_s_at 
244377_at 
223082_at 
1554168_a_at 
222876_s_at 
242647_at 
225124_at 
232767_at 
 
Total 
 
19 genes 
C6ORF32 
ENOSF1 
SCN7A 
WDR20 
BRAF 
VARS 
DGCR6 
ZNF813 
KIAA1671 
LOC148987 
LOC120364 
PRAMEF5 
ZC3H3 
ZMIZ2 
B3GAT1 
DNAJC14 
HP 
WNT2B 
HNT 
 
12 genes 
C1ORF105 
EMX2 
PITPNC1 
LOC339804 
OGT 
SLC1A4 
SH3KBP1 
SH3KBP1 
CENTA2 
USP34 
PPP1R9B 
CADM1 
 
31 genes 
 
 
6 
18 
2 
14 
7 
6 
22 
19 
22 
1 
11 
1 
8 
7 
11 
12 
16 
1 
11 
 
 
1 
10 
17 
2 
X 
2 
X 
X 
17 
2 
17 
11 
 
 
 
-9.75 
-4.32 
-2.79 
-2.36 
-2.23 
-2.03 
-1.78 
-1.64 
-1.64 
-1.62 
-1.62 
-1.51 
-1.44 
-1.25 
-1.23 
-1.18 
-1.18 
-1.14 
-1.08 
 
 
29.2 
9.85 
7.89 
5.7 
2.6 
2.31 
2.04 
1.95 
1.64 
1.55 
1.4 
1.4 
 
Genes were arranged based on the heights of fold change. Ctrl: Control. _at: probe-
sets  that  binds  to  anti-sense  targets.  _s:  probe-sets  that  have  multiple  transcripts 
shared  between  different  genes.  _a:  probe-sets  that  can  recognize  an  alternative 
splice variant of a gene. 
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4.4.2.  DIFFERENTIALLY  EXPRESSED  GENE  LISTS  OF  HORIZONTAL 
DEFORMITIES 
The  second  analysis  generated  four  differentially  expressed  gene  lists  comparing 
different horizontal groups. The groups included 11 controls, 4 Class II and 10 Class III 
patients.  Out  of  38,500  genes,  a  total  of  85  genes  were  found  to  be  differentially 
expressed between the various horizontal deformities. Table 4.4 presents details of both 
the up- and down-regulated genes from the four gene lists.   
 
Table 4.4: Differentially expressed gene lists for Class II and Class III horizontal patterns. 
Affy probe-set ID  Gene symbol  Chromosome  Fold change 
1.  Class II vs. Ctrl 
Down-regulated genes 
221950_at 
229414_at 
1568658_at 
1553071_a_at 
213555_at 
1553070_a_at 
1554168_a_at 
223082_at 
218472_s_at 
 
Up-regulated genes 
1556462_a_at 
212240_s_at 
209829_at 
 
Total 
 
9 genes 
EMX2 
PITPNC1 
LOC339804 
MYOZ3 
RWDD2 
MYOZ3 
SH3KBP1 
SH3KBP1 
PELO 
 
3 genes 
LOC730245 
PIK3R1 
C6ORF32 
 
12 genes 
 
 
10 
17 
2 
5 
6 
5 
X 
X 
5 
 
 
13 
5 
6 
 
 
 
-24.1 
-13.5 
-9.45 
-9.13 
-5.31 
-3.92 
-3.27 
-2.77 
-2.25 
 
 
3.41 
3.18 
1.92 
 
2.  Class III vs. Ctrl 
Down-regulated genes 
210794_s_at 
236977_at 
229414_at 
204472_at 
203649_s_at 
221950_at 
206404_at 
210444_at 
201609_x_at 
221922_at 
 
21 genes 
MEG3 
LOC646588 
PITPNC1 
GEM 
PLA2G2A 
EMX2 
FGF9 
NPY6R 
ICMT 
GPSM2 
 
 
14 
7 
17 
8 
1 
10 
13 
5 
1 
1 
 
 
-22.0 
-21.7 
-12.9 
-11.1 
-10.7 
-9.78 
-8.22 
-6.19 
-5.78 
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Affy probe-set ID  Gene symbol  Chromosome  Fold change 
213555_at 
232531_at 
218678_at 
219747_at 
232983_s_at 
223082_at 
212627_s_at 
218780_at 
1554168_a_at 
224523_s_at 
209452_s_at 
 
Up-regulated genes 
224209_s_at 
205007_s_at 
209829_at 
208148_at 
215629_s_at 
241764_at 
1560750_at 
1556462_a_at 
204347_at 
215262_at 
1554549_a_at 
201797_s_at 
244791_at 
217365_at 
209563_x_at 
 
Total 
RWDD2 
EMX2OS 
NES 
C4ORF31 
SERGEF 
SH3KBP1 
EXOSC7 
HOOK2 
SH3KBP1 
C3ORF26 
VTI1B 
 
15 genes  
GDA 
CIB2 
C6ORF32 
MYH4 
KIAA1799 
LOC284825 
LOC151121 
LOC730245 
LOC645619 
OXNAD1 
WDR20 
VARS 
PHFDHL1 
PRAMEF5 
CALM1 
 
36 genes 
6 
10 
1 
4 
11 
X 
3 
19 
X 
3 
14 
 
 
9 
15 
6 
17 
1 
21 
2 
13 
12 
3 
14 
6 
13 
1 
14 
 
-2.97 
-2.95 
-2.75 
-2.5 
-2.48 
-2.28 
-2.25 
-2.17 
-2.14 
-2.10 
-1.71 
 
 
25.8 
7.84 
6.77 
4.38 
4.2 
3.81 
2.87 
2.33 
2.19 
2.16 
2.13 
1.73 
1.62 
1.55 
1.48 
 
3.  Class II vs. III 
Down-regulated genes 
227556_at 
203364_s_at 
214279_s_at 
1555278_a_at 
1568955_at 
224836_at 
229474_at 
 
Up-regulated genes 
229250_at 
 
7 genes 
ATP1B1 
KIAA0652 
NDRG2 
CKAP5 
SRGAP2 
TP53INP2 
MICAL3 
 
5 genes 
TPCN2 
 
 
1 
11 
14 
11 
1 
20 
22 
 
 
11 
 
 
-3.94 
-2.62 
-2.58 
-1.83 
-1.76 
-1.73 
-1.67 
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Affy probe-set ID  Gene symbol  Chromosome  Fold change 
1555439_at 
240451_at 
228271_at 
220575_at 
 
Total 
GTF3C3 
HIRA 
SND1 
FAM106B 
 
12 genes 
2 
22 
7 
17 
 
2.51 
1.87 
1.84 
1.44 
 
4.  All vs. Ctrl 
Down-regulated genes 
236977_at 
210794_s_at 
221950_at 
207992_s_at 
229414_at 
201609_x_at 
239860_at 
1568658_at 
213555_at 
203151_at 
203695_s_at 
1553070_a_at 
1554168_a_at 
232983_s_at 
219747_at 
223082_at 
224523_s_at 
218472_s_at 
209452_s_at 
 
Up-regulated genes 
209829_at 
1556462_a_at 
212240_s_at 
201797_s_at 
244791_at 
209563_x_at 
 
Total 
 
19 genes  
LOC646588 
MEG3 
EMX2 
AMPD3 
PITPNC1 
ICMT 
NPY6R 
LOC339804 
RWDD2 
MAP1A 
DFNA5 
MYOZ3 
SH3KBP1 
SERGEF 
C4ORF31 
SH3KBP1 
C3ORF26 
PELO 
VTI1B 
 
6 genes 
C6ORF32 
LOC730245 
PIK3R1 
VARS 
PHGDHL1 
CALM1 
 
25 genes 
 
 
7 
14 
10 
11 
17 
1 
5 
2 
6 
15 
7 
5 
X 
11 
4 
X 
3 
5 
14 
 
 
6 
13 
5 
6 
13 
14 
 
 
 
-28.1 
-24.9 
-15.3 
-15.2 
-13.2 
-6.63 
-6.59 
-5.7 
-3.97 
-3.63 
-3.61 
-2.73 
-2.66 
-2.64 
-2.62 
-2.51 
-2.45 
-2.1 
-1.7 
 
 
11.4 
2.81 
2.46 
1.91 
1.75 
1.58 
 
Genes were arranged based on the heights of fold change. Ctrl: Control. _x: probe-sets 
where it was not possible to design them with a unique sequence to the corresponding 
gene and can cross-hybridise. 
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4.4.3.  FILTERING THE DATA 
The  forward  stepwise  logistic  regression  analysis  was  conducted  twice.  The  first 
analysis included the GCRMA values of the 31 genes reported in the vertical gene list. 
Out of the 31 differentially expressed genes, two genes (KIAA1671 and DGCR6) were 
found to be significantly different and down-regulated in long face patients compared to 
the controls. The 85 genes of the horizontal groups, on the other hand, were included in 
the  second  analysis  which  revealed  three  significantly  different  genes.  One  gene 
(NDRG2) was found to be down-regulated in Class II patients compared to Class III 
individuals, while Class III samples showed down-regulation of one gene (SERGEF) 
compared to the controls. Another gene (LOC730245) was up-regulated in both Class II 
and Class III patients compared to the controls. All five genes had a highly significant 
p-value of ≤ 0.001. Table 4.5 lists the five significantly different genes.   
 
Table 4.5: Final candidate gene list for both vertical and horizontal deformities. 
Patient ‘s group  Gene name  Symbol  FC  Ch 
Location 
Microarray gene 
expression status 
Vertical groups 
Long vs. Ctrl 
2 genes 
1) KIAA1671  
 
2) DiGeorge syndrome 
Critical Region gene 
family member 6 
 
KIAA1671  
 
DGCR6 
 
-1.64 
 
-1.78 
 
22q11.23 
 
22q11.21 
 
Down-R long face 
 
Down-R long face 
 
Horizontal groups 
Class II vs. III 
 
 
 
Class III vs. Ctrl 
 
 
 
 
Class II and Class 
III vs. Ctrl 
3 genes 
1) N-myc Down 
Regulated Gene family 
member 2  
 
2) Secretion 
Regulating Guanine 
nucleotide Exchange 
Factor  
 
3) Hypothetical protein 
Locus 730245  
 
NDRG2 
 
 
 
SERGEF 
 
 
 
 
LOC730245 
 
-2.58 
 
 
 
-2.64 
 
 
 
 
2.81 
 
14q11.2 
 
 
 
11p14.3 
 
 
 
 
13q22.1 
 
Down-R Class II 
 
 
 
Down-R Class III 
 
 
 
 
Up-R Class II and 
Class III 
FC: Fold change. Ch: Chromosome. Ctrl: Control. R: Regulated. 
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4.5.  DISCUSSION 
The aim of the current microarray analysis was to identify masseter muscle candidate 
genes in relation to various craniofacial deformities. The initial differentially expressed 
gene  lists  that  were  generated  for  the  long  face,  Class  II  and  Class  III  deformities 
contained  many  up-  and  down-regulated  genes,  any  of  which  can  be  considered  a 
masseter muscle candidate gene and would warrant further investigation in relation to 
craniofacial deformities. However, the process of selecting a specific gene from the 
candidate gene list to be further followed-up is not a standardised procedure.  
 
Novel genes may have been overlooked during the selection procedure, particularly in 
studies  of  original  design  that  have  not  been  previously  duplicated  (Chuaqui  et  al., 
2002). It is for this reason that several authors have implemented logistic regression 
statistical analyses to filter microarray data and to identify potential genes from the 
candidate gene list (Wang et al., 2006; Eijssen et al., 2008). The current research has 
used  the  forward  stepwise  logistic  regression  analysis  to  filter  the  gene  list  and 
identified 2 novel  genes associated with  the long face deformity  and 3  other genes 
associated with horizontal deformities, and these will be investigated further.   
 
4.5.1.  NOVEL MASSETER MUSCLE GENES IN RELATION TO LONG FACE 
DEFORMITY 
Out of 38,500  genes,  a total  of 31  genes were found to  be  differentially expressed 
between long face patients and controls, 19 of which were down-regulated and 12 up-
regulated  in  long  face  patients  compared  to  individuals  with  average  vertical  facial 
phenotypes. Out of the 31 candidate genes, statistical analysis revealed 2 genes, namely 
DGCR6 and KIAA1671, that were down-regulated in the long face pattern compared to 
the controls. 
 
4.5.1.1.  DGCR6 gene  
The  DGCR6  gene  (DiGeorge  syndrome  Critical  Region  gene  number  6)  was  first 
described by Demczuk and colleagues (1996), who observed the presence of this gene 
in a critical region (22q11.21) with 500 kilo bases (Kb) close to deletion regions at the 
22q11 area that were mainly linked to DiGeorge syndrome (Lindsay, 2001), and was 
associated with mild forms of the condition. Patients with DiGeorge syndrome exhibit a Chapter 4. Microarray gene expression 
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wide range of clinical phenotypes including palatal malformations (clefts), nasal and ear 
abnormalities  and  a  small  mandible  associated  with  a  retrognathic  appearance  (de 
Lonlay-Debeney et al., 1997).  
 
Protein activity of the DGCR6 gene has been suggested to play an important role in cell 
migration and attachment (Demczuk et al., 1996) and was found to be over-expressed in 
skeletal muscle, as well as heart, liver and cancer cell lines compared to other tissue 
cells such as brain and pancreas (Pfuhl et al., 2005). Furthermore, the DGCR6 gene has 
been found to modulate expression of other neighbouring genes, one of which was the 
TBX-1 gene (Hierck et al., 2004). The TBX-1 (Arnold et al., 2006) and other members 
of the T-box gene family (Braybrook et al., 2002) have been reported in patients with 
various types of orofacial clefts.  
 
This may suggest that the DGCR6 gene may recruit different pathways with either a 
direct effect on the development of the mandible resulting in a retrognathic appearance, 
or an indirect role, modulating other genes which further affect the development of the 
maxilla and may result in the formation of a prognathic appearance. Interestingly, the 
current  microarray  data  showed  down-regulation  of  this  gene  in  relation  to  both 
prognathic and retrognathic patients who shared similar long face appearance compared 
to individuals with average vertical facial features. This may suggest impaired function 
of  this  gene  not  only  in  relation  to  horizontal  deformities,  but  also  in  relation  to 
imbalanced vertical facial development. 
 
4.5.1.2.  KIAA1671 gene 
Genes  with  the  name  KIAA  are  human  genes  that  encode  large  proteins  with  an 
unidentified function (Suyama et al., 1999). These types of genes were investigated by 
the Kazusa DNA Research Institute and have been designated the name “KIAA” with 
four-digit  numbers  (Kikuno  et  al.,  2004).  Large  microarray  platforms  such  as 
Affymetrix®  often  included  uncharacterised  genes  such  as  KIAA  and  hypothetical 
protein genes to aid in the identification of their function in various tissues (Handrigan 
et al., 2007). Up to date, no specific function has been identified for the KIAA1671 
gene  which  is  located  on  chromosome  22q11.23  and  is  in  close  proximity  to  the 
DGCR6 gene (chromosomal location 22q11.21). As discussed earlier, the DGCR6 gene Chapter 4. Microarray gene expression 
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has  been  reported  to  modulate  the  expression  of  neighbouring  genes  which  have 
followed  a  similar  gene  expression  to  DGCR6  (Hierck  et  al.,  2004).  The  current 
microarray data showed a down-regulation of the DGCR6 gene in long face patients, a 
reason  that  may  have  affected  transcription  of  the  KIAA1671  gene  and  resulted  in 
under-expression of this gene also in long face individuals. 
 
4.5.2.  NOVEL  MASSETER  MUSCLE  GENES  IN  RELATION  TO  CLASS  II 
AND CLASS III DEFORMITY 
Out of 38,500 genes, a total of 12 genes (9 down-regulated and 3 up-regulated) were 
associated with a Class II pattern compared to the controls (average horizontal features), 
while  Class  III  patients  had  a  total  of  36  differentially  expressed  genes  (21  down-
regulated and 15 up-regulated) compared to the controls. Analysis of the Class II group 
compared to the Class III pattern revealed a total of 12 differentially expressed genes (7 
up-regulated and 5 down-regulated in the Class II pattern). Further, statistical analysis 
ascertained  3  genes  to  be  further  investigated  in  relation  to  the  various  horizontal 
craniofacial  deformities.  One  gene  was  found  to  be  down-regulated  in  Class  II 
individuals compared to Class III patients, namely NDRG2. As for the remaining two 
genes, one was up-regulated (hypothetical protein LOC730245) in both Class II and 
Class III patterns compared to the controls, and the other gene (SERGEF) was down-
regulated in only Class III patients compared to the controls.  
 
4.5.2.1.  NDRG2 gene  
The  NDRG2  (Neuroblastomas-myelocytomatosis  “N-myc”  Downstream  Regulated 
Gene number 2) has a chromosomal location 14q11.2 and is a member of the NDRG 
family, which is composed of three other members (Zhang et al., 2006). The expression 
of the NDRG family is believed to be involved in cell proliferation and differentiation 
(Knoepfler et al., 2002). The NDRG2 gene has been found to be highly expressed in 
adult skeletal muscles than other NDRG members (Qu et al., 2002) and has been found 
to be down-regulated by high levels of N-myc gene, while low levels of N-myc have 
resulted in over-expression of the NDRG2 gene  (Zhang et al., 2006). 
 
The current microarray results indicate a down-regulation of the NDRG2 gene in Class 
II patients compared to Class III individuals. This may suggest that under-expression of Chapter 4. Microarray gene expression 
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the NDRG2 gene is associated with a retrognathic phenotype, while over-expression 
may be related to a prognathic appearance. However, a complex cascade with other 
regulatory genes such as N-myc is suspected to be involved.  
 
4.5.2.2.  Hypothetical protein LOC730245 gene  
The hypothetical proteins are genetic transcripts with unknown function which are often 
included  in  microarray  gene  chips  to  discover  their  role  in  particular  tissues 
(Suravajhala, 2007). The hypothetical protein locus (LOC) 730245 was located on the 
13q22.1 area. No specific function has been previously identified for the LOC730245. 
However,  interstitial  deletions  at  the  13q22.1  region  have  been  associated  with 
Hirschprung’s  disease  (Lamont  et  al.,  1989).  Some  forms  of  this  disease  were 
accompanied by general growth retardation, narrow forehead, restricted upper dental 
arch, protruded upper incisors, cleft palate and general muscle weakness  (Amiel and 
Lyonnet, 2001). The present study’s microarray data showed an over-expression of the 
LOC730245 gene in both Class II and Class III patterns compared to the controls, with 
the Class II group having a higher fold change (3.41) than Class III patients (2.33).  
 
A combination of long face pattern with both Class II and Class III deformities was 
reported  with  weak  masseter  muscle  activity  compared  to  individuals  with  average 
vertical and horizontal facial morphology (Cha et al., 2007). Class II patients recruited 
for the current study were long face patients, while the Class III group exhibited both 
long and average vertical facial features. This may explain the higher fold change of the 
LOC730245  in  Class  II  patients  than  Class  III  individuals.  Furthermore,  this  may 
suggest  that  over-expression  of the  LOC730245  gene  may be associated with  weak 
masseter muscle activity of patients with combined vertical and horizontal craniofacial 
deformities.  
 
4.5.2.3.  SERGEF gene  
The SERGEF gene (Secretion Regulating Guanine-nucleotide Exchange Factor), was 
first described and characterised at a chromosomal location 11p14.3 which was critical 
(in  close  proximity)  to  a  locus  associated  with  various  hereditary  severe  congenital 
deafness disorders (Uhlmann et al., 1999). Furthermore, the amino acid sequence of the 
SERGEF protein showed high sequence homology to a large protein super family called Chapter 4. Microarray gene expression 
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the  guanine  nucleotide  exchange  factor.  Therefore  the  SERGEF  gene  was  initially 
called  Deafness  Locus  associated  putative  Guanine-nucleotide  Exchange  Factor 
(DelGEF).  Under-expression  of  the  DelGEF  protein  has  been  found  to  increase  the 
secretion, but not the synthesis, of the chondroitin sulphate proteoglycans in cancer cell 
lines  and  was  therefore  called  Secretion  Regulating  Guanine-nucleotide  Exchange 
factor (SERGEF) (Sjölinder et al., 2002).  
 
The synthesis of chondroitin sulphate proteoglycan was found to be increased during 
adult muscular regeneration following injury (Carrino et al., 1988). This indicates a 
major role of the chondroitin sulphate proteoglycans during muscle regeneration. The 
present microarray data showed a down-regulation of the SERGEF in patients with a 
Class III prognathic appearance which may lead to the over-expression of chondroitin 
sulphate proteoglycans in the extracellular matrix of the masseter muscle, suggesting a 
need in the masseter muscles of such patients for continuous repair and regeneration.  
 
No definite conclusion can be drawn from microarray data without further testing. This 
is due to the nature of microarray platforms, where thousands of genes and hypotheses 
are tested in one experiment, and it is expected that false positive results may occur (Shi 
et al., 2006). Therefore, the gene expression of the 5 novel genes needs to be tested 
against the clinical, dental and radiographic criteria of patients with various craniofacial 
discrepancies using quantitative RT-PCR, which is a more sensitive technique (data are 
presented in Chapter 6).        
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4.6.  SUMMARY AND CONCLUSION 
  To the best of my knowledge, this has been the first study to ascertain masseter 
muscle candidate genes in relation to non-syndromic craniofacial deformities 
using microarray technology.   
 
  A total of 25 samples were analysed twice to produce candidate gene lists in 
relation  to  both  vertical  and  horizontal  craniofacial  phenotypes.  Further 
statistical analysis of initial candidate gene lists has pointed out 5 novel genes 
not  previously  reported  in  relation  to  the  masseter  muscle  of  non-syndromic 
individuals exhibiting various craniofacial deformities. 
 
  Out of the 5 novel genes, two were related to the long face pattern (DGCR6 and 
KIAA1671), while three other genes (NDRG2, LOC730245 and SERGEF) were 
differentially expressed in relation to horizontal deformities.  
 
  Although  the  DGCR6  gene  has  been  down-regulated  in  long  face  patients 
compared to the controls, this gene may be involved in the development of both 
vertical and horizontal craniofacial phenotypes. 
 
  The KIAA1671 gene which lies in a chromosomal location close to the DGCR6 
gene was also down-regulated in long face patients compared to the controls. 
The  DGCR6  gene  was  reported  to  modulate  the  expression  of  neighbouring 
genes which follow similar expression to DGCR6. Therefore, it is possible to 
hypothesise that the expression status of the KIAA1671 gene may have been 
modulated by the DGCR6 gene.  
 
  The NDRG2 gene was down-regulated in Class II patients compared to Class III 
individuals. However, the NDRG2 gene has been known to be regulated by the 
N-myc  gene.  Therefore,  a  complicated  mechanism  is  suspected  with  various 
other genes affecting the NDRG2 expression in the masseter muscle of patients 
with a prognathic and a retrognathic appearance. 
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  The LOC730245 gene was up-regulated in both Class II and Class III patients 
compared to the controls.  Over-expression of the LOC730245 gene has been 
suggested  to  be  related  to  weak  masseter  muscles  of  patients  with  various 
vertical and horizontal craniofacial deformities. 
 
   The SERGEF gene was down-regulated in Class III patients compared to the 
controls. Under-expression of SERGEF gene has been known to increase the 
secretion  of  the  chondroitin  sulphate  proteoglycan  which  is  involved  in 
regenerative  processes.  Hence,  it  is  suspected  that  the  masseter  muscle  of 
patients  with  a  prognathic  appearance  is  subject  to  continuous  micro trauma 
which may necessitate continued regeneration. 
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5.1.  INTRODUCTION 
The main aim of a phenotype-genotype study is to relate a specific clinical scenario to a 
particular  genetic  background,  whether  at  genomic  (Braybrook  et  al.,  2001), 
transcriptomic (Suchak et al., 2009) or proteomic level (Tippett et al., 2008). However, 
craniofacial deformities exhibit a wide range of clinical phenotypes which can be found 
in both syndromic (Whitaker et al., 1981; Kimonis et al., 2007) and non-syndromic 
(Singh and Bartlett, 2005) individuals, showing varying degrees of severity (Renier et 
al., 2000).  
 
To overcome this challenge, clinicians have critically analysed craniofacial morphology 
to  identify  basic,  combined  and  comprehensive  descriptive  features  which  were 
significantly  different  between  average  individuals  and  patients  with  craniofacial 
deformities (Sassouni, 1969; Jacobson et al., 1974; Schendel et al., 1976). For example, 
a Class III pattern describes single dimensional criteria, while a Class III long face 
explains  two  dimensional  features.  Comprehensive  description,  on  the  other  hand, 
provides details of affected skeletal and dental components, such as Class III horizontal 
deformity with a retruded maxilla, protruded mandible and long face vertically with 
dental anterior open bite. 
 
Previous genetic studies of the masseter muscle have investigated single dimensional 
discrepancies  looking  at  either  vertical  or  horizontal  features  of  recruited  subjects. 
However, it is more frequent to see a patient with a combination of both vertical and 
horizontal patterns rather than a single dimensional discrepancy (Sassouni, 1969; Proffit 
and White, 1990). It was, therefore, not known whether grouping patients based on a 
single craniofacial phenotype is sufficient for genetic analysis.     
 
The previous chapter demonstrated the use of basic types of craniofacial classifications 
(vertical classification -long face and average vertical face; horizontal classification -
Class  II,  Class  III  and  average  horizontal  face)  with  the  microarray  technology. 
However,  a  detailed  analysis  of  the  clinical,  dental  and  skeletal  components  of  the 
craniofacial deformities is needed to produce a better correlation between phenotypic 
appearance and genotypic background. The aims of this chapter are therefore to: Chapter 5. Patient’s classifications for phenotype-genotype studies 
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  Briefly  review  the  literature  to  identify  the  various  classifications  and 
subdivisions of basic craniofacial patterns. 
 
  Highlight the types of classifications that have been used previously in masseter 
muscle genotype-phenotype research.  
 
  Identify the clinical, dental and skeletal criteria of the subjects for the current 
research and assess the feasibility of implementing these criteria into different 
phenotypic  classifications  to  be  further  used  in relation  to  qRT-PCR  genetic 
data. 
 
5.2.  CLASSIFICATION OF CRANIOFACIAL PATTERNS 
 
5.2.1.  BASIC CLASSIFICATION OF CRANIOFACIAL PATTERNS 
Sassouni (1969) identified four basic craniofacial patterns based on either vertical or 
horizontal skeletal discrepancies. These basic patterns were described in Chapter 1 as 
the long and short faces of the vertical dimension and Class II and Class III in the 
horizontal plane.  
 
5.2.2.  COMBINED CLASSIFICATION OF CRANIOFACIAL PATTERNS 
A  more  detailed  classification  would  include  a  combination  of  both  vertical  and 
horizontal patterns (Sassouni, 1969), more often seen clinically than single dimensional 
discrepancies  (Proffit  and  White,  1990).  For  example,  Class  II  or  Class  III  facial 
horizontal patterns can be associated with average, long or short vertical dimensions.  
 
5.2.3.  COMPREHENSIVE  CLASSIFICATION  OF  CRANIOFACIAL 
PATTERNS 
A comprehensive classification would include skeletal and dental subdivisions of the 
basic facial pattern. The long face (Schendel et al., 1976), short face (Opdebeeck and 
Bell, 1978), Class II (Antonini et al., 2005) and Class III (Jacobson et al., 1974) patterns 
have  all  been  reported  with  various  subdivisions  and  varying  degrees  of  maxillary, 
mandibular and dental discrepancies.  Chapter 5. Patient’s classifications for phenotype-genotype studies 
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5.2.3.1.  Subdivisions of the long face pattern 
Depending on the mandibular ramus height (RH), the mandibular angulation and the 
presence  or  absence  of  an  anterior  open  bite  (AOB),  two  subdivisions  have  been 
reported  with  the  long  face  pattern.  One  division  was  observed  with  a  short  RH, 
increased mandibular angulation and AOB, while the other variant was reported with an 
increased RH, average mandibular angulation and without AOB (Schendel et al., 1976; 
Fields et al., 1984). Figure 5.1 shows examples of radiographic tracings of the two types 
of the long face pattern. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.3.2.  Subdivisions of the short face pattern 
Two subdivisions have also been reported with the short face pattern, by which the 
posterior vertical maxillary length, ramus height and the relationship of the mandibular 
plane to the cranial base were all different between subdivisions. One type of the short 
face had a normal posterior vertical maxillary height, long ramus and a sharply reduced 
mandibular plane to the cranial base angle. The other subgroup exhibited a short ramus, 
marked deficiency in the posterior maxillary height leading to a closing rotation of the 
Figure 5.1: Subdivisions of the long face pattern. Both groups show increased lower anterior 
face height (LAFH). a) Long face patient with increased ramus height (RH), average mandibular 
angulation and no anterior open bite (AOB). b) Long face individual with short RH, increased 
mandibular angulation and AOB. Chapter 5. Patient’s classifications for phenotype-genotype studies 
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mandible, a deep bite and a reduced mandibular plane angle in relation to the cranial 
base (Opdebeeck and Bell, 1978). Figure 5.2 shows examples of radiographic tracings 
of the two subdivisions of the short face pattern. 
 
 
 
 
5.2.3.3.  Subdivisions of Class III pattern 
Several authors (Björk, 1955; Sanborn, 1955; Jacobson et al., 1974) have identified 
different  types  of  skeletal  Class  III  depending  on  the  affected  skeletal  component, 
whether it be the maxilla, the mandible or both. Four main subgroups of skeletal Class 
III have been reported in the literature (Figure 5.3): 
 
1.  Normal  maxilla  and  prognathic  mandible:  This  subgroup  is  one  of  the  most 
common  types  seen  in  non-syndromic  individuals  (Sanborn,  1955;  Lew  and 
Foong, 1993). However, this type has also been reported in male patients with 
aneuploidal abnormalities in the x-chromosome (XXY -Klinefelter syndrome) 
where mandibular growth is increased (Gorlin et al., 1965).  
 
2.  Normal mandible and retruded maxilla: This type is associated with various cleft 
anomalies  (Hayashi  et  al.,  1976),  some  of  the  craniosynostotic  conditions 
Figure  5.2:  Subdivisions  of  the  short  face  pattern.  Both  groups  show  reduced  LAFH  and 
mandibular  angulation.  a)  Short  face  patient  with  increased  ramus  height  (RH)  and  normal 
vertical maxillary length (VML). b) Short face individual with short RH and reduced VML. This 
diagram was adapted and modified from Opdebeeck and Bell (1978).  Chapter 5. Patient’s classifications for phenotype-genotype studies 
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(Costaras-Volarich and Pruzansky, 1984; Langford et al., 2003) as well as non-
syndromic individuals (Dietrich, 1970).  
 
3.  Combination of retrusive maxilla and prognathic mandible: This type is also 
common in non-syndromic individuals (Ellis and McNamara, 1984).  
 
4.  Maxilla and mandible within the normal range of prognathism: This type was 
described as the maxilla being at the lowest average range of SNA° and the 
mandible  at  the  highest  average  range  of  the  SNB°.  It  is  the  least  common 
subgroup of the Class III pattern (Sanborn, 1955).  
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Figure 5.3: Subdivisions of the Class III pattern. The normal range of prognathism marked in 
yellow was identified as the normal range of both the SNA° (dictates the position of the maxilla) 
and the SNB° (dictates the position of the mandible) (Jacobson et al., 1974). a) Normal maxilla 
and prognathic mandible. b) Normal mandible and retruded maxilla. c) Maxilla and mandible 
within the normal range of prognathism. d) Combination of retrusive maxilla and prognathic 
mandible. This diagram was adapted from Jacobson et al., 1974. Chapter 5. Patient’s classifications for phenotype-genotype studies 
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5.2.3.4.  Subdivisions of Class II pattern 
Similar  to  the  Class  III  pattern,  different  types  of  Class  II  retrognathic  skeletal 
appearance  have  been  reported  in  the  literature.  Maxillary  protrusion  and  normal 
mandibular growth (Antonini et al., 2005), a normal maxilla and an underdeveloped or 
retruded position of the mandible (Ngan et al., 1997; Sayin and Turkkahraman, 2005) 
and a protruded maxilla with a retruded mandible (Akemi, 2005) are all variations that 
have been reported in both syndromic (e.g. XO -Turner syndrome with deficient growth 
of  the  mandible)  (Gorlin  et  al.,  1965)  and  non-syndromic  (de  Freitas  et  al.,  2005) 
individuals. However, the normal maxilla and underdeveloped mandible  is the most 
common type of the Class II phenotype (Sidlauskas et al., 2006).  
 
Figure  5.4  illustrates  the  different  subdivisions  of  the  vertical  and  horizontal 
craniofacial patterns. 
 
  
 
 
Classification of craniofacial patterns 
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Combined V & H 
patterns 
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& H patterns 
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Class II 
Class III 
Class II  
long face 
Class II  
short face 
Class II 
average face 
Class III  
long face 
Class III  
short face 
Class III 
average face 
AVH 
Short face 
Long face  Short face  Class II  Class III 
Long face  
with AOB 
Long face 
without AOB 
Short face 
NVMG 
Short face  
VMD 
N maxilla 
R mandible 
 
P maxilla 
N mandible 
P maxilla 
R mandible 
N maxilla 
P mandible 
R maxilla 
N mandible 
R maxilla 
P mandible 
 
 
 
Figure 5.4: The various subdivisions of the vertical and horizontal facial patterns. V: Vertical. H: Horizontal. AOB: Anterior open bite. AVH: 
Average vertical and horizontal. NVMG: Normal vertical maxillary growth. VMD: Vertical maxillary deficiency. N: Normal. R: Retruded. P: 
protruded. 
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5.3.  CLASSIFICATIONS  USED  IN  PREVIOUS  MASSETER  MUSCLE 
GENOTYPE-PHENOTYPE STUDIES 
Previous masseter muscle genotype-phenotype studies  have looked at  either vertical 
(mainly long face) (Nelson-Moon et al., 1998; Price et al., 1998; Singh et al., 2000; 
Tippett et al., 2008; Suchak et al., 2009) or horizontal dimensional discrepancies (Class 
II and Class III) (Gedrange et al., 2005; 2006; Harzer et al., 2007; Maricic et al., 2008). 
These studies have mainly used basic vertical and horizontal types of classifications. 
 
5.3.1.  STUDIES ASSESSING VERTICAL FACIAL DEVELOPMENT 
Nelson-Moon and colleagues (1998) in a study of six myosin heavy chain (MYH) genes, 
recruited 15 patients, all undergoing orthognathic surgery, 9 of whom were long face. 
The  remaining  6  patients  exhibited  horizontal  facial  deformities  but  with  average 
vertical  facial  features  and  were  considered  as  controls.  Similarly,  Tippett  and  co-
workers  (2008)  recruited  20  subjects,  10  of  whom  were  identified  clinically  and 
radiographically  as  long  face  subjects,  while  the  other  10  controls  were  patients 
receiving surgical correction of horizontal deformities and were identified with average 
vertical facial features. Other investigators have used a “weighted-points system” based 
on various vertical cephalometric parameters to group patients into either long face or 
average controls (Price et al., 1998; Singh et al., 2000). Most of these studies have 
included patients with horizontal deformities having average vertical facial features as 
controls. As such it is likely that both Class II long face and Class III long face patterns 
were combined as one single deformity group.  
 
5.3.2.  STUDIES ASSESSING HORIZONTAL FACIAL DEVELOPMENT 
Horizontal assessment of patients who were classified for masseter muscle genotype-
phenotype analysis have been based mainly on clinical appearance, radiographic ANB 
angle and the dental overjet, with patients classified into either Class II or Class III 
regardless  of the vertical  facial  pattern (Gedrange et  al.,  2005;  2006). 10 deformity 
patients  (5  Class  II  and  5  Class  III  individuals)  were  recruited  but  there  were  no 
controls. A recent study with a larger sample size (30 subjects -16 Class II and 14 Class 
III)  selected  patients  with  pure  horizontal  deformities,  using  the  SN-MP  angle  to 
exclude patients with vertical discrepancies (Harzer et al., 2007).  Chapter 5. Patient’s classifications for phenotype-genotype studies 
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None of the previous masseter muscle genotype-phenotype studies, whether vertical or 
horizontal, have included patients with average vertical and horizontal facial features as 
controls. Furthermore, the effect of various subdivisions of Class II, Class III and long 
face  patterns  on  masseter  muscle  gene  expression  analysis  has  not  been  previously 
tested. The following sections will identify the clinical, dental and radiographic criteria 
of the 29 subjects in the present study to assess the feasibility of implementing their 
criteria into various phenotypic classifications to be further analysed in relation to qRT- 
PCR masseter muscle gene expression. 
 
5.4.  MATERIALS AND METHODS 
The following sections will briefly describe the materials and methods that were used to 
assess the clinical, dental and radiographic criteria of the 29 subjects. 
 
5.4.1.  CLINICAL ASSESSMENT 
Clinical assessment of both vertical and horizontal patterns was conducted based on the 
previously described criteria in Chapter 2 (Section 2.7.8.1). The clinical assessment was 
used for simple and combined pattern grouping, including average control (vertically 
and horizontally), long face, short face, Class II and Class III patterns.  
 
5.4.2.  DENTAL ASSESSMENT 
  Overbite 
Overbite was assessed clinically using a dental ruler and was measured in millimetres. 
The dental assessment was used to identify the various vertical subgroups including 
AOB or deep bite.  
 
  The number of dental occlusal contacts 
The number of dental occlusal contacts has been found to affect masseter muscle gene 
expression (Nelson-Moon et al., 1998; Harzer et al., 2007) and was therefore recorded 
for the current research and used to assess whether these were different between various 
craniofacial  groups.  The  pre-treatment  study  models  were  trimmed  to  match  the 
occlusion of the 29 subjects and were used to record the static occlusal contacts using 
pink wax blocks. By adjusting the trimmed margins of both the upper and lower casts 
on a bench, to simulate the occlusion of the patient, the wax was heated and pressed Chapter 5. Patient’s classifications for phenotype-genotype studies 
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against both casts and an imprint of the occlusion was recorded on the wax. This was 
followed by counting the number single contacts imprinted on the wax.  
 
5.4.3.  RADIOGRAPHIC ASSESSMENT 
  Vertical variables 
Both the LAFH% and TAFH were used as general parameters to identify vertical facial 
pattern (normal mean value + 1 SD –control; above norm –long face; below norm –
short face), while  overbite, TPFH, RH and SN-MP angle were used to  identify the 
various vertical subgroups (as described by Schendel et al., 1976; Opdebeeck and Bell, 
1978). 
 
  Horizontal variables 
The ANB angle was used to identify the general horizontal pattern (normal mean value 
+ 1 SD –control; above norm –Class II; below norm –Class III). Both the SNA and SNB 
angles were used to assess the position of the maxilla and the mandible, respectively, in 
relation  to  the  cranial  base  (normal  mean  value  +  1  SD  –normal;  above  norm  –
protruded;  below  norm  –retruded).  All  cephalometric  variables  and  cephalometric 
Caucasian norms are described in details in Chapter 2 (Section 2.4.4.3).  
 
5.4.4.  STATISTICAL ANALYSIS 
 
5.4.4.1.  Data analysis of radiographic variables 
  Bland and Altman’s approach (described in Chapter 2, Section 2.3.6.4.2) was 
used to assess the reliability and reproducibility of the cephalometric variables 
using repeated measurements of 25 cephalometric radiographs. 
 
  To assess the significance of variation in vertical and horizontal cephalometric 
variables between the different classified groups, both the Mann Whiney U-test 
(two groups) and Kruskal Wallis test (more than two groups) were conducted 
using SPSS v14 (statistical package of social sciences). A p-value of ≤ 0.05 was 
considered  to  be  statistically  significant.  The  graphical  representation  of 
cephalometric variations between groups was generated using SPSS v14 in the 
form of box plots.  Chapter 5. Patient’s classifications for phenotype-genotype studies 
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5.4.4.2.  Data analysis of the number of dental occlusal contacts 
To assess the significance of differences in the number of occlusal contacts between the 
different classified groups, both the Mann Whiney U-test (two groups) and Kruskal 
Wallis test (more than two groups) was conducted using SPSS v14. A p-value of ≤ 0.05 
was  considered  to  be  statistically  significant.  The  graphical  representation  of  the 
variations in the number of occlusal contacts between groups was generated using SPSS 
v14 in the form of box plots.  
 
5.5.  RESULTS 
 
5.5.1.  RELIABILITY  AND  REPRODUCIBILITY  OF  RADIOGRAPHIC 
MEASUREMENT 
Bland  and  Altman’s  approach  revealed  good  correlation  and  agreement  between 
repeated  measurements  as  shown  by  the  Lin’s  concordance  correlation  coefficient 
which were close to 1. The lowest value was 0.95 which was related to the LAFH%. 
The mean difference between paired measurements was less than 0.5 in all radiographic 
variables, while the paired t-tests revealed no significant differences between paired 
measurements. Thus minimal systematic errors were encountered.  
 
As for random errors, the LAFH, RH and SNA angle showed the highest coefficient of 
repeatability  and  a  wide  range  of  the  limits  of  agreement,  indicating  difficulty  in 
repeating these measurements. This may have been attributed to the poor quality of 
some of the radiographs which made it difficult  to  assess the N-point (affected the 
LAFH),  the  A-point  (affected  the  SNA),  and  the  Go-  and  Ar-points  (affected  RH). 
These  anatomical  landmarks  have  been  reported  to  be  more  difficult  to  locate  on 
cephalometric radiographs and are less reliable than others (Sandler, 1988). However, 
this did not affect the classification, as most of the subjects had severe deformities with 
extreme  radiographic  measurements  compared  to  the  controls.  Table  5.1  represents 
values  obtained  by  using  Bland  and  Altman’s  approach,  while  Figures  5.5  and  5.6 
represent the horizontal and vertical Bland and Altman’s graphs. 
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Table  5.1:  Reliability  and  reproducibility  of  radiographic  variables  using  the  Bland  and 
Altman’s approach. 
Radiographic 
parameter 
Lin’s 
Concordance 
Correlation 
Coefficient 
Bland and Altman’s approach 
Systematic error  Random error  Limits of agreement 
Mean 
difference 
 
paired t-
test 
p-value 
SDD  CR 
 
 
SNAº  0.98  -0.40  0.09  1.15  2.25  -2.7-1.9 
SNBº  0.99  -0.20  0.23  0.82  1.60  -1.8-1.4 
ANBº  0.99  -0.26  0.09  0.74  1.45  -1.7-1.2 
LAFH%  0.95  0.20  0.12  0.64  1.26  -1.1-1.5 
TAFH mm  0.98  -0.46  0.26  1.99  3.90  -4.4-3.4 
TPFH mm  0.98  0.32  0.29  1.50  2.90  -2.6-3.3 
RH mm  0.97  0.16  0.60  1.54  3.02  -2.9-3.2 
SN-MPº  0.98  0.24  0.30  1.30  2.55  -2.3-2.8 
All radiographic variables had good correlation and agreement between repeated measurements as shown 
by the Lin’s concordance correlation coefficient. Minimal systematic errors were detected as evident by 
the non significant p-values of the paired t-test and low mean differences between repeated measurements. 
The TAFH, RH and the SNA measurements were difficult to repeat as shown by the high coefficient of 
repeatability (CR). SDD: Standard deviation of differences.  
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Figure 5.5: Bland and Altman’s graphs for horizontal cephalometric variables. Generally, all 
horizontal variables showed low systematic errors as indicated by the close proximity of the 
observed  horizontal  line  in  relation  to  the  zero  horizontal  line  which  represents  the  perfect 
agreement. The SNA angle showed higher limits of agreement (-2.7-1.9), as indicated by the two 
horizontal red lines, than the SNB (-1.8-1.4) and the ANB angle (-1.7-1.2), which indicates higher 
random error of the SNA angle.  
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Figure 5.6: Bland and Altman’s graphs for vertical cephalometric variables. Generally, all 
vertical  variables  showed  low  systematic  errors  as  indicated  by  the  close  proximity  of  the 
observed horizontal line in relation to the zero perfect agreement line. The LAFH showed the 
highest limits of agreement (-4.4-3.4) with higher random errors, compared to the lowest limits of 
agreement of the LAFH% (-1.1-1.5).  
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5.5.2.  CLINICAL,  DENTAL AND RADIOGRAPHIC ASSESSMENT OF  THE 
SUBJECTS 
Following the clinical, dental and radiographic assessment of the 29 subjects, it was 
found  they  exhibited  variable  clinical  and  radiographic  combinations  of  dental  and 
skeletal components both in the vertical and horizontal dimensions. Furthermore, the 29 
subjects could be grouped in different ways based on the previously discussed basic, 
combined  (Sassouni  1969)  and  comprehensive  classifications  and  subdivisions 
(Jacobson et al., 1974; Schendel et al., 1976; Opdebeeck and Bell, 1978). Figure 5.7 
shows how patients move from one group to another depending on the investigated 
dimensional discrepancy and classification implemented. 
  
 
Various classifications of the 29 recruited patients 
Basic V patterns 
n = 29 
 
Basic H patterns  
n = 29 
 
Class II 
n = 5 
 
Long face 
n = 15 
 
Control AVF 
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Class III 
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Subdivisions of the V and H patterns 
Control AHF 
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R mandible 
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P mandible 
n = 4 
 
R maxilla 
N mandible 
n = 8 
 
R maxilla  
P mandible 
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Class III LF 
without AOB   
 n = 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Clinical, dental and radiographic criteria of the recruited patients described through various classifications.  The arrows indicate how 
various groups of patients shifted from one group to another based on the classification (e.g. a group of Class III patients with average vertical facial 
features were grouped as controls in the basic vertical classification and as deformity when using the basic horizontal classification). V: Vertical. H: 
Horizontal. LF: Long face. AVF: Average vertical face. AHF: Average horizontal face. AVHF: Average vertical and horizontal face. AOB: Anterior 
open bite ≥ 3mm. N: Normal. R: Retruded. P: Protruded. 
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Classification  of  subjects  for  a  phenotype-genotype  study  is  clearly  difficult,  as 
encountered  in  previous  studies,  because  of  the  low  numbers  of  subjects  in  each 
subdivision  compared  to  the  wide  range  of  clinical,  dental  and  radiographic 
components. However, it was felt useful to consider the basic vertical and horizontal 
classifications to allow comparison to previous masseter muscle studies (Harzer et al., 
2007; Suchak et al., 2009), as well as studying the combined vertical and horizontal 
classification and subdivisions of the long face pattern (with and without AOB). This 
was done to assess whether different classifications of the same subjects could have an 
effect on the genetic analysis. Furthermore, the Class II, Class III and long face patterns 
exhibited varying degrees of maxillary, mandibular and dental severity. Therefore, it 
was  appropriate  to  use  non-parametric  correlation  analysis  (Spearman’s  correlation 
coefficient analysis), where all skeletal cephalometric and dental variations could be 
tested separately against masseter muscle gene expression (details of the phenotype-
genotype correlation analysis are presented in Chapter 6).  
 
5.5.3.  PHENOTYPIC CLASSIFICATIONS GENERATED 
 
5.5.3.1.  Basic vertical classification 
The 29 subjects were classified on their vertical facial appearance regardless of any 
horizontal deformities. This classification generated two groups; 14 control and 15 long 
face patients. None of the subjects exhibited a short face appearance. This classification 
was similar to the vertical facial grouping that was used to analyse microarray data 
(Chapter 2, Section 2.7.8.1).  
 
Table 5.2 summarises the clinical, radiographic and dental variations between the long 
face pattern and the controls, while Figure 5.8 illustrates variations in the number of 
dental occlusal contacts between vertically classified groups. 
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Table 5.2: Clinical, dental and radiographic criteria of the subjects based on basic vertical 
facial classification. 
Group 
Criteria 
British norms*  Control 
n = 14 
Long face 
n = 15 
Clinical 
Vertical (V) 
 
- 
 
Average 
 
Increased 
Radiographic 
TAFH mm** 
SN-MP°** 
LAFH% 
TPFH mm 
RH mm 
Mean  SD  Mean  SD  Mean  SD 
111.0 
34.3 
54.6 
71.4 
44.0 
± 5.8 
± 6.0 
± 1.9 
± 4.3 
± 4.2 
111.0 
34.5 
55.8 
69.0 
42.0 
+ 3.7 
+ 5.0 
+ 2.4 
+ 3.0 
+ 3.0 
122.0 
43.0 
57.8 
70.0 
42.0 
+ 8.6 
+ 5.6 
+ 2.5 
+ 7.6 
+ 6.6 
Dental 
Number of occlusal contacts** 
 
- 
 
26.0 
 
+ 5.0 
 
14.0 
 
+ 3.0 
*Female British norms (Bhatia and Leighton, 1993). **Significant p-value ≤ 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Variations in the number of dental occlusal contacts between the long face pattern 
and controls. The number of dental occlusal contacts was significantly lower in the long face 
group compared to the controls. However, the long face group showed skewed data with a top 
shift of the median from the centre.   
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5.5.3.2.  Basic horizontal classification  
The 29 subjects were classified based on their horizontal facial appearance regardless of 
vertical  facial development.  The classification generated three  groups;  11 control,  5 
Class II and 13 Class III patients. This classification was similar to the horizontal facial 
grouping that was used to analyse microarray data (Chapter 2, Section 2.7.8.1).  
 
Table 5.3 summarises the clinical, radiographic and dental variations between the Class 
II, Class III and the controls, while Figure 5.9 illustrates the variation in the number of 
dental occlusal contacts between horizontally classified groups. 
 
Table 5.3: Clinical, dental and radiographic criteria of the subjects based on basic horizontal 
facial classification. 
Group 
Criteria 
British 
norms* 
Control 
n = 11 
Class II 
n = 5 
Class III 
n = 13 
Clinical 
Horizontal (H) 
 
- 
 
Average 
 
Retrognathic 
 
Prognathic 
Radiographic 
SNA°** 
SNB°** 
ANB°** 
Mean  SD  Mean  SD  Mean  SD  Mean  SD 
80.5 
78.0 
2.6 
± 3.4 
± 3.4 
± 2.4 
81.7 
79.4 
2.3 
+ 2.5 
+ 2.0 
+ 1.0 
79.0 
71.4 
6.4 
+ 5.5 
+ 3.4 
+ 5.7 
75.2 
80.5 
-5.3 
+ 6.5 
+ 4.7 
+ 3.6 
Dental 
Number of occlusal contacts** 
 
- 
 
27.0 
 
+ 4.0 
 
11.0 
 
+ 2.0 
 
14.0 
 
+ 3.0 
*Female British norms (Bhatia and Leighton, 1993). **Significant p-value ≤ 0.05. 
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5.5.3.3.  Combined vertical and horizontal classification  
The 29 subjects were classified based on both vertical and horizontal facial appearance. 
This classification generated four groups; 11 controls, 5 Class II long face, 10 Class III 
long face and 3 Class III average vertical facial patterns.  
 
Table  5.4  summarises  the  clinical,  radiographic  and  dental  variations  between  the 
various  combined  vertical  and  horizontal  groups,  while  Figure  5.10  illustrates  the 
variation in the number of dental occlusal contacts between various combined patterns. 
 
 
 
 
 
 
 
Figure 5.9: Variations in the number of dental occlusal contacts between Class II, Class III 
and controls. The number of dental occlusal contacts was the lowest in the Class II followed by 
Class III patients compared to the controls. The Class II group showed skewed data, while the 
Class III group had one extreme case with increased number of dental occlusal contacts marked 
as an asterisk. 
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Table  5.4:  Clinical,  dental  and  radiographic  criteria  of  the  subjects  based  on  combined 
vertical and horizontal facial patterns. 
Group 
 
Criteria 
British 
norms* 
Control 
 
n = 11 
Class II  
long face 
n = 5 
Class III  
long face 
n = 10 
Class III 
average face 
n = 3 
Clinical 
V 
H 
 
- 
- 
 
Average 
Average 
 
Increased 
Retrognathic 
 
Increased 
Prognathic 
 
Average 
Prognathic 
H-variables 
SNA°** 
SNB°** 
ANB°** 
 
V-variables 
LAFH%** 
TAFH** 
TPFH ** 
RH** 
SN-MP°** 
M  SD  M  SD  M  SD  M  SD  M  SD 
80.5 
78.0 
2.6 
 
 
54.6 
111.0 
71.4 
44.0 
34.3 
± 3.4 
± 3.4 
± 2.4 
 
 
± 1.9 
± 5.8 
± 4.3 
± 4.2 
± 6.0 
81.7 
79.4 
2.3 
 
 
55.0 
124.0 
78.5 
48.0 
34.0 
+ 2.5 
+ 2.0 
+ 1.0 
 
 
+ 2.0 
+ 4.3 
+ 3.8 
+ 3.0 
+ 5.0 
79.0 
72.6 
6.4 
 
 
56.6 
129.0 
72.0 
42.0 
46.7 
+ 5.5 
+ 2.3 
+ 5.7 
 
 
+ 4.3 
+ 0.6 
+ 4.0 
+ 2.4 
+ 6.0 
73.6 
80.0 
-6.0 
 
 
59.0 
139.4 
83.3 
50.0 
40.0 
+ 6.0 
+ 4.7 
+ 3.7 
 
 
+ 1.2 
+ 8.3 
+ 7.6 
+ 6.0 
+ 5.5 
80.6 
83.6 
-3.0 
 
 
57.2 
123.7 
75.5 
47.3 
38.6 
+ 5.2 
+ 4.0 
+ 2.0 
 
 
+ 0.3 
+ 6.0 
+ 1.6 
+ 6.4 
+ 3.0 
Dental 
Number of 
occlusal 
contacts** 
     
27 
 
+ 4.0 
 
 
11 
 
+ 2.0 
 
 
13 
 
+ 2.0 
 
 
18 
 
+ 2.0 
 
*Female British norms (Bhatia and Leighton, 1993). **Significant p-value ≤ 0.05. V: Vertical. H: 
Horizontal. M: Mean. SD: Standard deviation. 
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5.5.3.4.  Subdivisions of the long face classification 
The  29  subjects  were  classified  based  on  their  vertical  facial  appearance  and  the 
presence or  absence of  an anterior open bite  (AOB),  regardless  of horizontal facial 
development. This classification generated three groups; 13 controls, 6 long faces with 
AOB and 9 long faces without AOB. The AOB in all patients of the long face with 
AOB group had an AOB higher than 3mm. Some of the long face without AOB patients 
had a minimal space (less than 1mm) between the upper and lower dentition which was 
counted as a dental AOB rather than skeletal AOB.  
 
Table 5.5 summarises the clinical, radiographic and dental variations between the long 
face with AOB, long face without AOB and the controls, while Figure 5.11 illustrates 
the  variations  in  the  number  of  dental  occlusal  contacts  between  the  various 
subdivisions of the long face pattern compared to the controls. 
 
 
Figure 5.10: Variations in the number of dental occlusal contacts between Class II long faces, 
Class  III  long  faces,  Class  III  average  vertical  faces  and  controls.  The  number  of  dental 
occlusal contacts was the lowest in the Class II long faces, followed by the Class III long faces 
and then the Class III average vertical faces compared to the controls. Both the controls and the 
Class III average vertical faces showed symmetric distribution of the data while both Class II and 
Class III long faces had skewed data. 
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Table  5.5:  Clinical,  dental  and  radiographic  criteria  of  the  subjects  based  on  long  face 
subdivisions. 
Group 
 
Criteria 
British 
norms* 
Control 
 
n = 13 
Long face 
with AOB 
n = 6 
Long face 
without AOB 
n = 9 
Clinical 
Vertical 
Dental bite 
 
- 
 
Average 
Average 
 
Increased 
With AOB 
 
Prognathic 
Without AOB 
Radiographic 
TAFH mm** 
LAFH%** 
TPFH mm ** 
RH mm** 
SN-MP°** 
Mean  SD  Mean  SD  Mean  SD  Mean  SD 
111.0 
54.6 
71.4 
44.0 
34.3 
± 5.8 
± 1.9 
± 4.3 
± 4.2 
± 6.0 
111.8 
55.7 
70.0 
42.8 
34.6 
+ 3.9 
+ 2.4 
+ 3.2 
+ 3.3 
+ 4.8 
115.9 
56.5 
62.8 
37.2 
47.2 
+ 3.0 
+ 2.6 
+ 4.7 
+ 4.4 
+ 5.4 
127 
58.8 
76.0 
45.5 
39.8 
+ 6.9 
+ 2.2 
+ 6.9 
+ 5.7 
+ 5.4 
Dental 
Number of occlusal contacts** 
AOB mm 
 
- 
 
26.0 
- 
 
+ 5.0 
- 
 
11.0 
4.5 
 
+ 4.0 
+ 1.5 
 
14.0 
- 
 
+ 2.0 
- 
*Female British norms (Bhatia and Leighton, 1993). **Significant p-value ≤ 0.05. AOB: Anterior open 
bite. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Variations in the number of dental occlusal contacts between long face with AOB, 
long face without AOB and controls. The number of dental occlusal contacts was the lowest in 
the long face with AOB, followed by the long face without AOB when compared to the controls. 
Both long face subdivisions showed skewed data. 
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5.6.  DISCUSSION 
Ideally, classification of patients for phenotype-genotype studies should be based on 
clearly  defined  craniofacial  groupings,  and  should  include  clinical,  dental  and 
radiographic criteria. However, due to the ethical and technical issues associated with 
invasive types of human genetic studies as well as large individual variations, two main 
issues have been encountered: First, insufficient sample size to allow for comprehensive 
grouping and second, minimal numbers of controls with average vertical and horizontal 
craniofacial features. Other similar studies have encountered similar problems due to 
small sample sizes (Nelson-Moon et al., 1998; Gedrange et al., 2005; Suchak et al., 
2009). Nevertheless, we report the largest number of control subjects (11) with average 
vertical and horizontal facial features.  
 
Using the clinical, dental and radiographic criteria of the 29 subjects, it was possible to 
generate four sets of phenotypic classifications to assess the effect of various groupings 
on the masseter muscle qRT-PCR gene expression data analysis.  
 
5.6.1.  BASIC VERTICAL CLASSIFICATION 
The  problem  with  this  classification  was  that  some  long  face  subjects  exhibited 
horizontal discrepancies which were not taken into account. Furthermore, although the 
control group included patients with average vertical facial appearance, some of these 
patients had horizontal deformities. Such combinations in both the deformity and the 
control group may have an effect on the genotype-phenotype analysis.   
 
5.6.2.  BASIC HORIZONTAL CLASSIFICATION 
The problem with this classification was that some of the Class III  subjects had an 
average  vertical  facial  appearance,  while  others  had  a  long  face  pattern.  Such 
combinations may also affect the genotype-phenotype analysis. 
 
5.6.3.  COMBINED VERTICAL AND HORIZONTAL CLASSIFICATION 
Combining both vertical and horizontal criteria has addressed two main issues. First, 
from a vertical point of view, it has segregated between the Class II long face and the 
Class  III  long  face  patterns,  which  was  the  main  problem  with  the  basic  vertical 
classification, as well as differentiating between the Class III long face and the Class III Chapter 5. Patient’s classifications for phenotype-genotype studies 
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average vertical face, which was the main problem of the basic horizontal classification. 
Second, from a horizontal point of view, this classification has addressed the issue of 
the  skeletal  differences  between  both  subgroups  of  the  Class  III  pattern,  where  the 
majority of the Class III long face patients showed a retruded maxilla and a normal 
mandible subtype, while all Class III average vertical faces had a normal maxilla and a 
prognathic mandible subtype. However, an obvious disadvantage was that the Class III 
average face group had a reduced sample size (3 patients).  
 
5.6.4.  SUBDIVISIONS OF THE LONG FACE 
Combining patients with similar vertical skeletal and dental criteria had the advantage 
of detecting differences between the various subdivisions of the long face pattern. These 
were evident clinically and radiographically between the long face with AOB (reduced 
TPFH, RH and increased SN-MP) and the long face without AOB (increased TPFH, RH 
and normal SN-MP). However, the disadvantage was that the horizontal pattern was not 
addressed since Class III average patients were considered part of the controls.    
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5.7.  SUMMARY AND CONCLUSIONS 
Each craniofacial classification has its own advantages and disadvantages. However, 
depending on the aims of the project, the sample size and the craniofacial criteria of the 
recruited subjects, one can use various classifications to answer the proposed research 
question. Using the various clinical, dental and radiographic features of the subjects it 
was possible to generate four sets of phenotypic data to be further analysed in relation to 
the masseter muscle genotype.  
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Chapter 6.  Masseter muscle genotype in relation to 
various craniofacial phenotypes: Analysis of 
quantitative RT-PCR data 
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6.1.  INTRODUCTION 
Investigation  of  myosin  heavy  chain  (MYH)  gene  expressions  in  previous  masseter 
muscle genotype-phenotype research has been based on either vertical (Nelson-Moon et 
al., 1998; Suchak et al., 2009) or horizontal (Gedrange et al., 2005 and 2006; Maricic et 
al.,  2008)  craniofacial  deformities.  However,  no  previous  study  has  assessed  both 
vertical and horizontal facial parameters of the subjects within the same study, and its 
effect on masseter muscle gene expression compared to patients with average vertical 
and horizontal facial features.  
 
Also, the current data set exhibited varying degrees of maxillary, mandibular and dental 
discrepancies as shown by radiographic variables and the number of dental occlusal 
contacts  (all  subjects’s  criteria  are  presented  in  Chapter  5,  Section  5.5.2).  The 
introduction  of  correlation  statistical  analyses  into  genotype-phenotype  studies  has 
proved useful in such situations (Sabaghnia et al., 2006). This type of analysis dictates 
the  relationship  between  one  dependent  variable  (gene  expression)  and  another 
independent variable (e.g. varying degrees of the number of dental occlusal contacts).  
 
Using the genetic data generated from the microarray experiment (Chapter 4 -five novel 
genes) and the phenotypic data generated from the previous chapter (Chapter 5 -four 
phenotypic classifications), the aims of the current analyses were to: 
  
  Assess masseter muscle gene expression of the novel genes ascertained from the 
microarray  experiment  (KIAA1671,  DGCR6,  NDRG2,  SERGEF  and 
LOC730245) and the previously investigated myosin heavy chain genes (MYH1, 
2,  3,  6,  7  and  8)  in  relation  to  basic  vertical,  basic  horizontal,  long  face 
subdivisions and combined vertical and horizontal  phenotypic classifications of 
the subjects. 
 
  Undertake  a  correlation  analysis  to  assess  the  effect  of  various  vertical  and 
horizontal  cephalometric  parameters  on  masseter  muscle  gene  expression  of 
novel and MYH genes. 
 Chapter 6. Masseter muscle genotype in relation to various craniofacial phenotypes  
 
137 
 
  Undertake a correlation analysis to assess the effect of the number of dental 
occlusal contacts on masseter muscle gene expression of novel and MYH genes. 
 
6.2.  MATERIALS AND METHODS 
 
6.2.1.  PHENOTYPIC IDENTIFICATION 
The  29  subjects  were  classified  four  times  based  on:  1)  Basic  vertical;  2)  Basic 
horizontal; 3) Combination of vertical and horizontal craniofacial parameters; 4) Long 
face  subdivisions  (details  of  each  classification  are  presented  in  Chapter  5,  Section 
5.5.3). 
 
6.2.2.  GENOTYPIC IDENTIFICATION 
 
6.2.2.1.  RNA samples 
A total of 29 RNA samples (details of RNA quality control for each sample is presented 
in  Chapter 3 Figure 3.7) were used to  assess the gene expression of novel  (KIAA, 
DGCR6, NDRG2, SERGEF and LOC) and previously tested genes (MYH 1, 2, 3, 6, 7 
and  8)  of  the  masseter  muscle  in  relation  to  different  clinical  and  cephalometric 
craniofacial features as well as dental occlusal contacts.  
 
6.2.2.2.  TaqMan® assays selected 
Each  gene  of  interest,  including  the  reference  gene  (GAPDH),  was  tested  in 
quadruplicate reactions (details of the laboratory protocol are available at Appendix C). 
A total of 12 TaqMan® gene expression assays were therefore undertaken. Eleven of 
the  12  assays  were  ready  to  use,  tested  by  the  company  (Applied  Biosystems)  and 
guaranteed with 92-100% amplification efficiency. Only one gene assay, representing 
one  of  the  novel  genes  ascertained  from  the  microarray  experiment  (Hypothetical 
protein  LOC730245  gene)  had  not  been  previously  manufactured.  Special  software 
downloaded from the Applied Biosystems website called file builder® v3.1.0 was used 
by the investigator to conduct bioinformatics on the sequence of interest (derived from 
the NetAffyx target sequence information of the U133 Plus 2.0 array GeneChip®). The 
gene sequence was then submitted to the company for the construction of a TaqMan® 
gene expression assay (details of the TaqMan® gene expression assay ID numbers and Chapter 6. Masseter muscle genotype in relation to various craniofacial phenotypes  
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LOC gene efficiency test (10 fold dilution)
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GenBank mRNA sequence reference, of the genes of interest, are available at Appendix 
B). 
 
Following delivery of the customised assay, an efficiency test was conducted by the 
investigator to ensure 92-100% amplification efficiency of the newly customised assay. 
The test was performed using a series of 10-fold dilutions of one cDNA sample as a 
template and was conducted 5 times for both the customised assay and the GAPDH 
assay  (as  a  control).  The  settings  of  the  real-time  PCR  plate  and  machine  were 
conducted as described in the previous section. The Ct values were exported from the 
qRT-PCR machine and were plotted against the log transformation of the concentration. 
The efficiency % (Ex) was calculated using the equation: Ex = 10 
(-1/slope) -1 x 100. The 
slope (y) was derived from the graph. The graph was generated using Excel® software 
2003. Once the graph was  generated, the slope was automatically calculated by the 
software (Figure 6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: LOC gene efficiency test. The Ct values presented on the y-axis indicate the cycle at 
which the gene expression was first detected, plotted against the log transformation of the total 
RNA  concentration  on  the  x-axis.  In  order  to  use  the  2
-∆∆Ct  equation  to  calculate  the  gene 
expression intensity, each gene has to have a constant correlation between the Ct value and the 
total RNA concentration (i.e. the higher the concentration the lower the Ct value – the earlier the 
gene is detected on the real-time PCR machine). The graph shows a strong constant regression 
correlation demonstrated by the straight line and a correlation coefficient of R
2= 0.99 between 
the Ct value and the sample concentration where the higher the concentration, the earlier the Ct 
cycle of the LOC gene. The GAPDH gene was also tested using the same sample to act as a 
control. y, slope; R
2, correlation regression coefficient, the closer this value to 1 the stronger the 
correlation.      Chapter 6. Masseter muscle genotype in relation to various craniofacial phenotypes  
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6.2.2.3.  Normalisation and generation of gene intensity values 
Using the equation 2
-∆∆Ct, 11 gene expression values were generated for each individual 
representing  the  five  novel  and  the  six  MYH  genes  (details  of  normalisation  and 
calculation of gene intensity values are presented in Chapter 2, Section 2.7.5.5).  
 
6.2.3.  GENOTYPE-PHENOTYPE ANALYSIS 
 
6.2.3.1.  Masseter  muscle  gene  expression  in  relation  to  basic  vertical 
phenotypes (long face vs. control) 
Variation in the masseter muscle gene expression of novel and previously determined 
genes between the control and long face patients was assessed using the Mann Whiney 
U-test (SPSS v14 -non-parametric type of analysis). A p-value of ≤ 0.05 was considered 
to be statistically significant. 
 
6.2.3.2.  Masseter  muscle  gene  expression  in  relation  to  basic  horizontal 
phenotypes (Class II vs. Class III vs. control) 
Variation in the masseter muscle gene expression of novel and previously determined 
genes  between  the  control,  Class  II  and  Class  III  patients  was  assessed  using  the 
Kruskal Wallis test (SPSS v14 -non-parametric type of analysis). A p-value of ≤ 0.05 
was considered to be statistically significant. 
 
6.2.3.3.  Masseter muscle gene expression in relation to combined vertical and 
horizontal  phenotypes  (Class  II  long  face  vs.  Class  III  long  face  vs. 
Class III average vertical face vs. control) 
Variation in the masseter muscle gene expression of novel and previously determined 
genes between the control, Class II long face, Class III long face and Class III average 
vertical face patients was assessed using the Kruskal Wallis test (SPSS v14). A p-value 
of ≤ 0.05 was considered to be statistically significant. 
 
6.2.3.4.  Masseter muscle gene expression in relation to long face subdivisions 
(long face with AOB vs. long face without AOB vs. control) 
Variation in the masseter muscle gene expression of novel and previously determined 
genes  between  the  control,  long  face  with  AOB  and  long  face  without  AOB  was Chapter 6. Masseter muscle genotype in relation to various craniofacial phenotypes  
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assessed using the Kruskal Wallis test (SPSS v14). A p-value of ≤ 0.05 was considered 
to be statistically significant. 
 
6.2.3.5.  Correlation between masseter muscle gene expression and craniofacial 
cephalometric variables 
The Spearman’s correlation coefficient analysis (SPSS v14 -non-parametric correlation) 
was used to establish the relationship between various cephalometric variables (vertical 
-LAFH%, TAFH, TPFH, RH and SN-MP angle and horizontal -SNA, SNB and ANB 
angles) and masseter muscle gene expression. A p-value of ≤ 0.05 was considered to be 
statistically significant. 
 
6.2.3.6.  Correlation between masseter muscle gene expression and the number 
of dental occlusal contacts 
The Spearman’s correlation coefficient analysis (SPSS v14 -non-parametric correlation) 
was used to establish the relationship between the number of dental occlusal contacts 
and  masseter  muscle  gene  expression.  A  p-value  of  ≤  0.05  was  considered  to  be 
statistically significant. 
 
6.3.  RESULTS  
 
6.3.1.  LONG FACE vs. CONTROLS  
None of the novel or the MYH genes was found to be statistically significantly different 
between  long  face  patients  and  the  controls  when  only  vertical  facial  criteria  were 
considered.  
 
6.3.2.  CLASS II vs. CLASS III vs. CONTROLS  
The MYH3, MYH6, MYH7, SERGEF and NDRG2 gene expressions were all found to 
be significantly different between various horizontal groups. The MYH3, MYH6 and 
MYH7 were all up-regulated in Class II patients compared to both Class III and the 
controls  (p-values  0.049,  0.042  and  0.011,  respectively).  Both  the  SERGEF  and 
NDRG2 genes were down-regulated in the Class III group compared to the Class II 
pattern and the controls with p-values of 0.016 and 0.044, respectively. Figure 6.2 is a Chapter 6. Masseter muscle genotype in relation to various craniofacial phenotypes  
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graphical representation of gene expression variations between Class II, Class III and 
the controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6.2:  Masseter  muscle  gene  expression  variations  between  Class  II,  Class  III  and 
controls. Generally, large individual variations and skewed data were noted in all three groups. 
1) The MYH3 gene expression was up-regulated in the Class II group compared to both Class III 
and the controls. 2) The MYH6 was up-regulated in the Class II group compared to both Class III 
and the controls. Two extreme cases were found in the control and the Class III group and were 
denoted as an asterisk. 3) The MYH7 was up-regulated in the Class II pattern compared to Class 
III patients and the controls. The Class III pattern had one extreme case denoted as an asterisk. 
4) The SERGEF gene was down-regulated in the Class III group compared to Class II and the 
controls. The Class III group had one extreme case marked as an asterisk. 5) The NDRG2 gene 
was down-regulated in the Class III group compared to Class II and the controls.  
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6.3.3.  CLASS  II  LONG  FACE  vs.  CLASS  III  LONG  FACE  vs.  CLASS  III 
AVERAGE VERTICAL FACE vs. CONTROLS 
The MYH7, SERGEF, NDRG2 and KIAA genes were found to be significantly different 
when both vertical and horizontal craniofacial features were taken into account. The 
MYH7 gene expression was up-regulated in Class II long face patients compared to both 
Class III subgroups and the controls (p-values 0.023). Both NDRG2 and KIAA genes 
were up-regulated in Class II long faces and down-regulated in both Class III subgroups 
(long and average vertical faces) compared to the controls (p-values 0.029 and 0.021, 
respectively). The SERGEF gene, on the other hand, was down-regulated in both the 
Class III long faces and Class III average vertical faces compared to both Class II long 
face patients and the controls (p-value 0.004). Figure 6.3 is a graphical representation of 
gene expression variations between Class II long faces, Class III long faces, Class III 
average vertical faces and the controls.  
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Figure 6.3: Masseter muscle gene expression variations between Class II long faces, Class III 
long faces, Class III average vertical faces and controls. 1) The MYH7 gene expression was up-
regulated in the Class II long face group compared to both Class III subgroups and the controls. 
Large individual variations were noted in the Class II long face and Class III average vertical 
face groups. 2) The NDRG2 gene expression was up-regulated in Class II long face group and 
down-regulated in both Class III subgroups compared to the controls. However, large individual 
variations were evident in Class II long face individuals. 3) The KIAA gene expression was up-
regulated  in  Class  II  long  face  patients  and  down-regulated  in  both  Class  III  subgroups 
compared  to  the  controls.  Both  the  controls  and  the  Class  II  long  face  groups  had  large 
individual  variations,  while  both  Class  III  subgroups  showed  more  coherent  data.  4)  The 
SERGEF gene was down-regulated in the both Class III subgroups compared to both Class II 
long face and the controls. The Class III long face pattern had one outlier sample marked as a 
circle and one extreme value marked as an asterisk, while the Class III average vertical face had 
largely skewed data. 
III average III Long II Long Ave V&H
aveVH_vs_2L_3L_3ave
3.00
2.50
2.00
1.50
1.00
0.50
0.00
N
D
R
III average III Long II Long Ave V&H
aveVH_vs_2L_3L_3ave
1.25
1.00
0.75
0.50
0.25
0.00
S
E
R
22
24
III average III Long II Long Ave V&H
aveVH_vs_2L_3L_3ave
4.00
2.00
0.00
m
y
h
7
III average III Long II Long Ave V&H
aveVH_vs_2L_3L_3ave
1.25
1.00
0.75
0.50
0.25
0.00
K
I
A
AChapter 6. Masseter muscle genotype in relation to various craniofacial phenotypes  
 
144 
 
6.3.4.  LONG  FACE  WITH  AOB  vs.  LONG  FACE  WITHOUT  AOB  vs. 
CONTROLS  
Both the MYH7 and KIAA1671 genes were up-regulated in long face individuals with 
AOB compared to long face patients without AOB and the controls (p-values 0.008 and 
0.005,  respectively).  Figure  6.4  is  a  graphical  representation  of  gene  expression 
variations between long face with AOB, long face without AOB and the controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Masseter muscle gene expression variations between long faces with AOB, long 
faces without AOB and controls. 1) The MYH7 gene expression was up-regulated in the long 
face with AOB group compared to both long face without AOB and the controls. Large individual 
variations were evident between the long face with AOB patients while the long face without AOB 
had one outlier sample marked as a circle. The control group had skewed data with one extreme 
value marked as an asterisk. 2) The KIAA gene expression was up-regulated in long face with 
AOB compared to both long face without AOB and the controls. Both subdivisions of the long 
face had skewed data. 
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6.3.5.  CORRELATION  BETWEEN  MASSETER  MUSCLE  AND  GENE 
EXPRESSION 
  Vertical variables 
No correlation was found between the gene expression of the novel or the MYH genes 
and any of the vertical cephalometric variables (TAFH, LAFH%, TPFH, RH and SN-
MP).  
 
  Horizontal variables 
The NDRG2 gene expression was positively related to the SNA angle. The higher the 
SNA angle as in Class II patients, the greater the gene expression (p-value of 0.006).  
Furthermore, the MYH7, SERGEF and NDRG2 genes were positively related to the 
ANB angle (p-values 0.029, 0.006, 0.012, respectively). The higher the ANB angle, as 
in Class II patients, the greater the MYH7 gene expression (encode slow contracting 
protein isoform). The lower the ANB angle, as in Class III individuals, the lower the 
SERGEF gene expression. The higher the ANB angle, as in Class II patients, the greater 
the NDRG2 gene expression. Figure 6.5 is a graphical representation of the correlation 
between horizontal cephalometric variables and the masseter muscle gene expression. 
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Figure 6.5: Masseter muscle gene expression correlation to cephalometric variables. Generally, 
the masseter muscle gene expression showed a positive correlation to the SNA and the ANB 
angles  of  the  horizontal  cephalometric  variables  1)  The  higher  the  SNA°,  as  in  Class  II 
phenotypes  (protruded  maxilla),  the  greater  the  NDRG2  gene  expression.  2)  The  higher  the 
ANB°,  as  in  Class  II  phenotypes  (distal  maxillary-mandibular  horizontal  relationship),  the 
greater the NDRG2 gene expression. 3) The greater the ANB°, as in Class II patients, the greater 
the  MYH7  gene  expression.  4)  The  lower  the  ANB°,  as  in  Class  III  phenotypes  (negative 
maxillary mandibular horizontal relationship), the lower the SERGEF gene expression.  
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6.3.6.  CORRELATION  BETWEEN  MASSETER  MUSCLE  GENE 
EXPRESSION  AND  THE  NUMBER  OF  DENTAL  OCCLUSAL 
CONTACTS 
Both SERGEF and NDRG2 gene expressions were significantly positively related to the 
number of dental occlusal contacts (p-values 0.019 and 0.032, respectively). The lower 
the number of dental occlusal contacts, as in Class II, Class III and long face patients, 
the  lower  the  SERGEF  and  NDRG2  gene  expressions.  Figure  6.6  is  a  graphical 
representation of the correlation between the number of dental occlusal contacts and the 
masseter muscle gene expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: masseter muscle gene expression  correlation to the  number of dental occlusal 
contacts.  Generally,  a  positive  correlation  was  observed  between  the  masseter  muscle  gene 
expression and the number of dental occlusal contacts. 1 and 2) The lower the number of dental 
occlusal contacts, as in Class II, Class III and long face patients (with and without AOB), the 
lower the gene expression of both the SERGEF and NDRG2 genes. 
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6.4.  DISCUSSION  
In the current chapter five main issues have been addressed. First, the effect of various 
phenotypic  classifications  on  the  genotypic  analysis.  Second,  variations  in  masseter 
muscle gene expression in relation to different craniofacial phenotypes. Third, the effect 
of various cephalometric variables on masseter muscle gene expression. Fourth, the 
effect of the number of dental occlusal contacts on the masseter muscle gene expression. 
Fifth, validation of microarray data.  
 
6.4.1.  THE  EFFECT  OF  VARIOUS  PHENOTYPIC  CLASSIFICATIONS  ON 
GENOTYPIC ANALYSIS 
It has been demonstrated that the genotypic analysis can be affected by the phenotypic 
classification used, and the need to segregate both Class II and Class III patterns is 
mandatory during vertical  classification even though they may have similar vertical 
facial  appearance.  Gedrange  and  colleagues  (2006)  in  a  study  of  10  patients  with 
horizontal deformities (5 Class II and 5 Class III subjects) found that the expression of 
MYH2  and  MYH7  was  higher  in  Class  II  patients  than  in  Class  III  individuals. 
Combining both Class II long face and Class III long face patterns as one single group 
may camouflage the true effect of the vertical deformity. This was evident in the present 
study. When the patients were classified based solely on vertical facial parameters into 
15 long face patients (including 5 Class II and 10 Class III patients) and 14 average 
vertical controls (including 11 average vertical and horizontal subjects and 3 Class III 
average vertical  face patients), none of the novel  or the  MYH  genes  were found to 
behave  significantly  differently.  However,  when  the  same  patients  were  regrouped 
based on both vertical and horizontal facial parameters into 5 Class II long faces, 10 
Class III long faces, 3 Class III average faces and 11 controls (average vertical and 
horizontal), the MYH7, NDRG2, KIAA1671 and SERGEF genes were all found to be 
differentially expressed between the various classified groups.  
 
Furthermore,  when  considering  subdivisions  of  the  long  face  pattern  using  vertical 
classifications, this also had an impact on masseter muscle gene expression analysis. 
This  was  clearly  shown  when  none  of  masseter  muscle  genes  were  differentially 
expressed when the patients were classified into only long face and average controls. 
However, MYH7 and KIAA1671 genes were found to be up-regulated in relation to Chapter 6. Masseter muscle genotype in relation to various craniofacial phenotypes  
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long faces with AOB compared to long faces without AOB and the controls when the 
patients were regrouped based on the various subdivisions of the long face pattern. This 
may suggest that different gene expression mechanisms  are related to the long face 
pattern with and without AOB. However, cautious interpretation of the data is required 
as the majority of the long faces with AOB were Class II patients, while all the long 
faces without AOB individuals exhibited a Class III pattern (clinical and dental details 
of subjects are presented in Chapter 5, Figure 5.7) which may have masked the vertical 
effect.  Further  investigation  on  a  larger  sample  size  with  less  variability  and  more 
coherent data is recommended. 
 
6.4.2.  MASSETER MUSCLE GENE EXPRESSION VARIATIONS BETWEEN 
VARIOUS CRANIOFACIAL DEFORMITIES 
Few studies have investigated the different MYH gene expression isoforms in relation to 
different craniofacial patterns (Maricic et al., 2008; Suchak et al., 2009). As already 
stated,  these  studies  have  been  based  on  either  vertical  (Nelson-Moon  et  al.,  1998; 
Suchak et al., 2009) or horizontal (Gedrange et al., 2006; Maricic et al., 2008) facial 
appearance and none have taken into account both vertical and horizontal criteria of the 
subjects. Furthermore, the studies have included few or no control patients with average 
vertical and horizontal craniofacial parameters for comparison (Suchak et al., 2009). 
The current research has investigated all six MYH genes (MYH1, MYH2, MYH3, MYH6, 
MYH7 and MYH8) as well as the novel genes ascertained from the current microarray 
data in relation to vertical, horizontal, combined vertical and horizontal criteria and the 
subdivisions of the long face pattern. 
 
  Long face vs. controls: None of the novel or MYH masseter muscle genes were 
found to be significantly different when the patients were classified based on 
only vertical facial parameters including 15 long faces and 14 average controls. 
These findings were similar to the results of Suchak and colleagues, (2009) who 
investigated all six MYH genes in 9 long face patients compared to 1 average 
control. Furthermore, the qRT-PCR gene expression analysis of the novel genes 
did not support the microarray results, where both the KIAA1671 and DGCR6 
genes were found to be down-regulated in long face patients compared to the 
controls.  Chapter 6. Masseter muscle genotype in relation to various craniofacial phenotypes  
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  Class II vs. Class III vs. controls: The embryonic MYH3, slow MYH6 and slow 
MYH7 genes were all found to be up-regulated in 5 Class II patients compared to 
13 Class III and 11 control patients. These results concur with the findings of 
Gedrange and colleagues, (2006) in a study of 5 Class II and 5 Class III patients 
who found that MYH7 gene expression was higher in Class II patients compared 
to Class III individuals (Gedrange et al., 2006). However, their study did not 
include  the  MYH3  or  MYH6  genes.  As  for  the  novel  genes,  SERGEF  and 
NDRG2 were down-regulated in Class III patterns compared to both the Class II 
and the controls. qRT-PCR analysis of SERGEF gene expression confirmed the 
microarray results. However, this did not support the other microarray finding 
where the NDRG2 was down-regulated in Class II patients compared to Class 
III individuals.   
 
  Class II long faces vs. Class III long faces vs. Class III average vertical faces vs. 
controls:  Instead  of  using  basic  vertical  or  simple  horizontal  grouping,  an 
adaptation of the classification recommended by Sassouni, (1969), which takes 
into  account  both  vertical  and  horizontal  patterns,  was  used.  The  MYH7, 
NDRG2 and KIAA1671 were found to be up-regulated in 5 Class II long face 
patients compared to both Class III subgroups (10 long and 3 average vertical 
faces)  and  11  controls  (average  vertical  and  horizontal).  Interestingly,  the 
SERGEF gene expression was not affected by splitting the Class III group into 
long and average vertical faces and was down-regulated in relation to all Class 
III subgroups. This suggests that the SERGRF gene expression may be affected 
more by horizontal patterns than vertical facial development. This classification 
has not been used previously by other investigators.  
 
  Long faces with AOB vs. long faces without AOB vs. controls: The MYH7 and 
KIAA1671 were up-regulated in relation to 6 long faces with AOB compared to 
9 long faces without AOB and 14 controls. As explained earlier, the majority of 
the long faces with AOB were Class II patients while all long faces without 
AOB  individuals  exhibited  a  Class  III  pattern  and  therefore,  careful 
interpretation  of  this  data  is  recommended.  This  classification  has  not  been Chapter 6. Masseter muscle genotype in relation to various craniofacial phenotypes  
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previously  used  in  masseter  muscle  genotype-phenotype  studies  and  a  larger 
sample size should be investigated in future. 
      
6.4.3.  MASSETER  MUSCLE  GENE  EXPRESSION  vs.  CEPHALOMETRIC 
VARIABLES  
The current data indicate that none of the vertical cephalometric variables were found to 
be correlated to masseter muscle gene expression. This finding concurs with one of the 
results  of  Suchak  and  colleagues,  (2009),  who  found  no  correlation  between  the 
expression of any of the six MYH genes and the LAFH%.  
 
Nevertheless, the present data indicate that the masseter muscle gene expression of the 
NDRG2 gene was positively correlated to the SNA and ANB angles, while the MYH7 
and SERGEF were positively correlated only to the ANB angle. The higher the SNA 
and ANB angles, as in the Class II pattern compared to the controls, the greater the 
NDRG2 gene expression. The higher the ANB angle, as in Class II patients, the greater 
the MYH7 gene expression. The lower the ANB angle, as in Class III patients, the lower 
the SERGEF gene expression.  
 
6.4.4.  MASSETER  MUSCLE  GENE  EXPRESSION  vs.  THE  NUMBER  OF 
DENTAL OCCLUSAL CONTACTS 
The  masseter  muscle  gene  expressions  of  only  SERGEF  and  NDRG2  genes  were 
positively correlated to the number of dental occlusal contacts. The lower the number of 
occlusal contacts, as in the long faces, Class II and Class III patients, the lower the 
SERGEF and the NDRG2 gene expression. None of the MYH genes or the remaining 
three novel genes have been found to be correlated to the number of dental occlusal 
contacts.  
 
Nelson-Moon  and  co-workers,  (1998),  investigated  the  correlation  between  MYH1, 
MYH2, MYH3, MYH6, MYH7 and MYH8 and the number of dental occlusal contacts in 
a group of patients with vertical facial discrepancies. An inverse correlation was found 
between  the  embryonic  MYH3  gene  expression  and  the  number  of  dental  occlusal 
contacts (i.e. the lower the number of occlusal  contacts, the higher the  MYH3 gene 
expression).  Although  the  current  data  does  not  directly  support  their  results,  the Chapter 6. Masseter muscle genotype in relation to various craniofacial phenotypes  
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correlation analysis showed that the Class II patients had the lowest number of occlusal 
contacts and the highest MYH3 gene expression compared to Class III individuals and 
the  controls.  The  reason  for  the  variations  between  the  studies  could  have  been 
attributed to the fact that the sample used in Nelson-Moon and colleagues’ study, (1998) 
included 9 long  face patients  and 6 average  controls,  all  of whom  had pre-surgical 
orthodontics prior to orthognathic surgery. This indicates that the controls were patients 
with horizontal deformities but had average vertical facial features. The present data 
included a broad range of deformities compared to patients with average vertical and 
horizontal features.  
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6.5.  SUMMARY AND CONCLUSIONS  
  Both vertical and horizontal facial patterns should be taken into account when 
considering phenotype-genotype analysis. 
 
  The qRT-PCR data suggests that the MYH3 (encode embryonic MyHC protein), 
MYH6 (encode α-cardica slow-contracting MyHC protein) and MYH7 (encode 
slower-contracting  MyHC  protein)  genes  were  all  up-regulated  in  Class  II 
individuals compared to Class III and control subjects. 
 
  Both SERGEF and NDRG2 gene expression was down-regulated in Class III 
subjects compared to the controls. 
 
  The masseter muscle expression of the NDRG2 gene was positively correlated 
to both SNA and ANB angles, while the MYH7 and SERGEF gene expressions 
were positively correlated to the ANB angle.  
 
  The masseter muscle expression of NDRG2 and SERGEF genes were correlated 
to the number of dental occlusal contacts. 
 
  The SERGEF gene showed consistent expression results when tested by both 
microarray and qRT-PCR techniques. 
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7.1.  SUMMARY OF THE RESULTS 
The current genotype-phenotype study was designed based on three main levels: firstly, 
to identify masseter muscle genotypes; secondly, to identify craniofacial phenotypes; 
thirdly, to relate masseter muscle genotypes to craniofacial phenotypes  according to 
clinical, dental and radiographic features. A summary of the main results for the current 
research is presented in Table 7.1. 
 
Table 7.1: Summary of the main results for the current research. 
The null hypothesis  Techniques 
implemented 
Result 
1) No novel masseter muscle genes can be 
identified in relation to craniofacial patterns, 
when using the microarray technology 
confirmed by quantitative RT-PCR (qRT-
PCR). 
-Microarrays 
-qRT-PCR  
-Null hypothesis rejected 
 
-SERGEF gene was down-
regulated in Class III pattern using 
both microarray and qRT-PCR. 
2) There is no relationship between masseter 
muscle gene expression and various 
combinations of vertical and horizontal 
craniofacial patterns. 
-qRT-PCR  -Null hypothesis rejected.  
 
- MYH3, MYH6 and MYH7were up-
regulated in Class II patients. 
- SERGEF and NDRG2 down-
regulated in Class III individuals. 
3) There is no correlation between masseter 
muscle gene expression and various vertical 
and horizontal cephalometric variables. 
-qRT-PCR data 
vs. cephalometric 
variables. 
-Null hypothesis rejected. 
 
- NDRG2 positively correlated to 
SNA and ANB angles. 
 
- MYH7 and SERGEF positively 
correlated to the ANB angle.  
4) There is no correlation between masseter 
muscle gene expression and the number of 
dental occlusal contacts associated with 
craniofacial deformities. 
 
-qRT-PCR data  
vs. dental occlusal 
contacts. 
-Null hypothesis rejected. 
 
- NDRG2 and SERGEF positively 
correlated to the number of dental 
occlusal contacts. 
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7.2.  IDENTIFICATION OF MASSETER MUSCLE GENOTYPE 
This  study is  the first  to report the use  of microarray technology in  relation  to  the 
masseter muscle gene expression of non-syndromic patients with variable vertical and 
horizontal  craniofacial  deformities.  Using  this  technology,  a  candidate  gene  list  has 
been identified for patients with long face features (12 up- and 19 down-regulated genes 
compared to the controls), Class II (3 up- and 9 down-regulated genes compared to the 
controls) and Class III patterns (15 up- and 21 down-regulated genes compared to the 
controls) that were not reported previously in relation to the masseter muscle (Chapter 
4,  Tables  4.3  and  4.4).  Any  of  these  genes  would  warrant  further  investigation  in 
relation to craniofacial phenotypes.  
 
Out  of  the  candidate  gene  list,  5  “novel”  genes  were  identified  based  on  statistical 
analysis, and these warrant further investigation alongside the “informative” MYH genes 
in relation to craniofacial phenotypes. The microarray gene expression status of one 
(SERGEF),  out  of  the  five  novel  genes,  showed  consistent  results  between  both 
microarray and qRT-PCR data, while the remaining four genes (DGCR6, KIAA1671, 
LOC730245 and NDRG2) presented inconsistent results. However, this does not rule 
out their involvement in relation to craniofacial deformities, and further investigation on 
genomic and proteomic levels is recommended. Table 7.2 summarises the microarray 
and the qRT-PCR gene expression status of the 5 novel genes. 
 
Table 7.2: Gene expression status of the five novel genes. 
Gene name  Gene symbol  Microarray data*  qRT-PCR data** 
Secretion Regulating Guanine 
nucleotide Exchange Factor  
SERGEF  Down-R in Class III 
compared to Ctrl 
Down-R in Class III 
compared to Ctrl 
KIAA1671  
 
KIAA1671   Down-R in LF  
compared to Ctrl 
Up-R in LF AOB  
compared to LF no AOB and Ctrl 
N-myc Downstream Regulated 
Gene family member 2 
NDRG2  Down-R in Class II 
compared to Class III 
Up-R in Class II  
compared to Class III 
DiGeorge syndrome Critical 
Region gene family member 6 
DGCR6  Down-R in LF 
compared to Ctrl 
No significant results 
p-value 0.232 
Hypothetical protein Locus 
730245 
LOC730245  Up-R in Class III 
compared to Ctrl 
No significant results  
p-value 0.361 
*Significant p-value ≤ 0.001. **Significant p-value ≤ 0.05. R: Regulated. Ctrl: Control. LF: Long face. AOB: 
Anterior open bite. Chapter 7. General discussion  
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Both microarray (Rogojina et al., 2003) and qRT-PCR (Levesque-Sergerie et al., 2007) 
are  sensitive  gene  expression  techniques.  A  possible  explanation  for  the  variations 
between  both  techniques  may  be  to  the  nature  of  the  microarray  experiment  where 
thousands of genes are tested and false positive results are more likely (Shi et al., 2006). 
Both technologies have been reported with different technical and analytical procedures 
(Table 7.3). However, one can combine the advantages of both techniques. Microarrays 
are considered powerful, large scale tools to examine thousands of genes and generate a 
list of candidate genes, whereas some might be novel and cannot be pointed out by 
small scale qRT-PCR experiments alone. Therefore, microarray data often provide the 
foundations for small scale qRT-PCR studies. 
 
Table 7.3: Variations between the microarray and the qRT-PCR technologies used for the 
current research. 
Feature  Affymetrix® microarray  qRT-PCR 
Number of genes tested  Large  Small 
Probe design  11 PM-MM probe-set design  
(Tian et al., 2004) 
TaqMan® assay 
(Shippy et al., 2004) 
cDNA amplification  Linear (IVT)  
(Van Gelder et al., 1990) 
Exponential  
(Nolan et al., 2006) 
Labelling   Direct  
(Do and Choi, 2007) 
Indirect  
(Busten and Nolan, 2004) 
Normalisation and calculation of 
gene intensity value 
GCRMA normalisation 
(Wu et al., 2004) 
2
-∆∆Ct 
(Livak and Schmittgen, 2001) 
Statistical analysis  Specialised data mining 
techniques 
Standard (non-parametric) 
techniques 
IVT, in-vitro transcription; GCRMA, G-C base pair robust multi-array average. 
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7.3.  IDENTIFICATION OF CRANIOFACIAL PHENOTYPES 
Craniofacial  deformities  exhibit  a  wide  range  of  clinical,  dental  and  radiographic 
phenotypes. Previous masseter muscle genotype-phenotype studies have used various 
phenotypic classifications. Most of these classifications were based on either vertical 
(Singh et al., 2000; Suchak et al., 2009) or horizontal (Gedrange, et al., 2005; Harzer et 
al., 2007) patterns, and none have assessed the effect of both dimensional discrepancies 
on  masseter  muscle  genotype.  Therefore,  prior  to  the  current  genotype-phenotype 
correlation, it was necessary to establish the craniofacial morphology of the subjects. 
Using various classifications reported in the literature (Sassouni, 1969; Schendel et al., 
1976), together with the analysis of the clinical, dental and radiographic features, four 
main phenotypic classifications were produced:  
 
1.  Basic vertical classification (long faces vs. controls –average vertical faces). 
 
2.  Basic  horizontal  classification  (Class  II  vs.  Class  III  vs.  controls  –average 
horizontal faces). 
 
3.  Combined vertical and horizontal classification (Class II long faces vs. Class III 
long  faces  vs.  Class  III  average  faces  vs.  controls  –average  vertical  and 
horizontal faces). 
 
4.  Subdivisions of the long face classification (long faces with AOB vs. long faces 
without AOB vs. controls –average vertical faces).     
 
The  reason  for  generating  four  sets  of  phenotypic  data  was  to  assess  whether  the 
grouping of patients based on different craniofacial dimensional patterns would have an 
effect on the interpretation of the genotypic data. The current research demonstrated that 
basic  vertical  and  horizontal  classifications  may  not  be  sufficient  for  genotypic 
correlation.  
 
This was evident when the “informative” MYH genes, as well as the “novel” genes 
ascertained from the present microarray experiment, showed no significant differences 
between patients, when grouped solely based on vertical facial development. While, Chapter 7. General discussion  
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regrouping  based  on  both  vertical  and  horizontal  patterns  or  using  the  long  face 
subdivisions (with and without AOB), some of the “informative” and “novel” genes 
showed significant differences between various groups. This indicates the effect of both 
vertical and horizontal facial development on masseter muscle gene expression, and that 
these dimensional patterns should not be ignored during classification.  
 
However, one has to acknowledge the difficulties of using detailed classifications which 
compromises the sample size, particularly invasive genetic studies, including the current 
research,  where limited numbers of patients are often encountered (Gedrange et al., 
2006; Suchak et al., 2009). Therefore, careful interpretation of the data is required and 
further  investigation,  using  a  large  sample  size  with  more  coherent  features  of  the 
different classified groups, is needed.   
 
7.4.  GENOTYPE-PHENOTYPE CORRELATION  
 
7.4.1.  INFORMATIVE MASSETER MUSCLE GENOTYPE IN RELATION TO 
CRANIOFACIAL PHENOTYPES 
Out of the six “informative” myosin heavy chain genes (MYH1; MYH2; MYH3; MYH6; 
MYH7; MYH8), the MYH3, MYH6 and MYH7 have been found to be up-regulated in 
Class II patients compared to Class III individuals and the controls.  
 
All  of  the  Class  II  patients  included  in  the  current  research  exhibited  a  long  face 
appearance with AOB. However, both MYH3 and MYH6 showed up-regulation in Class 
II patients when the recruited subjects were classified based on only horizontal facial 
features, while when the patients were regrouped using the various other classifications, 
no variations have been found. This may have been attributed to the large individual 
variations  that  were  observed  in  the  expression  of  the  MYH3  and  MYH6  genes  (as 
shown by the box plots presented in Chapter 6, Figure 6.2).  
 
MYH7  on  the  other  hand,  showed  consistent  up-regulation  in  relation  to  Class  II 
appearance, Class II long face pattern and the long face with AOB group when using the 
various classifications. Furthermore, the present data indicate that the masseter muscle 
gene expression of the MYH7 was positively correlated to ANB angle. This suggests Chapter 7. General discussion  
 
160 
 
that Class II individuals with severe retrognathic appearance (increased ANB) and long 
face pattern with AOB tend to have over-expression of the MYH7. The current results 
confirm the findings of Gedrange and co-workers, (2006) who reported up-regulation of 
MYH7 in Class II patients compared to Class III individuals.  
 
Whether the gene expression of the MYH7 can be considered a predictor of a specific 
facial type or as an indicator for possible relapse following orthognathic surgery, would 
require  extensive  investigation  on  genomic,  proteomic  and  transcriptomic  levels, 
particularly before and after surgical correction. Harzer and colleagues, (2007) found a 
shift in MYH7 gene expression in Class II patients six months following mandibular 
advancement. However, long-term studies are required to establish whether the mode of 
the shift is transitional or permanent.  
 
7.4.2.  NOVEL  MASSETER  MUSCLE  GENOTYPE  IN  RELATION  TO 
CRANIOFACIAL PHENOTYPES 
Out of the five “novel” masseter muscle genes, two new discoveries have been reported. 
Both  SERGEF  (Secretion  Regulating  Guanine  nucleotide  Exchange  Factor)  and 
NDRG2  (N-myc  Downstream  Regulated  Gene  family  member  2)  genes  have  been 
found to be down-regulated in relation to the Class III pattern.  
 
7.4.2.1.  NDRG2 masseter muscle gene expression 
Although the gene expression status of the NDRG2 showed inconsistent results between 
the microarray (up-regulated in Class III compared to Class II) and qRT-PCR (down-
regulated in Class III compared to Class II) data, the clinical, dental and radiographic 
analysis in relation to qRT-PCR gene expression has been found to be consistent. This 
was  evident  since  the  NDRG2  gene expression, as  dictated by  qRT-PCR, has  been 
found to be down-regulated in relation to the general clinical appearance of the Class III 
pattern  including  both  subgroups  (Class  III  long  face  and  Class  III  average  face 
compared to Class II long face) and was positively correlated to the number of dental 
occlusal contacts, SNA and ANB angles. 
 
NDRG2 has been found to be down-regulated in progressively dividing cancer cells 
compared to normally dividing cells (Zhao et al., 2008), while up-regulation was found Chapter 7. General discussion  
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to suppress cancer cell proliferation (Kim et al., 2009). Down-regulation of NDRG2 
gene in Class III patients may indicate the craving situation of masseter muscle cells to 
proliferate and regenerate as a result of the continuous micro trauma generated from the 
imbalanced  relationship  between  masseter  muscle  and  the  underlying  prognathic 
skeletal deformity.  
 
7.4.2.2.  SERGEF masseter muscle gene expression 
Both the microarray and qRT-PCR results for the gene expression of SERGEF were 
consistent  in  relation  to  the  clinical,  dental  and  radiographic  features  of  Class  III 
individuals compared to Class II subjects and the controls. SERGEF gene expression 
was down-regulated in relation to a general prognathic clinical appearance, regardless of 
the vertical facial development in both Class III subgroups, without being affected by 
the fact that some of the Class III patients exhibited long face appearance while others 
had  average  vertical  facial  features.  SERGEF  gene  expression  was  also  positively 
correlated to the ANB angle and the number of dental occlusal contacts. 
 
A possible cause for the involvement of SERGEF in the masseter muscle of Class III 
prognathic patients could be the reduced masseter muscle activity associated with the 
Class III pattern (Cha et al., 2007) and the reduced number of dental occlusal contatcts 
(Kobayashi et al., 2001). As a result, intracellular ion exchange is affected so that high 
levels  of  Ca
2+  ions  appear  in  fast-contracting  muscles  (Allen  and  Leinwand,  2002), 
while  Mg
2+  tend  to  increase  in  weak  muscles  (Dell  Castillo  and  Engbaek,  1954). 
Increased Mg
2+ levels promote binding of down-regulated SERGEF to an exocyst called 
Sec5 (Sjölinder et al., 2004). The exocysts are a group of proteins that can modulate the 
secretion and traffic pathway of various extracellular molecules (Kee et al., 1997). The 
compound of SERGEF attached to Sec5 has been found to modulate and increase the 
secretion but not the synthesis of chondroitin sulphate proteoglycans in cancer cell lines 
(Sjölinder et al., 2002). Chondroitin sulphate proteoglycan is one of the extracellular 
matrix proteins that is developmentally regulated (Velleman et al., 1999) and highly 
expressed during embryonic development of skeletal muscles. A marked reduction in 
expression has been observed in adults (Carrino, 1999; Velleman et al., 1999) except 
following injury (Carrino et al., 1988).  This may suggest the need  for the masseter 
muscle to regenerate in compensation for the imbalanced musculo-skeletal relationship Chapter 7. General discussion  
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associated  with  a  Class  III  pattern.  However,  these  speculations  need  to  be  further 
investigated and proven prior to any conclusion. Figure 7.1 illustrates a hypothesised 
role of the SERGEF gene in the masseter muscle of Class III patients.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: A hypothesised role of SERGEF gene in the masseter muscle of patients with a 
Class III pattern. Weak masseter muscle activity associated with Class III appearance would 
increase  the  intracellular  levels  of  Mg
2+,  which  would  promote  binding  of  down-regulated 
SERGEF  to  sec5  and  subsequently  induce  masseter  muscle  regeneration  via  increasing  the 
secretion of chondroitin sulphate proteoglycans.     
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7.5.  CONCLUSIONS 
  The current research has provided an insight into the transcriptome profile of the 
masseter  muscle  and  has  identified  new  genes  that  affect  musculo-skeletal 
morphology.   
 
  By  using  microarray  technology,  foundation  for  the  pre-treatment  gene 
expression  profile  of  the  masseter  muscle  in  relation  to  various  craniofacial 
deformities has been set. 
 
  The use of combined vertical and horizontal classifications is a better approach 
than either type of grouping alone in identifying the phenotype of craniofacial 
deformities in genotype-phenotype analysis. 
 
  The greater the retrognathic appearance, the higher the MYH7 gene expression  
 
  The greater the prognathic appearance, the lower the NDRG2 and SERGEF gene 
expression. 
 
  Results including Class II subjects should be interpreted with caution since the 
facial heights were greater than normal.  
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 7. General discussion  
 
164 
 
7.6.  SUGGESTIONS FOR FUTURE WORK 
 
7.6.1.  PATIENT CLASSIFICATION FOR MASSETER MUSCLE RESEARCH 
  The use of a comprehensive patient classification including clinical, dental and 
radiographic  criteria  is  recommended  when  assessing  the  masseter  muscle 
genotype, whether on genomic, transcriptomic or proteomic levels. This would 
provide a precise genotype-phenotype correlation.  
 
7.6.2.  ON A GENOME LEVEL 
  DNA sequencing of the SERGEF and NDRG2 genes of patients with variable 
craniofacial morphologies is recommended. This would enable an assessment as 
to whether the gene expression variations were due to mutations of the genes or 
a gene expression response to the skeletal discrepancy. 
 
7.6.3.  ON A TRANSCRIPTOME LEVEL 
  Post-surgical  follow-up  of  the  masseter  muscle  gene  expression  in  patients 
undergoing corrective surgery, preferably on a long-term basis including relapse 
cases  using  both  microarray  and  qRT-PCR,  is  recommended.  This  would 
provide an insight into the behaviour of the genes, and whether or not any genes 
would demonstrate a transitional shift or permanent adaptation in response to the 
surgical correction, as well as the possibility of identifying certain genes that 
may be considered predictors for orthognathic surgical relapse.  
 
  Gene expression microarray of the masseter muscle of both syndromic and non-
syndromic patients having similar craniofacial patterns would provide valuable 
information regarding the mechanism of action and the various genetic pathways 
in syndromic and non-syndromic conditions. This could be combined with pre- 
and post-surgical assessment. 
 
7.6.4.  ON A PROTEOME LEVEL 
  Future experimentation of the protein activity of the MYH and novel genes of the 
masseter  muscle  pre-  and  post-surgical  correction  of  jaw  deformities  may Chapter 7. General discussion  
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establish their role in relation to existing discrepancies and in response to jaw 
modification.  
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Invitation letter 
 
Version 1.0 
Date: 14/10/2005 
 
Study title: A genetic study of facial /masticatory muscle and bones of the jaws in 
patients with variable facial features. 
         
You are kindly invited to take part in the above mentioned study. Before you decide it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the information sheet and leaflet supplied with this letter and 
discuss it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information.  
 
Thank you for taking the time to read this. 
 
For further information please contact any of the Researchers listed below. 
  Professor Nigel Hunt  
Chairman of Division of Craniofacial and Developmental Sciences, and Head of Units 
of Orthodontics and Paediatric Dentistry. 
UCL Eastman Dental Institute. 
256 Grays Inn Road 
London WC1X 8LD 
Phone: +44 (0) 20 7915 1239 
E-Mail: n.hunt@eastman.ucl.ac.uk 
 
  Miss Hadwah A.M Moawad 
PhD postgraduate, Unit of Orthodontics 
UCL Eastman Dental Institute  
256 Grays Inn Road 
London WC1X 8LD 
Phone: +44 (0) 20 7915 1054 
E-Mail: h.moawad@eastman.ucl.ac.uk  Appendix A. Ethical papers  
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Participant’s information sheet -1 of 5 pages 
 
This  information  sheet  was  supplied  for  both  the  deformity  and  control  groups. 
However, questions number 4, 6 and 7 were modified for the control group. 
   
Version: 2.0 
Date: 19/12/2005 
Project ID:  
 
1. Study title  
A genetic study of facial /masticatory muscle and bones of the jaws in patients with 
variable facial features.  
 
2. Invitation 
You are kindly invited to take part in this study, which will provide valuable genetic 
information  about  the  muscle-bone  interaction  to  layout  facial  features.  Before  you 
decide, it is important for you to understand why the research is being conducted and 
what it will involve. Please take time to read this information sheet as well as the leaflet 
given carefully and discuss it with others if you wish. Ask us if there is anything that is 
not clear or if you would like more information. Take time to decide whether you wish 
to take part or not. 
 
3. What is the purpose of the study? 
Previous  studies  have  shown  that  both  bone  and  facial  muscles  contribute  to  the 
development of facial features. However, the question as to whether the shape of the 
bones of the jaws are affected by the development of facial muscles or that the muscles 
adapt to the underlying bone remains unanswered. Therefore, this study will investigate 
the  genetic  variation  of  the  bones  of  the  jaws  and  facial  muscles  of  patients  with 
variable facial features compared to individuals with average facial form. Furthermore, 
orthodontic /jaw surgery treatment modifies the shape of the bones of the jaws which 
gives  an  opportunity  to  assess  the  effect  of  changing  the  underlying  bone  on  the 
adaptability of facial muscles.  
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4. Why have I been chosen? 
A clinical examination has shown that you have a variation in your jaw form which you 
have agreed to correct surgically. Therefore, you are invited to take part in this research 
which will include 2 main groups (average and variation group). You are considered 
one out of many other patients within the variation group. 
 
5. Do I have to take part? 
Participation in this study is completely voluntary and up to you. If you decided to take 
part, you will be given this information sheet as well as a leaflet to keep and will be 
asked to sign a consent form. If you decide to withdraw, you are free to do so at any 
time without giving a reason. A decision to withdraw or not to take part in the study will 
not affect your care and treatment at the Eastman Dental Hospital in any way. 
 
6. What is involved in the study? 
Taking part in this research will not require any additional appointments other than the 
appointed time for orthodontic /jaw surgery treatment. Three different tissue samples 
(an oral swab, muscle biopsy and the remaining bone fragments) will be required. The 
remaining bone fragments will be collected only following the removal of your wisdom 
teeth and jaw surgery. The oral swab and the muscle biopsy will be collected from the 
inner cheek at three different appointments spread over the entire treatment. The three 
appointments are: 
At the time of removal of the wisdom teeth. 
At the time of jaw surgery. 
At least 6 months after surgery.  
  
7. What are the procedures being conducted? 
The oral swab is a simple procedure done by rubbing the inner cheek with a special 
brush. As for muscle samples, at the first two appointments, general anaesthesia will be 
administered  for  the  surgical  procedures.  Therefore,  no  additional  anaesthesia  is 
required.  On  the  third  appointment,  the  biopsy  will  be  conducted  under  local 
anaesthesia following a routine orthodontic appointment, which would require about 10  Appendix A. Ethical papers  
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Participant’s information sheet cont -3 of 5 pages 
 
minutes extra than the appointed time for orthodontic treatment. As for bone, only the 
remaining fragments following surgery will be collected.  
 
8. What are known risks of the study or the side effects of any procedure conducted?  
No  complication  or  side  effects  are  expected  from  collecting  the  remaining  bone 
fragments or the oral swab. As for the muscle sample, over the last 5 years, several 
other studies at the Eastman Dental Hospital have collected muscle biopsies from a 
large number of patients with no reported complications. However, you may feel slight 
discomfort or oozing of blood following the biopsy. Therefore, to ensure maximum 
comfort and safety, your general practitioner will be informed about the study and the 
time when the samples will be collected.  
 
9. What are the possible benefits of taking part?  
The information we get from this study may help us as professionals to improve the 
quality of treatment provided for future patients to last for a lifetime.  
 
10. The information held about the research subject    
All collected samples will be stored at the UCL/ Eastman Dental Institute and used for 
genetic analysis for this study only. All the information collected for this research will 
be strictly confidential. In order to maintain confidentiality, once collected, the samples 
will  be  given  an  identifier  code  (eg.  NBS  1  i.e.,  normal  bone  sample  from  patient 
number one) purely to relate the data. Therefore, all personal details (name, age, etc) 
will not be required and will only be known by the principle investigators.  
 
11. Studies on tissue 
We are very grateful to all subjects that the oral swab, muscle biopsy and the remaining 
bone fragments will be donated as a gift which will be used in this study only. Once the 
research is finished, all samples will be destroyed. 
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12. Gene studies 
This study was designed to identify genes involved in bone development and muscle 
adaptability. Therefore, any identified genes will be related to facial features rather than 
the patient's general health status. Furthermore, the genetic analysis will be linked to 
one group (either the average or the variation group) rather than to a single patient. 
 
13. What happens when the research study stops? 
All samples will be destroyed when the study is finished. 
 
14. What will happen if the findings may affect the subject personally? 
It is unlikely that the results of the study will affect any of the subjects personally. If 
any of the patients are interested to know the end results, it could be arranged to send 
them a copy whenever the study is published. 
 
15. What if something goes wrong? 
If  you  have  any  comments  or  concerns  you  may  discuss  these  with  any  of  the 
researchers. If you wish to go further and complain about any aspect during the course 
of the research  you may do so. You should contact the Complaints Manager, UCL 
Hospital. Please Quote the UCLH project number at the top of this information sheet. 
 
16. What will happen to the results of the research study? 
The results of this study will be published in scientific journals. However, none of the 
patients will be identified in any way. The genetic and facial feature comparison will be 
purely  between  groups  (variation  and  average)  rather  than  individuals.  If  you  are 
interested in finding out the final results, please let us know then we could either send 
you  an  abstract  of  the  published  paper  or  the  name  of  the  journal  and  the  date  of 
publication. 
 
17. Who is organising and funding the research? 
This study is part of a postgraduate research programme sponsored by the University 
College London/ Eastman Dental Institute. Appendix A. Ethical papers  
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18. Inducements 
Participation in this research will not affect  your care and treatment at the Eastman 
Dental Institute in any way. 
 
19. Withdrawal from the project   
Your participation in the trial is entirely voluntary. You are free to decline to enter or to 
withdraw form the study any time without having to give a reason. If you choose not to 
enter the trial, or to withdraw once entered, this will in no way affect your future dental 
care.  All  information  regarding  your  medical  records  will  be  treated  as  strictly 
confidential and will only be used for medical purposes. Your medical records may be 
inspected  by  competent  authorities  and  properly  authorised  persons,  but  if  any 
information  is  released  this  will  be  done  in  a  coded  form  so  that  confidentiality  is 
strictly maintained. Participation in this study will in no way affect your legal rights. 
 
20. Who has reviewed the study? 
This study has been reviewed by one of the UCLH Research Ethics Committees/ The 
National Hospital for Neurology and Neurosurgery  and Institute of Neurology Joint 
REC. 
 
21. Contact for further information 
If you have any questions at any time, please feel free to contact any of the researchers 
listed below. 
 
  Professor Nigel Hunt  
  Miss Hadwah A.M Moawad 
 
 
Thank you for your cooperation 
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Consent form 
 
Version 1.0 
UCLH Study ID number:   05/Q0512/120   
Date: 14/10/2005 
 
Study title: A genetic study of facial /masticatory muscle and bones of the jaws in 
patients with variable facial features. 
 
Name of Researchers: Professor Nigel Hunt and Miss. Hadwah A.M Moawad 
 
  I confirm that I have read and understand the information sheet and leaflet for 
the above study and have had the opportunity to ask questions. 
  I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights 
being affected. 
  I understand that sections of my medical notes may be looked at by responsible 
individuals  from  the  Eastman  Dental  Hospital.  I  give  permission  for  these 
individuals to have access to my records. 
  I give permission for the Researchers to collect tissue samples from the inner 
cheek, bones of the jaws and masseter muscle to conduct gene analysis for this 
study only. 
I agree to take part in the above study. 
 
……………………………..              ………………………           …………………….. 
Name of patient                   Date              Signature   
……………………………..             ………………………            …………………….. 
Name of person taking consent     Date       Signature 
(If different from Researcher)  
……………………………..             ………………………            …………………… 
Name of Researcher         Date       Signature 
 
1 copy for patient; 1 for researcher; 1 to be kept with hospital notes Appendix A. Ethical papers  
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Patient information Leaflet 
Attached as a separate document to the back cover of the thesis.  
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Materials used for handling masseter muscle biopsy  
 
Experimental step  Materials  Supplying company 
Sample collection  -RNAlater® tissue protect tubes  -Qiagen,  West  Sussex, 
UK 
Dissection 
 
-Vanna’s microscissors, straight 
-Springbow dissecting scissors, extra fine, straight  
-Dumont tweezers, stainless steel 
-Agar  Scientific  Ltd, 
Stansted, UK 
 
Weighing of the sample  -Electronic balance Precisa 1600C  -Precisa  balancers  Ltd, 
Milton Keynes, UK 
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Materials used for RNA extraction and quality control 
 
Experimental step  Materials  Supplying company 
RNase inhibition 
-Clean surfaces 
 
-Tips 
-Centrifuge tubes  
 
-Water 
 
-RNaseZap® wipes 
-RNase® Zap spray 
-Eppendorf® epT.I.P.S, 
-RNase/ DNase free 
centrifuge tubes 
-RNase free water 
 
-Ambion (Europe) Ltd, Applied 
Biosystems, Warrington, UK 
-Sigma-Aldrich Ltd, Dorset, UK. 
-Qiagen, West Sussex, UK 
 
-Qiagen, West Sussex, UK 
Disruption and homogenisation 
-Lysing matrix beads 
-Crushing machine 
 
-x2ml Lysing Matrix D 
-FastPrep 120 
 
-Q-BIOgene, Cambridge, UK 
-Q-BIOgene, Cambridge, UK 
Purification and elution 
-selective binding 
 
-Elusion 
-DNase digestion 
 
-Ethanol 
 
-RNeasy®  mini kit 
-RNase-free DNase set 
 
-Fisher Scientific UK Ltd, 
Loughborough, UK 
-Qiagen, West Sussex, UK 
-Qiagen, West Sussex, UK 
RNA quantity and purity 
-Spectrophotometer  
 
 
-Ultrospec 2000 machine 
 
-Amersham Pharmacia Biotech, GE 
Healthcare Ltd, Buckinghamshire, UK 
QC using the Bioanalyser 
-Preparation of gel dye mix 
 
-Loading the chip 
 
 
-Loading into the Bioanalyser 
 
 
-Bioanalyser 6000 Nano kit 
 
-Priming station  
-Chip vortex (Nano chip 
was used) 
-RNeasy Zap solution 
 
-RNase free water 
-Agilent Bioanalyser 2100 
machine 
-G2938A CellPro 2100 
Bioanalyser Chip Reader v 
1.4 
 
-Agilent Technologies Ltd, West 
Lothian, UK 
-Agilent Technologies Ltd, West 
Lothian, UK 
 
-Ambion (Europe) Ltd, Applied 
Biosystems, Warrington, UK 
-Qiagen, West Sussex, UK 
-Agilent Technologies West Lothian, 
UK 
-Agilent Technologies West Lothian, 
UK 
 
QC: Quality control.   
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Materials used for Microarray laboratory work 
 
Experimental step  Materials  Supplying company 
Sample preparation   -GeneChip® Expression Eukaryotic Poly-A 
  RNA Control kit 
* 
cDNA/cRNA synthesis and 
amplification 
-GeneChipﾮ Expression 3’-Amplificatoin 
  Tow-Cycle cDNA Synthesis kit 
-MEGAscrip®T7 kit (for IVT) 
* 
 
- Ambion (Europe) Ltd, 
Applied Biosystems, 
Warrington, UK 
Synthesis of Biotin-
labelled cRNA  
-GeneChipﾮ Expression 3’-Amplificatoin 
  GeneChip IVT Labelling kit 
* 
cRNA fragmentation   -GeneChip® Sample cleanup module  * 
 Hybridisation   -GeneChip® Eukaryotic hybridisation 
  control kit 
-GeneChip® Hybridisation oven 640 
* 
 
* 
Washing and staining    -GeneChip® Operating software (GCOS) v1.4 
-GeneChip® Fluidics station 450 
* 
* 
Data extraction (scanning)  -GeneChip® Scanner 3000  
-GCOS 
* 
* 
General materials 
 
 
-GeneChip® Sample Cleanup Module 
-Bioanalyser 6000 Nano kit + Nano chip 
* 
-Agilent Technologies 
Ltd, West Lothian, UK 
*Supplied by Affymetrix UK Ltd, High Wycombe, UK.  
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Materials used for quantitative RT-PCR (qRT-PCR) 
 
Experimental step  Materials   Supplying 
company 
cDNA synthesis   
-High-capacity cDNA reverse transcription kit  
- PTC-100 Thermocycler machine,  
 
* 
-MJ Research Inc, 
Genetic research 
instrumentation 
Ltd, Essex, UK 
Genes of interest 
-MYH1 
Assay ID number  GenBank mRNA    
* 
 
* 
 
* 
* 
* 
 
 
 
* 
 
 
 
* 
 
 
* 
 
* 
 
* 
 
* 
 
 
 
Hs00428600_m1  AF111785.1  BC114545.1 
-MYH2  Hs00430042_m1  AF111784.1  BX510904.2 BC1264409.1 
-MYH3  Hs00159463_m1  X13988.1  BP232245.1  BQ956249.1 
-MYH6  Hs00411908_m1  D00943.1  BC117511.1  BC132667.1 
-MYH7  Hs00165276_m1  M58018.1  X51591.1  AY518538.1 
AB209708.1  DQ248310.1  BC112173.1  
BC112171.1  EF560725.1 EU747717.1 
-MYH8  Hs00267293_m1  X51592.1  Z38133.1  M36769.1  
AK303395.1  
-LOC gene  Custom TaqMan®  
gene expression 
assya  
BE675108.1 
-SERGEF  Hs00183730_m1  AJ243950.1  AJ243951.1 BC000707.2 
BC065375.1  AK292286.1 
-KIAA1671  Hs01369792_m1  AL832019.1  BC171801.1   
-DGCR6  Hs00606390_mH  X96484.1  AF228707.1  GR456434.1  
BC047039.1  AK098780.1  AK35115.1 
-NDRG2  Hs00212263_m1  AF159092.3  AW163815.1  AK024521.1  
CR596981.1  CR597040.1  CR598346.1  
CR601715.1  CR607901.1  CR611368.1  
BC093038.1  AF087872.1  BX247987.1 
BX647748.1  BI759006.1 AF304051.1  
AK096999.1  
qRT-PCR   
-File builder software (to design LOC gene assay) 
-TaqMan® universal PCR master mix 
-MicroAmp® optical 96-well reaction plates 
-MicroAmp® optical adhesive cover 
-7300 Real time PCR machine* 
-7300 system software*  
-Large centrifuge 
 
* 
* 
* 
* 
* 
* 
-Jouan CR4.12, 
DJB labcare Ltd, 
Buckinghamshire, 
UK. 
Hs: Homo sapiens. _m1: An assay which spans an exon junction and will not detect genomic DNA. _mH: 
The assay is  very  sensitive  as it  was designed to a transcript  belonging to a  gene  family  with high 
sequence homology. *Supplied by Applied Biosystems, Warrington, UK. 
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Final RNA extraction protocol 
 
Laboratory steps  Materials   Volume   Settings 
i) Prior to start 
Clean the working bench, pipettes 
and all plastic ware used 
 
-RNaseZap® wipes 
-RNaseZap spray 
 
 
 
 
ii) Handling the sample 
 -Cutting the muscle biopsy in the 
RNAlater® tube (30mg) 
 
Microscissors 
Tweezers 
   
iii) Disruption and 
homogenisation 
 
 
 
 
 
 
 
 
 
 
 
Total 
 
Muscle biopsy 
Lysing matrix D 
RLT buffer 
 
 
 
 
 
 
Measure lysate 
70% ethanol 
 
~30mg 
 
600µl  
 
 
 
 
 
 
~450 µl  
~450 µl * 
~900 µl 
FastPrep® homogeniser 
 
 
1
st round 
Speed 6         20s 
Cool on ice    5m 
2
nd round 
Speed 6         20s 
Cool on ice   5m 
Centrifuge    5m 10,000 rpm. 
 
iv) Purification** 
-Use the lysate from the previous 
step 
 
Spin column 
 
RW1 buffer 
DNase I mix**** 
RW1 buffer 
RPE buffer 
RPE buffer 
New tube open cap 
 
~900 µl 
 
350µl 
80µl 
350µl 
500 µl 
500 µl 
- 
 
Centrifuge   15s 10,000 rpm*** 
 
Centrifuge   15s 10,000 rpm 
Keep            15m at room T  
Centrifuge   15s 10,000 rpm 
Centrifuge   15s 10,000 rpm 
Centrifuge   2m maximum speed 
Centrifuge   1m maximum speed 
v) Elution** 
 
 
RNase free water 
 
30 µl 
 
Keep            5m at room T 
Centrifuge   1m maximum speed 
*Measure the remaining lysate after homogenization and add equal volume of ethanol. ** Following the 
RNeasy® mini kit manual. ***Capacity of the spin column is only 700 µl, hence the spinning can be 
conducted more than once.  ****Using the RNase-free DNase set manual. T, temperature. 
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Agilent Bioanalyser Nano chip laboratory protocol 
 
Laboratory steps  Materials   Volume   Settings 
i) Preparation of the gel dye mix 
 
 
Total 
 
RNA gel matrix 
Blue dye 
Gel dye mix 
 
65µl  
1µl  
66µl  
 
 
ii) Loading the chip 
-Place the Nano chip in the priming 
station. 
-Add gel dye mix to the well marked 
G 
-Add to all remaining 12 wells in the 
Nano chip 
-Add to wells being used + ladder 
-Add to blank wells 
-Load into the ladder well 
-Load into the samples wells 
 
 
 
Gel dye mix 
 
Gel dye mix 
 
Marker 
Marker 
Ladder 
RNA samples 
 
 
 
9µl 
 
9µl 
 
5µl 
6µl 
1µl 
1µl 
Priming station 
-Plunger at 1ml 
 
-Press the plunger and hold 
for 30s then release to 1ml 
 
 
 
 
 
Vortex        1m 
iii) Cleaning the Bioanalyser  
-Load the Zap clear chip, then remove 
-Load  the  RNase  H2O  clear  chip, 
then remove 
-Leave the led open to dry 
 
RNeasy Zap solution 
RNase free water 
 
350µl 
350µl 
 
2100 Bioanalyser machine 
Load          1m  
Load          10s  
 
                  10s 
iv) Loading the Bioanalyser  
-Load the 6000 Nano chip and close 
the lid 
 
- 
 
 
- 
 
2100 Bioanalyser machine 
Use the 2100 software to 
operate and read the chip 
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Microarray laboratory protocol 
 
Laboratory steps  Materials   Volume   Settings 
i) Target preparation  
   -Spike in Poly-A controls 
 
   -Add Oligo(dt)  
 
 
 
 
Total  
 
diluted poly-A RNA 
controls 
Concentrated T7-Oligo(dT) 
RNase free water 
RNA sample (total 
concentration  100ng) 
RNase free water              
Mixture 1 
 
0.2µl 
0.2µl 
1.6µl 
Variable  
 
Variable 
Variable  
5µl 
 
ii) cDNA/cRNA synthesis 
1
st cycle, 1
st strand cDNA 
 
-1
st cycle, 1
st strand MM 
 
 
 
 
 
Total  
 
 
 
1
st cycle 2
nd strand cDNA 
-1
st cycle 2
nd strand MM 
 
 
 
 
 
Total  
 
 
IVT 
   -IVT MM 
 
 
 
 
 
 
Total  
 
cRNA cleanup 
 
 
 
 
 
 
 
 
Average 
 
 
 
Mixture 1 
 
5X 1
st strand reaction mix 
DTT (0.1M) 
RNase inhibitor 
dNTP (10mM) 
SuperScript II. 
Mixture 1 
Mixture 2 (1
st strand cDNA) 
 
 
 
 
RNase H  
E.coli DNA polymerase I 
 dNTP (10mM) 
 RNase free water  
Freshly diluted MgCl2 
Mixture 2 
Mixture 3 (ds-cDNA) 
 
 
 
10X reaction buffer 
Enzyme mix 
ATP solutions 
CTP solutions 
UTP solutions 
GTP solutions 
Mixture 3 
Mixture 4 (cRNA) 
 
RNase free water 
IVT cRNA binding buffer  
Ethanol (96-100%)  
Mixture 4        
Cleanup spin column  
IVT cRNA wash buffer  
80% Ethanol  
Dry off the membrane 
RNase free water  
Mixture 5 (cRNA elute) 
 
 
 
5µl 
 
2µl 
1µl 
0.5µl 
0.5µl 
1µl 
5µl      
10µl 
 
 
 
 
0.2µl 
0.6µl 
0.4µl 
4.8µl 
4µl 
10µl 
20µl 
 
 
 
5µ 
5µ 
5µ 
5µ 
5µ 
5µ 
20µl 
50µl 
 
50µl 
350µl 
250µl 
50µl 
700µl 
500µl 
500µl 
 
13µl 
11µl 
 
 
Heating blocks 
70°C  6m 
4°C*   
 
 
 
 
 
 
42°C  1h 
70°C  10m 
4°C* 
 
 
 
 
 
 
 
 
16°C  2h 
75°C  10m 
4°C  hold*  
 
 
 
 
 
 
 
 
37°C  16h (overnight) 
 
 
 
 
 
Centrifuge 15s ≥ 10,000 rpm. 
Centrifuge 15s ≥ 10,000 rpm. 
Centrifuge 15s ≥ 10,000 rpm. 
Centrifuge 5m at maximum speed 
Centrifuge 1m at maximum speed 
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Laboratory steps  Materials   Volume   Settings 
Q.C of  cleaned cRNA 
   -Biophotometer 
 
 
 - Agilent Nano kit protocol 
 
2
nd cycle, 1
st strand cDNA 
 
 
 
 
Total  
 
    -2
nd cycle, 1
st strand MM 
 
 
 
 
 
Total  
 
 
 
Total  
 
 
 
2
nd cycle, 2
nd strand cDNA 
 
Total  
 
-2
nd cycle, 2
nd strand MM 
 
 
 
 
Total  
 
 
 
Total  
 
 
ds-cDNA cleanup 
 
 
 
 
 
 
Average  
 
Mixture 5 
RNase free water  
 
Mixture 5 
 
Freshly diluted random 
primers  
Adjusted mixture 5 (total 
concentration 600ng) 
RNase free water  
Mixture 6  
 
5X 1
st strand reaction mix 
DTT (0.1M) 
RNase inhibitor 
dNTP (10mM) 
SuperScript II 
Mixture 6 
Mixture 7 (1
st strand cDNA) 
 
Mixture 7 
RNase H  
Mixture 8 
 
 
 
Freshly diluted T7 Oligo-dT  
Mixture 8 
Mixture 9 
 
RNase free water 
5X 2
nd strand reaction mix 
dNTP (10mM) 
E.coli DNA polymerase I 
Mixture 9 
Mixture 10 (ds-cDNA) 
 
T4 DNA polymerase 
Mixture 10 
Mixture 11 (blunt-ended ds-
cDNA) 
 
cDNA binding buffer  
Mixture 11 
Cleanup spin column 
cDNA wash buffer  
Dry off the membrane 
cDNA elution buffer  
 
Mixture 12 (ds-cDNA elute) 
 
2µl 
78µl 
80µl 
1µl 
 
 
2µl 
 
Variable  
Variable  
11µl 
 
4µl 
2µl 
1µl 
1µl 
1µl 
11µl 
20µl 
 
20µl 
1µl 
21µl 
 
 
 
4µl 
21µl 
25µl 
 
88µl 
30µl 
3µl 
4µl 
25µl 
150µl 
 
2µl 
150µl 
152µl 
 
 
600µl 
152µl 
 
750µl 
 
14µl 
 
12µl 
 
-Eppendorf biophotometer 
 
 
-2100 Agilent Bioanalyser 
Acceptable A260/A280 = 1.8-2.29 
 
 
 
 
 
70°C  10m 
4°C* 
 
 
 
 
 
 
42°C  1h 
4°C* 
 
 
37°C  20m 
95°C  5m 
4°C* 
 
 
 
70°C  6m 
4°C* 
 
 
 
 
 
16°C  2h 
 
 
 
16°C  10m 
4°C* 
 
 
 
Centrifuge 1m ≥ 10,000 rpm 
Centrifuge 1m ≥ 10,000 rpm 
Centrifuge 5m at maximum speed 
Incubate 1m  Room T, then 
Centrifuge 1m ≥ 10,000 rpm 
 
iii) cRNA synthesis and 
labeling  
 
 
 
 
Total  
 
Mixture 12 
10X IVT labelling buffer 
IVT labelling NTP mix 
 IVT labelling enzyme mix 
RNase free water  
Mixture 13 (labeled cRNA) 
 
12µl 
4µl 
12µl 
4µl 
Variable 
40µl 
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Laboratory steps  Materials   Volume   Settings 
Labeled cRNA cleanup 
 
 
 
 
 
 
 
 
 
Average 
 
Q.C of labeled cRNA 
  -Biophotometer 
        
 
 -Agilent Nano kit  protocol  
RNase free water 
IVT cRNA binding buffer 
Ethanol (96-100%)  
Mixture 13 
cRNA cleanup spin column  
IVT cRNA wash buffer 
80% Ethanol  
Dry off the membrane 
RNase free water  (1
st elute) 
RNase free water (2
nd elute) 
Mixture 14 (final elute, 
cleaned and labeled cRNA) 
 
Mixture 14 
RNase free water   
 
Mixture 14 
60µl 
350µl 
250µl 
40µl 
700µl 
500µl 
500µl 
 
11µl 
10µl 
21µl 
 
 
2µl 
78µl 
80µl 
1µl 
 
 
 
 
Centrifuge 15s ≥ 10,000 rpm. 
Centrifuge 15s ≥ 10,000 rpm. 
Centrifuge 15s ≥ 10,000 rpm. 
Centrifuge 5m at maximum speed 
Centrifuge 1m at maximum speed 
Centrifuge 1m at maximum speed 
 
 
 
-Eppendorf biophotometer 
 
 
-2100 Agilent Bioanalyser 
Acceptable A260/A280 = 1.8-2.29 
iv) cRNA fragmentation 
 
 
 
Total  
 
Q.C of fragmented cRNA 
 -Agilent Nano kit  protocol 
Mixture 14 (total 
concentration 25µg) 
5X fragmentation buffer  
RNase free water  
Mixture 15 (35-200 base 
fragmented cRNA) 
 
Mixture 15 
Variable  
 
8µl 
Variable  
40µl 
 
 
1µl 
 
 
 
 
94°C  35m 
 
 
-2100 Agilent Bioanalyser 
v) Hybridisation 
  -Hybridisation cocktail  
 
 
 
 
 
 
 
 
 
 
 
Total  
 
  -Preparation of the chip  
  -Loading the array chip 
 
Mixture 15 (total 
concentration 15µg) 
Control Oligonucleotide B2 
20X Eukaryotic 
hybridisation controls 
(bioB, bioC, bioD, cre) 
Herring sperm DNA 
(10mg/ml) 
BSA (50mg/ml) 
2X hybridisation buffer 
DMSO 
RNase free water  
Mixture 16 (hybridisation 
cocktail) 
2X hybridisation buffer 
Remove the 2X 
hybridisation buffer and add 
mixture 16 
 
 
Variable  
5µl 
 
 
15µl 
 
3µl 
3µl 
150µl 
30µl 
Variable 
300µl 
 
150µl 
 
 
200µl 
49 Format (Standard)/ 64 
Format Array  
 
 
 
 
 
 
 
 
 
 
 
Hybridisation oven  
99°C  5m  
 
45°C  10m (with rotation) 
 
 
45°C  16h (60 rpm rotation) 
vi) Washing and staining  
1
st wash  
 
2
nd wash 
 
   -Preparation of SAPE 
    staining solution  
 
 
 
Total  
 
Remove mixture16 
Non-stringent wash (Buffer 
A) 
Stringent wash (Buffer B) 
 
2X stain buffer  
BSA (final concentration 2mg/ml) 
SAPE (final concentration 
10µg/ml) 
DI H2O 
Mixture 17 (SAPE solution) 
 
 
250µl 
 
250µl 
 
600µl 
48µl 
 
12µl 
540µl 
1200µl 
 
Fluidics Station 450/250 
25°C  10 cycles 2 mixes 
 
50°C  4 cycles 15 mixes 
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Laboratory steps  Materials   Volume   Settings 
  -Preparation of Antibody 
   staining solution  
 
 
 
 
 
Total  
 
 
1
st stain  
Post stain wash 
2
nd stain  
3
rd stain  
Final wash 
2X stain buffer 
BSA (final concentration 2mg/ml)  
Goat  IgG stock (final 
concentration 0.1mg/ml) 
Biotinylated antibody (final 
concentration 3µg/ml) 
DI H2O 
Mixture 18 (Antibody 
solution) 
 
Mixture 17 
Buffer A 
Mixture 18 
Mixture 17 
Buffer A 
300µl 
24µl 
 
6µl 
 
3.6µl 
266.4µl 
600µl 
 
 
600µl 
250µl 
600µl 
600µl 
250µl 
 
 
 
 
 
 
 
 
 
 
25°C  10m  
25°C  10 cycles 4mixes 
25°C  10m  
25°C  10m  
30°C  15 cycles 4mixes 
*Cooling down is at least for 2m. MM: Master mix. T: Temperature. 
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qRT-PCR laboratory protocol  
 
Laboratory steps  Materials   Volume   Settings 
i) cDNA synthesis 
 -Adjusting RNA concentration 
    (equal volume to the cDNA MM) 
 
Total 
 
  -Preparation of cDNA MM  
 
 
 
 
 
Total 
   
   -cDNA synthesis 
 
Total 
 
RNA sample (total 
concentration 5ng/reaction)  
RNase free water 
Adjusted RNA sample 
 
10X RT Buffer  
25X dNTP mix (100mM) 
10X RT Random primers  
MultiScribe Reverse 
transcriptase enzyme  
RNase free water 
cDNA MM/reaction 
 
cDNA MM 
Adjusted RNA sample 
cDNA mixture  
 
 
Variable 
Variable 
10µl 
 
2µl 
0.8µl 
2µl 
 
1µl 
4.2µl 
10µl 
 
10µl 
10µl 
20µl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T/ cycle (35 cycles used) 
25°C  10m  
37°C  120m  
85°C  5s 
4°C  ∞ 
ii) qRT-PCR 
   -Preparation of qRT-PCR mix 
 
 
 
 
Total 
   
   -Loading each well andcover 
    the whole plate 
   -Applying the 96-well plate 
   into the relative quantification 
   real-time PCR machine 
 
TaqMan Universal PCR 
MM 
RNase free water 
cDNA mixture 
Gene of interest assay 
qRT-PCR mixture/well 
 
qRT-PCR mixture 
 
 
 
 
12.5µl 
8.75µl 
2.5µl 
1.25µl 
25µl 
 
25µl 
 
 
 
 
 
 
 
 
 
 
 
Centrifuge 15s maximum speed 
in a large centrifuge 
T/ cycle (40 cycles used) 
50°C  2m  
95°C  10m  
95°C  15s 
60°C  1m 
MM: Master mix.  T: Temperature.  
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GeneChip® quality control, values for each chip 
 
Chip  Ploy-A 
controls 
3’/5’ ratio 
GAPDH   ß-actin      
Hybridisation 
controls 
% gene 
present 
Back 
ground 
Raw 
noise 
Scaling 
factor 
1 (R)  Lys 137.7 
Phe 112.52 
Thr 231.77 
Dap 525.56 
1.43            1.16  BioB 235.6 
BioC 621.73 
BioD 2567.42 
Cre    8129.5 
31  86.18  2.73  1.755 
2 (R)  Lys 147.37 
Phe 191.53 
Thr 357.26 
Dap 970.5 
1.37            1.05  BioB 257.63 
BioC 771.49 
BioD 3217.92 
Cre    9847.17   
34.02  62.94  2.02  1.932 
3  Lys 120.2 
Phe 129.55  
Thr 249.18 
Dap 638.63 
1.52             1.42        BioB 235.03 
BioC 648.41 
BioD 2481.85 
Cre    8269.92 
38  65.98  2.17  1.483 
4  Lys 204.88 
Phe 190.56 
Thr 342.76 
Dap 970.41 
1.59             0.86  BioB 276.69 
BioC 753.86 
BioD 3268.68 
Cre   10060.08 
32.4  59.15  1. 92  2.379 
5  Lys 145.77 
Phe 124.74 
Thr 244.07 
Dap 767.22 
1.46              2.21  BioB 133.38 
BioC 131.01 
BioD 1460.4 
Cre    5292.6 
47.0  57.82  2  0.596 
6  Lys 142.09 
Phe 143.11 
Thr 374.07 
Dap 1006.99 
2.42             3.0  BioB 161.81 
BioC 146.57 
BioD 1649.44 
Cre    6967.69 
44.3  77.57  2.53  0.903 
7  Lys 123.14 
Phe 110.01 
Thr 315.89 
Dap 874.97 
1.77             3.27  BioB 133.8 
BioC 130.42 
BioD 1377.26 
Cre   6233.56 
46.6  66.89  2.17  0.818 
8  Lys 143.37 
Phe 108.46 
Thr 252.64 
Dap 669.2 
1.67             3.34  BioB 135.9 
BioC 115.31 
BioD 1326.16 
Cre    2664.72 
45.7  71.94  2.27  0.998 
9  Lys 130.08 
Phe 90.81 
Thr 236.19 
Dap 698.28 
1.85            1.94  BioB 160.25 
BioC 143.53 
BioD 1631.71 
Cre   7399.14 
41.6  68.61  2.2  1.082 
10  Lys 155.35 
Phe 149.53 
Thr 273.91 
Dap 838.54 
3.09             6.22  BioB 166.41 
BioC 174.22 
BioD1991.18 
Cre   7639.73 
50.9  64.54  2.09  0.864 
11  Lys 129.33 
Phe 92.65 
Thr 262.38 
Dap 902.49 
1.67            2.75  BioB 134.67 
BioC 114.83 
BioD 1605.79 
Cre    5873.5 
46.9  69.13  2.15  0.696 
12  Lys 94.28 
Phe 61.12 
Thr 127.53 
Dap 393.68 
1.43            1.76  BioB 152.57 
BioC 139.74 
BioD 1809.45 
Cre    7093.53 
43.7  67.19  2.12  0.865 
13  Lys 341.06 
Phe 332.59 
Thr 757.38 
1.58            2.03  BioB 156.24 
BioC 167.31 
BioD 1860.27 
42.9  63.37  2.01  0.871 Appendix D. Microarray  
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Chip  Ploy-A 
controls 
3’/5’ ratio 
GAPDH   ß-actin      
Hybridisation 
controls 
% gene 
present 
Back 
ground 
Raw 
noise 
Scaling 
factor 
Dap 2306.55  Cre   6986.89 
14  Lys 248.00 
Phe 221.90 
Thr 521.30 
Dap 1557.16 
1.55            3.00  BioB 114.26 
BioC 109.02 
BioD 1428.08 
Cre   5413.53 
48.9  73.71  2.3  0.682 
15  Lys 179.21 
Phe 128.06 
Thr 207.95 
Dap 1068.76 
3.69            11.26  BioB 272.41 
BioC 289.29 
BioD 2552.6 
Cre   8671.71 
52  55.18  1.94  0.778 
16  Lys 338.84 
Phe 336.87 
Thr 588.47 
Dap 1986.02 
1.74            3.96  BioB 301.34 
BioC 313.41 
BioD 2986.91 
Cre   9843.64 
45.7  57.36  1.95  1.002 
17  Lys 158.76 
Phe 126.52 
Thr 198.62 
Dap 813.02 
1.85            2.77  BioB 222.91 
BioC 219.59 
BioD 2542.9 
Cre   8433.6 
45.7  61.93  2.04  0.88 
18  Lys 281.12 
Phe 254.85 
Thr 369.28 
Dap 1590.98 
1.44            2.69  BioB 265.03 
BioC 273.4 
BioD 3083.47 
Cre   10460.94 
44.4  43.19  1.44  1.017 
19  Lys 166.48 
Phe 162.72 
Thr 291.31 
Dap 1074.75 
1.73            3.66  BioB 263.16 
BioC 269.35 
BioD 3098.78 
Cre   10401.02 
43.9  60.3  1.96  1.02 
20  Lys 159.62 
Phe 145.45 
Thr 226.66 
Dap 811.04 
1.39            3.58  BioB 213.57 
BioC 229.1 
BioD 2625.79 
Cre   8330.86 
47  64.11  2.09  0.796 
21  Lys 162.26 
Phe 122.61 
Thr 211.22 
Dap 841.5 
1.69            1.82  BioB  268.73 
BioC  271.76 
BioD  3085.56 
Cre   10721.94 
42.5  58.4  1.91  1.069 
22  Lys 150.83 
Phe 109.2 
Thr 165.88 
Dap 686.27 
1.61            3.97    BioB 213.09 
BioC 219.6 
BioD 2430.91 
Cre   8451.39 
44.4  66.34  2.11  0.896 
23  Lys 256.73 
Phe 222.85 
Thr 355.37 
Dap 1382.18 
2.99            5.88  BioB 236.05 
BioC 239.48 
BioD 2516.03 
Cre    9094.16 
47.1  64.3  2.07  0.993 
24  Lys 240.5 
Phe 162.62 
Thr  297.28 
Dap 1198.63 
1.19            1.98  BioB 229.58 
BioC 263.29 
BioD 2899.7 
Cre   10235.29 
41.3  60.09  1.95  1.112 
25  Lys 264.57 
Phe 266.75 
Thr 434.89 
Dap 1433.26 
1.24            2.19  BioB 184.76 
BioC 182.74 
BioD 2136.91 
Cre   7445.37 
40.7  50.61  1.74  0.960 
26  Lys 145.33 
Phe 143.4 
Thr 247.73 
Dap 806.72 
1.43            1.57  BioB 231.31 
BioC 233.83 
BioD 2349.94 
Cre   8784.93 
43.4  49.68  1.67  1.070 
27  Lys 191.45  1.39           2.26  BioB 187.69  44.2  56.68  1.85  1.061 Appendix D. Microarray  
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Chip  Ploy-A 
controls 
3’/5’ ratio 
GAPDH   ß-actin      
Hybridisation 
controls 
% gene 
present 
Back 
ground 
Raw 
noise 
Scaling 
factor 
Phe 150.91 
Thr 297.77 
Dap 982.31 
BioC 189.76 
BioD 2268.69 
Cre   8069.67 
GQ  Expressed 
genes 
≤ 3  Increasing 
intensity  from 
BioB to Cre 
< 10%*   20-100  Similar 
values  
≤ 2 SD  
Samples were numbered from 1 to 27 starting with the 1
st batch going through to the 4
th batch samples. Both 
samples 1 and 2 were the technical replicates (R) and had comparable results. Samples 10 and 15 have failed 
the 3’/5’ ratio of both genes. Samples 7, 8, 16, 19, 20, 22 and 23 have failed the 3’/5’ ratio of the ￟-actin 
gene only. The samples that have failed any criteria were marked in red. *Less than 10% difference between 
technical replicates. GQ: Good quality. SD: Standard deviation. 
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Pre-processing data and normalisation 
 
Box plots 
 
 
 
 
 
 
 
 
 
 
 
Box plots of both raw and normalised data. Samples were colour coded based on the horizontal 
facial deformity (blue, Class III; green, Class II; red, control patients). The black vertical line 
present in the middle of each box plot represents the median log intensity for each chip. In the 
raw data it is clear that the position of the median line is largely different between samples as it 
is affected by the raw noise and un-specific hybridisation. Once the data have been normalised 
and all systematic variations have been removed, the median line of all samples was aligned 
close to teach other and the data were more comparable.  Appendix D. Microarray  
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Perfect-match (PM) signal histograms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This histogram is a measurement of the density of the probe intensities of both the PM probes and 
the noise. Typical histogram appearance of normalised PM signals which is separated from the 
noise would appear with the density skewed to the right with 2 distinct peaks. One is long and 
narrow that represents the noise and the other one is small and broad that is the actual PM 
signal. All samples showed typical PM histogram appearance with no obvious outliers. Appendix D. Microarray  
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Histogram of PM vs. MM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The  mis-match  (MM)  probes  measure  non-specific  hybridisation  while  PM  probes  measure 
specific hybridisation. It is therefore, expected that the PM probes will produce strong intensities 
while  the  MM  probes  weaker  intensities.  All  27  samples  had  a  typical  PM-MM  histogram 
appearance with the MM probes (red colour peak) having a narrower intensity peak than the PM 
probes (blue colour peak). Appendix D. Microarray  
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RNA degradation plot 
 
 
 
 
 
 
 
 
 
 
 
The 0 probe presenting the most 5’ sequence and the 10th probe is the most 3’ sequence. Since 
RNA degradation starts at the 5’ end, and labelling occurs from the ‘3 end, therefore, a typical 
RNA degradation plot would show increasing intensities from the 5’ to the 3’ end. All 27 samples 
had increasing intensities from the 5’ probes to the 3’ probes. Appendix D. Microarray  
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MvA plots of the controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Each MvA plot was a graphical representation of two samples only, where the fold-change (M) at 
the y-axis is plotted against the average fluorescence intensity (A) of both samples at the x-axis. If 
both samples were highly comparable they will have a symmetric appearance around the x-axis 
(leaf like appearance) similar to the correlation of sample 17 with samples 18, 20, 21 and 22 
(marked  in  green).  While if  a  sample  was  not correlated  to  the  other  samples,  the  leaf like 
appearance will have extensions, similar to sample 8 in relation to all other samples (marked in 
red). Appendix D. Microarray  
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MvA plots of the Class II group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample  15 shows  vertical  widening  of the  leaf  like  appearance  which  indicates  a large fold 
change  variation  and  poor  correlation  to  all  other  samples  (marked  in  red).  Both  technical 
replicates were well correlated (marked in green). Appendix D. Microarray  
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MvA plots of the Class III group  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All chips within this group were correlated where all samples showed a leaf like appearance with 
no extensions and no marked increase in the fold change. Samples 3 and 19 (marked in green) 
are examples of good MvA correlations. Appendix D. Microarray  
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Correlation plot 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The heatmap was a chip-chip Spearman’s rank correlation coefficient that is colour coded. The 
lighter  the  colour,  the  greater  the  correlation.  Both  technical  replicates  (R)  were  highly 
correlated (0.98). Both samples 8 and 15 are showing darker colours compared to other samples, 
with sample 15 being less correlated to other samples than chip 8.  Appendix D. Microarray  
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Summary of the study following MIAME guidelines 
 
  MIAME guidelines   Description 
Study design 
Main aim 
-Ascertain masseter muscle candidate genes in relation to craniofacial 
deformities 
Study type  -Case control study (deformity vs. control) 
Experimental factor  -Gene expression variation 
Experimental design 
 
-Long face vs. control (vertical classification) 
-Class II vs. Class III vs. control (horizontal classification) 
Quality control  -Biological replicates included 11 control and 18 deformity patients 
-Technical replicates included 2 
Sample description 
Sample origin  
 
-Fresh human masseter muscle biopsies collected prior to any 
orthodontic intervention during the surgical removal of third molars 
Sample manipulation 
 
-Samples stored in tubes containing RNAlater® reagent at -80 C° until 
RNA extraction   
RNA extraction 
 
 
 
 -Optimised protocol using the lysing matrix D®, the FastPrep® 
machine, 20 seconds, speed 6, 5 minutes cool down on ice, repeated 
twice. Qiagen™ RNeasyﾮ mini kit protocol with DNase digestion step 
for 15 minutes. 
RNA quality control  -Good quality shown by the Bioanalyser profile Nano LabChip® kit 
Microarray laboratory design 
Amplification for microarray 
 
-Two cycle amplification protocol 
Labelling  -Labelled cRNA (standard Affymetrix® protocol) 
Hybridisation  -Standard Affymetrix®  protocol 
Spike controls  -Standard Affymetrix®  protocol 
Data analysis 
Data extraction 
 
-Standard Affymetrix®  procedure 
Raw data  - CHP file generated using the Affymetrix® suite -MAS 5.0 
Pre-processing data  -Standard Affymetrix® procedure 
Normalised data  -GCRMA normalisation  
Results  -Long face vs. controls (12 up- and 19 down-regulated in long face) 
-Class II vs. control (3 up- and 9 down-regulated in Class II) 
-Class III vs. control (15 up- and 21 down-regulated in Class III) 
-Class II vs. class III (5 up- and 7 down-regulated in Class II) 
-All deformity vs. control (6 up- and 19 down-regulated) 
Array design 
Array name 
 
HG U133 Plus 2.0 Array GeneChip® 
MIAME: Minimum Information About a Microarray Experiment 
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